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Abstract
Novel polysaccharide-based micelles were prepared to exploit their solubilizing
potential towards poorly-water solttble drugs in order to improve their oral bioavailability.
Hydrophobically-modifjed (HM) dextran (DEX) and hydroxypropylcellulose (HPC)
copolyrners were synthesized. In aqueous solution, HM DEX and HM HPC fortn polymeric
micelles with low onset ofmicellization and small size. Cyclosporin A (CsA) was selected
as model drng. CsA-loaded polyrneric micelles were prepared by a dialysis procedure. The
CsA incorporation in micelles of HM polysaccharides was significantly higher than in
corresponding unrnodified polysaccharides. Tlie polymeric micelles exhibited high stabi I ity
in gastric and intestinal fluids. On the celtular level, the polymeric micelles presented no
significant cytotoxicity towards Caco-2 cells. The apical to basal permeability of CsA
across Caco-2 monolayers increased significantly, whcn loaded in polymeric micelles,
compared to free CsA. Meanwhile, penneability of the host polysaccharides was
demonstrated, where the amount of transported HPC-based micelles was greater than that
of DEX-based micelles. Targeted Vitamin B12-modified polymeric micelles enhanced the
permeability of CsA across the intestinal barrier compared to unmodified micelles.
Therefore, Polysaccharide-based polymeric micelles are promising carriers for the oral
deliveiy of poorly-water soluble drugs.
Keywords : Poorly-water soluble drug, Polysaccharides, Polymeric micelles,
Solubilization, Orat dmg deliveiy, Caco-2, Penueability, Vitamin B12.
iv
Résumé
Des micelles polymères à base de polysaccharides ont été préparées afin d’évaluer
leur potentiel comme agent de solubilisation de principes actifs hydrophobes pour en
augmenter la biodisponibilité. Des copolymères à base de dextran (DEX) et
d’hydroxypropylcellulose (HPC) modifiés aux groupements hydrophobes ont été
synthétisés. En solution aqueuse, DEX et HPC modifiés forment des micelles polymères de
petite taille à des basses concentrations. La Cyclosporin A (C5A) a été choisi comme
modèle de principe actif hydrophobe. Des micelles polymères contenant de la CsA ont été
préparées par une procédure de dialyse. Le pourcentage d’incorporation de la CsA dans les
micelles de polysaccharides modifiés a été significativement plus élevé que dans le cas des
polysaccharides non-modifiés. Les micelles polymères ont été démontrées stables dans les
fluides gastriques et intestinaux. Au niveau cellulaire. les micelles polymères n’ont pas
présenté de cytotoxicité significative envers les cellules intestinales Caco-2. La
perméabilité apicale-basale de la CsA à travers une monocouche de Caco-2 a augmenté
significativement lorsque incorporée dans les micelles polymères en comparaison avec le
principe actif seul. L’étude de la perméabilité de copolymères a démontré une
augmentation de la perméabilité des micelles polymères à base de HPC par rapport aux
micelles à base de DEX. Les micelles polymères greffées de vitamine B2 ont démontré une
plus grande perméabiLité de la CsA à travers les cellules intestinales en comparaison avec
les micelles non-greffées. En concltision, les micelles polymères à base de polysaccharides
représentent une technologie prometteuse de vecteurs pharmaceutiques pour l’absorption
orale de principe actif hydrophobe.
VMots-clés Médicament peu-soluble dans l’eau, Polysaccharides, Micelles polymères,
Solubilisation, Voie orale, Caco-2. Penueabilité, Vitamin 312.
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CHAPTER ONE
INTRODUCTION — PART I
AN OvERvIEw ON THE M0RPH0L0GIcAL, PHYsI0L0GIcAL AND
PHYSICAL CHEMIcAL BARRIERs FAcING THE ORAL
ABsoRPTIoN 0F THERAPEuTIc5
Part one of this two-part review addresses the transport of therapeutics across the intestinal
barrier, and focuses on the anatornical, physiological and physicochernicaÏ parameters
impacting transcellular uptake of orally administered drugs. Part two wiÏÏ cover approaches
for overcoming obstac’es limiting successful oral delivery of poorly-water solut)le drugs,
narnely poÏyrneric rnicelle-based carrier system.
The average development cost of a new chernical entity (NCE) is approxirnately
US$ 300—550 mitÏion (Frantz, 2004; Preziosi, 2004). It often costs substantialÏy Ïess to
develop new methods of administration foi- an existing dmg. which resuits in improved
efficacy and bioavaiÏability together with reduced dosing frequency to minimize side
effects. Therefore, the pharmaceutical industry is under constant pressure to maxirnize the
full potential of a dnig candidate at an early stage of its life cycle. This objective can be
accomplished by incorporating the dmg into various dnig delivety systems. Such exercise
can lead to extended patent life and convenient dosage foi-iris that overcome prcviously
presented administration problems. for the last two decades. there has been an enhanced
dernand for more patient-compliant dosage forrns. As a result, novel drug delivery systems
evolved over a short period of time to optimize the dosage regimen of a drug without
compromising its therapeutic efficacy. There are now approximately 350 dnig delivery
corporations and 1000 medical device companies. The dernand for their teclmologies was
approxirnately $14—20 billion in 1995 (Annual report on drug deliveiy, 1996) and,
according to industry reports, this is expected to grow to $60 billion annually.
Peroral administration of therapeutics, when appropriate, remains the route of
choice for drug delivery. On the one hand, from the patient standpoint, the oral route is the
most popular means of delivering drugs into systemic circulation due to case of
administration (ingestion) and pain avoidance (Li, VJ-LK. et aÏ., 1987). On the other hand,
oral delivery systems do not require sterile conditions and are, therefore, less expensive to
manufacture.
jUnfortunately, formulating a drug for oral delivery is a technically challenging
process. Methodologies for systematically optimizing drug stability in the gastrointestinal
(GI) tract, obtaining the desired pharmacokinetic profile and biodynarnics, as well as
reducing absorption variabilities and side effects are not well-established routine processes.
Delivery issues become even more complex when the phanriaceutical scientist is
confronted with designing formulations for the ever-expanding number of poorly soluble
therapeutic drug candidates that are currently being identified and evaluated for oral
administration (Fasano, 199$; Charman, 2000; Saha et aï., 2000; Dressrnan, J. et cii., 2001).
The success of an oral drug deliveiy system depends on various biological and
physicochemical factors. The biological considerations that will determine the success of an
oral drug delivery system include intestinal mobility, the composition (e.g. pH. enzymes,
food) of intestinal lumen and intestinal mucosal ceils (Lipka et aï., 1996; Daugherty et al..
1999; Kurosaki et aï., 2000). The physicochemical factors include: a) formulation factors
(e.g. dosage form size, deaggregation and dissolution of dosage form, and rates of drug
release from the drug carrier), and b) drug factors (e.g. solubility, chernicat and enzymatic
stability, lipophilicity, hydrogen bonding potential, conformation, pKa, molecular size, and
affinity for endogenous transporters).
Tïijs review wiïl address u number of issues reïaied to trcmseellular intestinal
transport mechanisrns that rnight be manipulated/àr improved oral drug delivery.
4Li. M0RPH0L0GIcAL BARRIERS
Absorption of solutes occurs mainly in three sections of the small intestine
(duodenum, jejunum and ileum). Each of these segments lias unique anatomical and
physiological properties that dictate parameters of digestion and solute absorption (Table
1.1.).
rj
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61.1.1. Morphology of the “intelligent intestine”
Consider Alfred Binet’s definition of intelligence, given at the end of’ the
19th
century: “intelligence is the range of processes involved in adapting to the environment”.
The srnall intestine is designed to impede the entiy of pathogens, toxins aiid
undi gested macrornoÏecules whi le simultaneously digesting and setecti vely absorbing
essentiaÏ nutrients, vitamins and cofactors (WaÏker, 1981). Unlike the skin, which Fias
keratin to provide an overwhelming physical barrier against bacterial entiy, the intestinal
mucosa uses biochernical and physiological rnechanisms to complement its physical barrier
to prevent entiy of unwanted materials. These protective mechanisms of the smali intestine
should be judiciously modified or circumvented for successful oral drug deliveiy. Such
obstacles include:
-
VaryingpH
-
The high enzyrnatic activity ofthe small intestine
-
The inherently low permeability of the intestinal mucosa
-
The binding capacities ofresident mucous and lurninal contents
-
The efflux pathways back into the gut lumen following intemalization into
epithelial cetis
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figure 1.1. MorphoÏogy of (A) the intestinal tract showing (B) the small intestine
mucosa with folds of Kerckring, (C) villi with proliferating and maturing
epithelial ceils traveling up the villi to be lost at the tip, and (D) microvilli
on epithelial celis of the apical brush-border membrane. Adapted from
(WaÏker, 1981; Carr et al., 1984; Madara et al., 1987).
$
Thc multifunctional characteristics of the small intestine make the epithelium an
extremely complex living system (Figure 1 .1.). The luminal mucosa is composed of a
monolayer of epithelial celis, the “lamina propria”, which is a connective tissue scaffold.
and the “muscularis mucosa”. which is a thin layer of srnooth muscle. The deeper
connective tissue layer underlying the mucosa is called “submucosa”.
The lamina propria is a structural support for the confluent monolayer of epithelial
ceils and is highly folded to form “villi” which are tiny finger-like projections that increase
the surface area of the mucosa by approximately 30-fold. Villi are absent in the large
intestine (colon). Microvilli. which are projections of I mm high that extend from the apical
surface of intestinal ceits, further increase the surface area for digestion and absorption by
approximately 600-fold. The “crypts of Lieberktihn”, from which the cells originate and
differentiate, reside at the base of the villi. The blood and lymphatic channels, which
transport absorbed molecules, are located in lamina propria.
By contracting, the muscularis mucosa may modulate the thickness of the unstirred
water layer at the surface of the mucosa, affecting the absorption of lipophilic molecules
and helping to empty the luminal contents ofthe crypt.
The epitheliat celis are a heterogeneous population of celis which include mainly:
enterocytes or “absorptive cells”; “goblet celis” which secrete mucin and M celis”, which
transport antigens present in the intestinal lumen to the lymph. In the crypt. the major ceil
type is the undifferentiated cdl. As cells move up the ciypt to the base of the villi, they
9differentiate into absorptive ceils, as well as goblet or M celis, and continue to the tip of
the vitti where they are extruded (Carr et al., 1984; Madara et al., 1987).
The most conm-ion epithelial celi is the enterocyte or the absorptive celi. This ceil is
responsible for the majority of the absorption ofboth nutrients and drugs that takes place in
the srnall intestine (Madara et al., 1987). It is highly polarized with distinct apical and
basolateral membranes (Figure 1. t .C). The absorptive ceils are separated by tight junctions
which are apical intercellular attachement zones and comprise a meshwork of strands
(Cereijido et al., 1988; Denker et al., 1998). The apical membrane has striking, unifom
microvilli measuring approxirnately I im in height (bntsh border) in which disaccharidases
and peptidases reside. The apical membrane also expresses receptor-mediated transport
systems (e.g. cobalamin (Seetharam et al., 1991)), together with ion, monosacchancle,
amino acid, peptide, and fatty acid transporters (Sigrist-Nelson et al., 1977). In contrast to
the apical membrane, the basolateral membrane has smooth contours with no sugar and
peptide hydrolases. However, Na-K ATPase, glycosyltransferases, and adenyl cyclase are
located in the basolateral membrane (Madara et al., 1987).
Absorptive cells are covered by a mucous layer which is bound to the apical cell
surface by “glycocalyx”. Microvilli and the associated glycocalyx establish a bnish border
structure that presents a considerable catabolic barrier of enzyrnatic activities. The mucous
coating of the epithelial surface contains mucin glycoproteins, enzymes and electrolytes.
Mucous is secreted by goblet ceils that are intercalated between enterocytes covering the
villi, as well as from subepithelial glands. The mucous acts as a defense mechanism against
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damage to the absorptive celis, and is a potential site for drug interaction and binding
(Kurosaki et cil., 2000). The pH of the various intestinal segments ranges from slightly
acidic to slightly basic. A slightly acidic microclimate at the immediate surface of
enterocytes has also been described. In some cases these variations in pH might impact a
drug’s stability or solubility. or both.
1.1.2. light junction
The integrity of the epithelial celi layer is maintained by intercellular junctional
complexes. At the apical side of the junctional complex (Cereijido et al., 1988), the tight
junction forms a continuous, circumferential, beit-like structure at the luminal end of the
intercellular space, where it serves as a gatekeeper of the paracellular pathway (Cereijido et
aï., 2000: Schneeberger et al.. 2004). The tightjunctions allow only the passage of ions and
small molecules, up to approximately 900 Da (Gumbiner et al.. 1988; Tang et aÏ., 2003).
However, the tight junctions appear to be a potential site for the action of absorption
enhancers (calcium chelators and surfactants). which when present, open tight junctions,
and afler their rernoval the process is reversed (van Hoogdalem et al., 1989). The
application of enhancers is usually necessary to increase the flux of therapeutic peptides
and proteins such as hurnan calcitonin (Shah et aï., 2004) and enaminone anticonvulsants
(Cox et aï., 2001).
1.2. PHY5I0L0GIcAL CONSIDERATIONS IN THE DESIGN 0F DRUG CARRIERS
FOR ORAL DELIVERY
1.2.1. Enzymatic barrier
Drugs and other xenobiotics that gain access to the body may undergo one or more
of 4 distinct fates:
) Elimination unchanged
2) Retention unchanged
3) Spontaneous chemical transformation
4) Enzymatic metabolism
Although each of these fates is of importance, it is the enzyrnatic metabolism of
drugs that predominates, and usualty resuits in Ioss of efflcacy.
The scope of drug metabolism is immense, and this is reflected in the range of
chemicaÏ reaction that are invoÏved in the metaboÏisrn of substrates, incÏuding oxidation,
reduction. hydroÏysis. hydration. conjugation and condensation. TypicaÏly, the process of
drug metabolism is biphasic whereby the compound first undergoes a functionalization
reaction (oxidation, reduction, or hydrolysis), which introduces or uncovers a functional
group, e.g. —OH, -NH2, -SH, suitable for subsequent conjugation with an endogenous
conj ugating agent.
hie main site of metabolism of foreign compounds is considered to be the liver,
although extrahepatic tissues, frequently at the site of entry to or excretion from the body
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(e.g. G! mucosa. lungs, kidney) also play a role in the rnetaboÏism of drugs (Lee, VJ-I.L.
etul., 1990).
An important consideration in the oral absorption of drugs becarne their pre
systemic metabolism since the finding that enzymes in humans are expressed at high levels
in mature enterocytes of the small intestine (Suzuki et cii.. 2000). This level constitutes
approximately 70% of cytochrome P450 (CYP) content in human enterocytes, while in the
liver it is only 30% of total hurnan hepatic CYP content. It bas been estimated that an orally
administered peptide or protein, during the passage across the GI tract, might encounter 40
different peptidase enzymes contained in the secretions of the stomacli and pancrease,
bound to the brush-border, and contained in the cytosol of the epithelial ceil along with the
degradative enzyme systems of tbe lysosome. Table 1.2. summarizes the typical peptidases
in the GI tract (adapted from references (Tobey et al., 1985; Guan et aï., 198$; Mackay et
aï., 1997):
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Table 1.2. Typical peptidases in the gastrointestinal tract.
f Type Enzyme Site of action
Endopeptidase Pepsin Stomach
Trypsin Pancreas
A-Chyrnotiypsin Pancreas
Elastase Pancreas
Endopeptidase-24. 1 1 Brush-border
Endopeptidase-24. 1$ Brush-border
Endopeptidase-3 Brush-border
Enteropeptidase Brush-border
Exopeptidase Aminopeptidase N Brush-border
NH2 terminus Arninopeptidase A Brush-border
Arninopeptidase P Brush-border
Aminopeptidase Brush-border
Dipeptidylpeptidase IV Brush-border
y-Glutamyltranspeptidase Brush-border
Exopeptidase Carboxypeptidase A Pancreas
COOH terminus Carboxypeptidase B Pancreas
Angiotensin-converting enzyme Brush-border
Carboxypeptidase P Brush-border
Carboxypeptidase M Brush-border
y-Glutarnyl Carboxypeptidase Brush-border
Exopeptidase Microsomal dipeptidase Brush-border
dipeptidase
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1.2.2. P-glycoprotein efflux pump
In humans, two members of the P-glycoprotein (P-gp) gene farnily (MDR1 and
MDR2) exist (Gottesman et aï., 1993). The P-gp encoded by human MDRY functions as a
drug efflux transporter, whiÏe hurnan MDR3 P-gp is believed to be functional in
phospholipid transport (van Helvoort et aï., 1996).
While the physiological function of P-gp is stili flot fully understood. the anatomical
localization of the human MDRI P-gp in the brush border region, on the apical surface of
intestinal epithelial ceils (Thiebaut et aï., 1987) suggests that P-gp pÏays an important rote
in the process of absorption. It functions as a biological baiiier by extruding a wide variety
of structurally and chemically unrelated cornpounds (drugs. toxic substances, xenobiotics,
...) out ofepithelial celis (Chin et aï., 1993).
furtherrnore, given that P-gp is located within the intestinal epithelium with the
major phase I metabolizing enzyme CYP 3A and the large number of substrates and
inhibitors they have in common (Wacher et aï.. 1 998). it has been proposed Ihat these
bioavailabitity-limiting processes can act in a cornplementaiy and synergistic marmer to
reduce systemic drug exposure (Tran et al., 2002).
1.2.3. Mechanisms of transepithelïal transport
A molecule can he transported across the intestinal epithelium via two routes, either
between adjacent ceils - termed paracellular pathway, or through adjacent celis - termed
transcellular pathway. Furthermore, the movement across the epithelium can occur in both
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directions: that is, apical (AP) to basolateral (BL) (movement from the intestinal ]umen
to the underlying tissue and circulation) and BL to A? (from the tissue out into the lumen
through the P-gp efflux pathway).
1.2.3.1. Parace!!ttlarpat!, way
Intestinal epithelial celis differentiate by polarizing into an A? and a BL domain and
by forming junctional complexes” between the cells (as stated in section
1 .1 .Morphological barriers). These junctional complexes regulate the paracellular transport
and contribute to the function of the transepithelial permeability bairier (Cereijido et al..
2000; Tang et al., 2003). In healthy intestinal epithelium, transport through the paracellular
pathway is minimal due to the presence of the tight junctions. Only small hydrophilic drug
molecules are allowed to pass through the paracellular route (Hayashi et aÏ., 1999). which
is the aqueous route that norrnally absorbs nutrients, vitamins, etc (Guy et aÏ., 2001;
Bronner. 2003).
1.2.3.2. Transcelliziar path way
Lipophilic drug molecules are transported across the intestinal epithelium through a
transcellular pathway, which can take place via either a passive rnechanism, or a specific
carrier system.
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A) Passive transcellular transport
For passive flux of a molecule to occur, the drug must have the correct
physicochemical properties (e.g. size, charge, lipophilicity, hydrogen bonding potential,
solution conformation) to cross both the apical and basolateral membranes, which are
lipophilic, and diffuse through the cytoplasm, an aqueous environrnent separating the two
membranes (Lee, V. H. et aï., 1989).
However, the epithelial celi is limited in its ability to exert a control over
transcellular passive absorption. Passive diffusion is modeled by fick’s law of diffusion.
which states that ‘the rate of diffusion is proportionat te the concentration gradient”
(Equation 1):
J = Equation(1)
where J is the rate of diffusion, D is the diffusion coefficient. AC is the
concentration gradient and h is the celi membrane thickness.
Meanwhile, it is thought that for conventional drug molecules, a strong correlation
exists between the partition coefficient and absorption. The partition coefficient measures
the relative lipophilicity of a molecule and has long been recognized as one of the major
determinants in membrane permeabiÏity of drugs. Most orally administered arnphipathic
drugs are absorbed through the passive pathway, by partitioning into and out of the ce!!
membrane !ipid bilayer (Walker, 1981).
However. compounds that are absorbed by the passive transcellular route may be
substrates for the apically polarized P-gp efflux mechanism (Hunter et al., 1997).
B) Carrier-mediated ccli uptake
A drug designed for delivery must either be small enough to diffuse paracellularly.
or lipophilic enough to pass through the celi. Compounds may also be absorbed
transcellularly by utilizing naturally occurring carriers that wiIl transport them from the
lumen into the celi. Intemalization occurs within minutes, and the rate of uptake is rnany
orders of magnitude higher than would be expected from bulk phase uptake or pinoeytosis
(Feger et al., 1994: $waan, 199$). for example, L-dopa and oral cephalosporins (Dantzig et
aÏ., 1990) are absorbed by amino aeid and dipeptide transporters, respectively.
In general, maeromolecules absorbed through random pinocytosis into intestinal
epithelial cells are catabolized in lysosomes and multivesieular bodies. A select group of
macromolecules, however, readily moves across the transcellular barrier presented by
intestinal epithelia. These molecules are too large to easily slip through facilitated transport
pathways and too constrained therrnodynamically to readily unfold and refold in a fashion
that rnight make traversing a lipid bilayer possible. Instead, they move through an efficient.
tightly regulated transport pathway known as “receptor-rnediated endocytosis” (feger et al.,
1994). Epidermal growth factor. immunoglobulins (e.g. thyroglobulin, IgA and IgG
(Mostov, 1994)), transferrin (Mazurier et aL, 1985) and the vitamin B12—intrinsic protein
complex (Seetharam, 1999) enter the intestinal celis by receptor-mediated endocylosis via
specific receptors. for epithelial ceils involved in endocytosis, the apical and basolateral
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membranes undergo continuous endocytosis. During receptor-mediated endocytosis, the
binding of receptor to ligand triggers the complex to be endocytosed from the ceil surface
into a coated pit. During this process, the endocytosed material is transported across the ccli
as follows:
-
Specific receptors on the apical membrane recognize and bind to a select set of
macromolecular ligands
-
The complex is then endocytosed and transported to endosornes via coated vesicles.
-
Ion channeis and transporters in the vesicle membrane act to drop the intra
endosome pH to approxirnately 5.5 while maintaining proper osmotic balance and
surface charge
- Most ligands are dissociated from their receptors by the low pH encountered in the
endosome and then transported across the cdl in a membrane vesicie.
In this fashion, the endocytosed material is somehow shuttled across the ccli away
from lysosomal attack and is eventually released from the ccli b)’ exocytosis.
A common feature of any of the endocytosis mechanisms described above is that
there is a high degree of specificity in the transport process. Thus celis lacking the specific
receptor or ligand are incapable ofendocytosis ofthe material or oftranscytosis.
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a) e.g. Absorption of Vitamin 312 in the small intestine following receptor
mediated endocytosis
The uptake of nutrients from the intestine occurs via a variety of mechanisms. Most
fat soluble motecules, such as vitamins A, D, E and K, are generally soïubilized in mixed
micelles (consisting of bile saits, phospholipids. monoglycerides, and fatty acids) from
which they are subsequently absorbed (Basu et aï., 2003; Borel, P., 2003; Li, E. et aL.
2003). The small water-soluble vitamins, such as vitamin C. thiarnine. nicotinic acid,
riboflavin, pyridoxine, biotin, folic acid and pantothenic acid, are mainly absorbed by
facilitated diffusion (foraker et aï.. 2003: Nabokina et al., 2004b; Subramanian et cii.. 2004;
Nabokina et al., 2004a; Crisp et al., 2004; Said, 2004). Amino acids, on the other hand are
absorbed by active transport, with separate transport systems for basic, neutral and imino
acids (Webb, 1990: Yang et aL. 1999; Daniel. 2004). Dietaty sugars are absorbed by
energy-dependent transport through smaÏl pores located on the epithelial membrane of the
enterocyte (Levin, 1994; Wright et al., 2003).
In contrast to the vitamins mentioned above, vitarnin B17 (VB17, cobalamin, Cbl) is
a large, water-soluble molecule (Mw 1356 Da) (figure 1.2.) and cannot pelTneate the
intestinal barrier through simple diffusion, facilitated diffusion or active transport. Its
absorption occurs tbrough a markedly different rnechanism to that of the other vitarnins,
involving a number of transport proteins. During the process of absorption. VB12 must first
be released from food substances by the action of pepsin in the stomach. The vitarnin is
then complexed to haptocorrin (Hc). a specific binding protein secreted in saliva. which is
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thought to protect the VB17 from degradation in the acid environrnent of the stornach.
The [VB12-Hc] complex leaves the stomach and enters the duodenum where the Hc is
degraded by the action of trypsin and chymotiypsin. Intrinsic Factor (IF), a VB12-binding
protein, subsequently binds to VB12, forming an {IF-V312] compÏex. The complex is in turn
bound to an IF receptor (1FR) located on the surface of intestinal epithelial celis. The
[V312-IF-IFRI complex is then intemalized by the enterocyte via receptor-.mediated
endocytosis. Once inside the celi, the V812 is released from IF foïtowing the action of
cathepsin L on IF. The released VB12 is bound to another VB12 binding protein,
Transcobalamin II (TcII), which completes the process of transcytosis of the VB12 and the
VB12-TcII complex enters the circulation (Dix et al., 1987; Dix et al., 1990; Seethararn,
1999; Okuda, 1999; Brada et al., 2001).
Several studies have shown that Vitamin B12 is capable of shuttling peptides and
proteins across the intestinal epithelia (from the apical to basal surfaces). when these
molecules are covalently linked to VB12 (Habberfield et aï., 1996b; Alsenz et al., 2000;
Russell-Jones, 2004). For example, Russell-Jones and co-workers observed a potential
increase in the oral uptake of luteinizing hormone releasing hormone (LHRH) analogues
(Russeil-Jones et al., 1995a). u-interferon, erythropoietin (EPO) (Habberfield et ctl., 1996a)
and granulocyte colony-stimulating factor (G-CSF) (Russell-Jones et aï., 1995b) which
have been covalently linked to the VB12 molecule.
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Figure 1.2. Structure ofVitamin B12 (VB12).
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1.3. Pilysico-CHEMIcAL BARRIERS
1.3.1. pH variation
According to the location in the GI tract, the pH value varies widely, as shown in
Table 1.1. Typical values in the fasted stomach are pH 1-2, while in the upper srnall
intestine the pH usually lies between 5.5 and 6.5.
Additionally, there are complex variations in pi-I between the fasted and fed state
(f igure 1.3). Upon ingestion of a meal, the gastric pH at first increases because of buffering
effects of food components. In response to food ingestion, however, gastric acid is secreted,
and by 3—4 h after the meal intake, the fasted state pH has usually been reestablished (A)
(Malagelada et al., 1976). In the srnall intestine, pH at first decreases in response to a meal
with the arrivai of acidic chyme from the stornach, but later the fasted state pH is
reestablished as a result ofpancreatic bicarbonate output (3) (Malagelada et cd., 1976).
Note that the pH of the lumenal fluids is also dependent on other factors like age,
pathophysiological conditions such as achlorhydria and AIDS, and concurrent drug therapy
such as H2-receptor antagonists and proton pump inhibitors. In the case of poorly soluble
weak bases, especially the irnidazole antifungals, ketoconazole and itraconazole., elevated
gastric pH in AIDS patients leads to a reduced rate of drug dissolution and consequently to
rnalabsorption(Lake-Bakaar et aï., 198$; Zimmermann et aï., 1994).
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Figure 1.3. (A) Gastric pH and (B) duodenal pH in the fasted state and afier food intake
in 10 healthy voÏunteers (adapted from Malagelada. 976).
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1.3.2. Charge state
Drug substances consisting of weak acids and bases ionize in solutions to varying
extent, depending on pH (Cleveland et al., 1993: Avdeef et al., 2001). This in tum affects
the solubility and bioavailability of the drug. The characteristic thermodynamic parameter
relating the pH to the charge state of a molecule is the ionization constant, pKa (Cleveland
et al., 1993; Avdeef et aï., 2001). A widely used rule ofthumb is that 50% ofthe compound
will be in the ionized statc and 50% in the ncutral state when the pH equals the pKa. As the
pH goes down, the ratio (ionized form/unionized form) increases for basic moieties, and
decreases for acidic ones (Avdeef 1993).
Cornpounds have an intrinsic soÏubility in the unionized forrn and solubility is
typically much grcater in the ionized form. Because cornpounds are permeable in the
unionized form, there is a dynarnic balance between solubility and permeability throughout
the pH gradient ofthe GI tract that affects absorption (Martinez et aÏ.. 2002).
On the one hand, poorly soluble weak acids with pKa values less than 6. e.g.
furosemide with PKa 3.9 and indomethacin With pKa 4.5 (Martindale. 1982). are relatively
insoluble in the preprandial gastric juice and dissolution occurs first in the upper srnaÏl
intestine. In the case of very weak acids, e.g. paracetarnol with pKa 9.5 and
hydrochiorothiazide with pKa 8.8 (Martindale. 1982: Deppeler. 1 981), the variations in pH
in the GI tract are irrelevant to the solubility because these compounds are always in the
free acid form over the physiological pH range.
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On the other hand, weak bases like itraconazole With pKa 3.7 (Zirnme1flairn et
aÏ., 1994) and dipyridamole with pKa 6.4 (Martindale, 1982), will be less soluble in the
stomach if given immediately afier food intake because the gastric fluid is less acidic. By
contrast, the solubility of fluconazole,a weak base with a pKa of 1.5, is sufficientiy high (6
mg/ml. dose:solubility ratio about 17 ml) that its administration to patients with elevated
gastric pH does flot lead to dissolution rate limited absorption (Blum et aÏ., 1991).
Knowledge of the PKa of a drug substance can also be used in optimizing chemical
reaction or synthesis yields. For example, solvent extraction can be best applied in a pH
region where the synthesized molecule is uncharged. Furthermore. knowledge of pKa S
useful to predict the absorption, distribution, and elimination of a drug following oral
administration. For example, urine pH (normally 5.7 5.8) can be altered (with oral doses
of NH4C1 or NaHCO3) to satisfy reabsorption of uncharged species to increase therapeutic
efficacy, or to ease excretion of ionized species in toxicological emergencies (Kems, 2001).
1.3.3. Particle size
An important factor determining the dissolution rate is the particle size ofthe dnig.
The dissolution rate is directly proportional to the surface area of the drug, which in turn
increases with decreasing particle size. The rate of dissolution of a drug is the rate lirniting
step for its absorption and thus controls its pharmacological action pattern (Horter et aï.,
2001). Micronization to particle sizes of about 3 — 5 tm is often a successful strategy for
enhancing the dissolution rate of a drug.
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The effective surface area also depends on the abitity of the fluid to wet the
particle surface. When the dissolution medium has only poor wetting properties,
micronization sometimes resuits in a decreased dissolution rate due to aggiomeration, as
reported by Finhoit for Phenobarbital (Solvang et aï., 1970).
The particle size is also an important parameter in determining sedimentation rates
in biphasic formulations (e.g. suspensions and emulsions), since the particle size of the
disperse phase is inversely proportional to the sedimentation rate.
1.3A. Solubility
The aqueous solubility of a drug is a key determinant of its dissolution rate and,
consequently, its oral bioavailability. Therefore, the solubility behaviour of a drug rernains
one of the most challenging aspects in formulation development.
The Nernst-Bruirner and Levicli modification of the Noyes-Whitney equation
(Equation 4) identified the important factors to the kinetics of in vivo drug dissolution.
these factors include drug diffusivity and solubility in the GI contents, the surface area of
the solid wetted by the tumenal fluids and the GI hydrodynarnics (Dressrnan, J,B. et aï.,
199$).
dC Ce-C
= AD Equation (4)
Ut h
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where dC7dt is the dissolution rate, A is the surface area available for dissolution.
D is the diffusion coefficient of the drug, Cs is the saturation solubility of the drug in the
dissolution medium, C is the concentration of drug in the medium at time t. and h is the
thickness ofthe diffusion boundaiy layer adjacent to the surface of dissolving drug.
Several physicochemical and physiological aspects can have a great influence on the
factors in Equation 4 and therefore on the dissolution rate, such as crystalline form, drug
lipophilicity, particle size. viscosity of the medium, solubilization by native surfactants and
co-ingested foodstuffs, and pKa in relation to the GI pH profile (Horter et aÏ., 2001).
1.3.4.1. The Biopharmaceutics Ctassfication Systent
In the past decade, a greater understanding of the molecular transport in relation to
physico-chemical properties (especially solubility) bas lcd to the evolution of a
biopharrnaceutics classification system (BCS), which is becoming a road rnap govcrning
future drug design, development and delivery (Amidon et aï., 1995).
The BCS sets the criteria for allowing a drug substance, in an immediae release
form, to circumvent a Bioequivalence study. It classifies the drugs into four major
categories (Table 1.3.) according to two main parameters: the solubility and perrneability
behaviours of each molecule (Lobenberg et aÏ., 2000; Zhao et aL. 2002).
28
Table 1.3. Biopharmaceutics Classification System (BCS) of drug molecules.
Biopharmaceutics Classification System
(1) High solubility — High permeability a (II) Low solubility — High permeahility h
(III) High solubili — Low permeability C 1 (EV)Low soÏubility — Low perrneability d
aExhibit dissolution rate-lirnited absorption (generally very welÏ absorbed)
bExil ibit solubil ity rate-Iimited absorption
cExilibit permeabi I ity rate-I irnited absorption
dExhibit both, solubility and perrneability rate-Iimited absorption with very poor oral bioavailability
Recognizing a need to demonstrate the bioequivalence of drug substances in
immediate release (IR) dosage forms, without performing the traditional bioequivalence
study. the United States Food and Drug Administration (fDA) has issued a set of
guidelines outiining what is now known as the BCS. According to the FDA guidance for
industry (FDA, 2000), the two individual parameters of classification are evaluated as
follows:
A) Solubility. The solubility class boundaiy is based on the highest dose strength of
an immediate release tIR) product that is subject of a biowaiver
request. The solubility scale is defined in terms ofthe volume (ml) of
water required to dissolve the highest dose strength at the lowest
solubility in the pH range 1.0 — 7.5 at 37°C, with 250 ml being the
dividing line between “high” and “low” aqueous solubility. The
volume estimate of 250 ml is derived from typical bioequivalence
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volume estirnate of 250 ml is derived from typical bioequivalence
study protocols that prescribe administration of a drug product to
fasting buman volunteers with a glass (about 8 ounces) of water. A
drug substance is considered highly soluble when the highest dose
strength is soluble in 250 ml or less of aqueous media over the
specified pH range and temperature (i.e. dose/solubility (D 5) ratio <
250 ml).
B) Permeability. The perrneability class boundaiy is based indirectly on the extent of
absorption (fraction of dose absorbed, not systemic bioavailabiÏity) of
a drug substance in humans, and directïy on measurements of the rate
of mass transfer across hurnan intestinal membrane. Alternatively,
non-human systems capable of predicting the extent of drug
absorption in humans can be used (e.g., in vitro epithelial cdl culture
models) (fDA, 2000). To date, computational methods (e.g. based on
polar surface area of the molecule) have not been accepted by the
fDA as sufficiently reliable for this purpose. Perrneability refers to
human jejunal values, with “high” being above J 0 cm/s. and low”
being below that value. The high permeability class boundaiy is
intended to identify drugs that exhibit nearly complete absorption
(90% or more of an adrninistered oral dose) from the small intestine,
based on a mass determination or in comparison to an in[ravenous
Jreference dose, in the absence of evidence suggesting instability in
the GI tract.
The FDA’s proposed biowaivers for in vivo bioavailability and bioequivalence
testing (fDA. 2000) will dramatically reduce a pharmaceutical companys research and
development (R&D) costs.
To be considered for a Biowaiver, the drug substance must 5e classified as being
highly soluble, highly permeable, and having a new formulation with a sirnilar dissolution
profile to the original (Yu, L.X. et aÏ., 2002). The FDA is accepting in vitro data for the
solubility and permeability components ofthe BCS.
Examples of molecules from the various four classes are presented in Table 1 .4.
According to the BCS, the dissolution rate is the limiting factor for the absorption of class
II and IV drugs. Currently, 40% of the NCE fall in these two classes. Such molecules
provide potential challenges to the formulation scientist. Their poor water solubility almost
inevitably leads to Iow oral bioavailability from conventional dose forms.
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1.3.4.2. Poorly-water soluble drugs
Poor aqueous solubility is an industry wide issue, especially for pharmaceutical
scientists in drug discovery and drtig development. A poorly water soluble drug is usually
associated with poor absorption and bioavailability upon oral administration (Lipinski et
aÏ., 2001). Although a certain degree of hydrophobicity is necessary fora drug molecule to
cross the celi membrane easily (Charman et aï., 1991). the overaïl rate of absorption is
dictated by the time required for the dosage fonri to release its contents, and for the drug to
dissolve in the GI fluid (Lipinski, 2000).
The water solubility of poorly soluble’ drugs is usually less than 100 jig/ml
(Fasano, 1998). A further parameter useftil for identifying poorly soluble’ drugs is the
dose:solubility ratio of the drug. The dose:solubility ratio is defined as the volume of GI
fluids necessary to dissolve the administered dose. When this volume exceeds the volume
of fluids available, one may anticipate incomplete bioavailability from solid oral dosage
fonris. Griseofulvin provides a classic illustration of the utility of the dose:solubility ratio.
With an aqueous solubility of 15 1g/ml at 37°C and a dose of 500 mg, griseoftïivin bas a
dose:solubility ratio of about 33 liters (Katchen et al., 1967). Thus the combination of its
poor solubility and high dose constitutes a severe limitation to its oral bioavailability.
During the past decade, drarnatic progress in the field ofbiotechnology lias resulted
in a sharp increase in the number of NCE. Through rational drug design, synthetic
medicinal chernists have prepared new specific drugs with enormous therapeutic potential
-‘-3
drzig design does not necessarily mean rationaÏ drttg de/iveiy, which strives to
incorporate into a molecule the molecular properties for optimal transfer between the point
of administration and the first target site in the body. Clinical requirement for such
molecules in order to have a therapeutic response in humans is that it has to be dosed more
than 20 mg/kg/day. Because of the poor physicochemical and biopharmaceutical Iroperties
of such molecules, their formulation for oral delivery represents one of the most frequent
and greatest challenges to formulation scientists in the pharmaceutical industry. As a resuit,
these drugs are commonly adrninistered by injection (intravenous, subcutaneous, or
intramuscular). However, parenteral drug administration, generally accepted by
hospitalized patients. when conducted in an out-patient setting ofien resuits in
noncompliance duc to inconvenience and patient discomfort. In the case of therapeutic
indications, such as HIV and cancer, it is more important to cure the disease or extend life
than the compliance. For such diseases, it can be possible to have a very high dose oral
formuLation. However, for diseases such as arthritis, diabetes and hypertension. it is very
important to have a low dose formulation because it lias to be taken everyday in a long-term
therapy.
Therefore, it is important that formulation scientists coordinate with the medicinal
chemists for a thorough understanding of the pharmacological, biopharmaceutical and
preformulation behaviour ofa NCE before it enters into the development phase.
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1.3.4.3. A case stitdy: CYcL0sP0RIÏVA
Chemically, the CsA molecule is designated as [R_[R*,R*(E)]]cyc1ic [(L-alany))
(D-alanyl)-(N-methyl-L-leucyl)-(N-rnethyl-L-1eucyl)-(N-methyl-L-valyl)-(3-hydroxy-N,4-
dimethyl-L-2-amino-6-octenoyl)-(L-(alpha)-arnino-butyryl)-(N-rnethylglycyl)-(N-rnethyl-
L-leucyl)-(L-valyl)-(N-methyl-L- leucyl)] with a molecular weight of 1202 g/mol (Wenger,
1983). This structure is rich in hydrophobic amino acids linked via 11 amide bonds (Figure
1.4.). seven of which are N-rnethylated, contributing to the extreme hydrophobicity
associated with the peptide. CsA is naturally produced as a metabolite by the fungi species
cytindrocarpon tucidtnn Booth and tolvpocÏadiuin inflattim Gains (Borel, J.f. et al., 1977;
Bore!, J.f. et aÏ., 1976). Although CsA is practically insoluble in water (its aqueous
solubility is as !ow as 23 tg/rn1 at 20°C), it is soluble in many organic so!vents such as
ethanol, methanol, acetonitrile, etc. With regard to the cunent ru!es of the US Food and
Dmgs Administration (fDA), CsA should be produced with a purity >98.5% (United States
Pharrnacopeia, 1995)
jH3C\
HC\
CH2
HIHO 10H —CH3
MeVal —N _CH — —Abu—MeGIy
MeIeu
0H3 O MeLeu
MeLeu
—D-Ala —AIa—MeLeu —Val
C62H111N11012
MW = J 202.63 glmol
Figure 1.4. Structure of Cyclosporin A, a cyclic undecapeptide, showing 11 arnino
acids.
Clinically, CsA is commonly used as immunosuppressant to prevent allografi
rejection in various allogenic transplantations involving kidney, liver. heart, skin. lung.
small intestine and pancreas (Merion et aÏ., 1984), as well as for prophylaxis of grafi
versus-host disease in patients who undergo bone-marrow transplantation (Powies et cil.,
1978). The drug has also been shown to be effective in the treatment of systemic and local
autoimmune disorders such as Freund’s adjuvant arthritis, psoriasis, and so forth (Borel, J.F.
et aï., 1986; Richardson et al., 1995: Galla et ai. 1995).
The exact mechanism of action of CsA is flot fully known (Bord, J.F. et aï., 1983).
Experimental evidence suggests that the effectiveness of CsA is due to specific and
reversible inhibition of immunocompetent lymphocytes (White et aÏ.. 1979; Kahan. 1 982),
which play a central roÏe in the induction of immune responsiveness. The 1-helper ceils
(producing interleukin-2 (IL-2) foïlowing antigenic stimulation) are the main target. CsA is
internalized in the cytoplasm, where it binds to a protein termed cyclophilin
(Handschumacher et aÏ.. 1984). The CsA-cyclophilin complex is transported into the ccli
nucleus, where it interacts with specific sites on the chromosome (figure 1.5). This process
interferes with the transcription of messenger ribonucleic acid (mRNA) encoding for IL-2
(Elliott et aÏ., 1984) (this might be the crucial CsA-sensitive step, because addition ofthe
drug beyond this stage, i.e. 2-4 h affer stimulation. remains ineffective). As a consequence,
the translation of mRNA and subsequent synthesis and release of IL-2 are inhibited (Bunjes
et ut., 1981; Schreier, 1984). The immunosuppressive activity of CsA is thought to be
dependent on the concentration of the drug in the lymptiatic system.
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Figure 1.5. Mechanism of action of Cyclosporin A (Borel. J.f. et al., 1985).
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The therapeutic window of CsA is rather narrow. Consequently, there is a risk of
possible organ rejection because of too low tevels of CsA, while an overdose of CsA may
cause a variety of adverse effects, in particular renal dysfunction and renal structural
changes (Mason, 1990; Skorecki et al., 1992).
Elimination of CsA is primarily biliary witb only 6% of the dose (parent drug and
metabolites) excreted in the urine (Wood et aÏ., 1983). Neither dialysis nor renal failure
alters CsA clearance significantly (Hamwi et aÏ., 2000). 0f 15 metabolites characterized in
human urine. 9 have been assigned structures (Loor et al., 2004). The major pathways
consist of hydroxylation of the C(gamma)-carbon of 2 of the leucine residues. C(eta)
carbon hydroxylation, and cyclic ether formation (with oxidation of the double bond) in the
side chain of the arnino acid 3-hydroxyl- N.4-dimethyl-L-2-amino-6-octenoic acid and N
dernethylation of N-rnethyl leucine residues (Christians et aÏ., 1993). Hydrolysis of the
cyclic peptide chain and/or conjugation of the aforementioned metabolites do not appear to
be important biotransformation pathways (Vine et al., 1987).
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(A) RX NOVARTIS PHARMACEUTICALS RX NOVARTIS
f1iii 78240 .D ug
l.\ 5 mL 250 mg; 0ai So;;;jri . 78•241’ 100 mg
50 mL 100 mg, mL SoU Gelatin Cepsies
Sandîmmune° Sandimmune°
cvckspojne: cvc!osporIne capsules, USP
(B) nx NOVARTIS PHARMACEUTICAL5 RX NOVARTIS PHARMACEUTICALS
• 25 mg
NEcRc
1OOm
100 mg
100 re %1L
50 L
NeoralG Oral Solution Neoral° Soft Gelatin Capsules
c:Qsn:e soiutIon, LSP ‘‘:eJ cot o )e;s. JSP oluJ:e
figure 1.6. Photos showing product samples of (A) Sandimrnune® ampul for
intravenous infusion, oral solution (50 ml) and soft gelatin capsules (25 mg
and 100 mg); and (B) Neoral® oral solution (50 ml) and soft gelatin
capsules (25 mg and 100 mg) (adapted from Thomson Physicians Desk
Reference (PDR), 2004, Montvale, NJ).
40
A) Commercially available intravenous formulation of CsA
CsA is very ofien given to patients during transplantation surgery by intravenous
infusion. Afier the acute operation period, most patients take the drug orally.
A commercially available concentrate for intravenous infusion (Sandirnmune
injection. Novartis Pharma Stem AG, Stem, Switzerland) is avallable in a 5 ml sterile
ampul. Each ml contains: - -
Cyclosporine, USP 50 mg
Cremophor EL 650 mg
Alcohol, Ph. HeÏv 32.9% by volume
Nitrogen qs
The concentrate is to lie diluted 1:20 to 1:100 with normal saline injection (D. 9%
sodium chloride) or 5% dextrose injection before tise.
Although Cremophor’-EL (CrEL, a polyoxyethylated castor ou. BASF
Aktiengesellschaft) is one of the best anionic surfactants used to dissolve lipophilic drugs,
the administration of Sandimmune® injection at high doses bas been associated with
anaphylactic reactions and histamine release due to the high content of CrEL (Howrie et al..
1985; Friedman etal., 1985).
Therefore, there was a need to find an alternative formulation for CsA. Knowing
that oral drug delivery is the prefen-ed route for drug administration, one of the greatest
challenges has been the administration of CsA by the peroral route.
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B) Regional Differences in CsA Absorption from CI tract
CsA lias been extensively studied with respect to its site of absorption in the GI
tract. Sawchuck and Awni (Sawchuck et aï., 1986) demonsti-ated that CsA was absorbed to
a greater extent from the duodenum than from the jejunum in the rabbit when these two
segments were simultaneously perfused with drug solution. Further evidence for the site
dependent CsA absorption cornes from the work of Grevel et al. (Grevel et al., 1986) who
observed a short lag-tirne of 0.38±0.11 h and an abrupt end of absorption at 2.8±1.6 h
following CsA administration in healtliy volunteers. Sucli a short Iag-time and short oral
absorption phase suggested that the absorption of CsA was conflned rnainly to the upper
part of the GI tract (Gupta et aï., 1989). In addition, Ritschel et al. (Ritschel et ai., 1990)
demonstrated 4-8 fold higher peak blood levels from the rat intestine cornpared to the
stornacli, large intestine and rectum for CsA administered in microernulsion.
It should be noted that the clinical use of CsA has historically been complicated by
incomplete and unpredictable absorption from the GI tract due to the presence of an
important ftrst-pass rnetabolism in the intestinal mucosa and in the liver (Maurer et aï.,
1984); (Kolars et aï., 1991). CsA absorption is partly controlled by the metabolizing
enzyme cytocbrome P-450 3A4 (CYP3A4) and the multi-drug transporter p-glycoprotein
(P-gp) in the srnall intestine as well as by hepatic CYP3A4 (Kolars et al., 1991; Fricker et
aI., 1996). CYP3A4 metabolizes the drug into more than 30 metabolites while P-gp pumps
the drug from the enterocyte cytosol out in the intestinal lumen (Tjia et aÏ.. 1991).
Moreover, the relatively high molecular weight of CsA. very high lipophilicity and minute
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solubility in aqueous fluids of the GI tract represent non-negligible absorption limiting
barriers of CsA through the GI mucosa (Gupta et aL, 1989; Ismailos et aÏ.. 1991; Hamwi et
aÏ., 2000). This poor absorption of CsA is one of the main reasons for its low ami variable
absolute bioavailability which increases significantly the risks of both acute and chronic
rejection and diminishes the predictive value of therapeutic drug monitoring (Lindholm,
1991; Lindholm et al., 1988; Schroeder et al., 1995).
C) Commercially available oral formulations ofCsA
Several attempts were made to find an optimal oral formulation of CsA that fulfills
the criteria to increase its bioavailability. An olive ou solution of 100 rng/rnl CsA (olive
oil:peglicol-5-oleate:ethanol 60:30:10) was clinically used as an oral dosage forrn (Ueda
et al., 1984). In view of both the high lipophilic property of CsA and the oily dosage forrn.
it was reasoned that the intestinal lymphatic absorption of CsA would be extensive.
Peglicol-5-oleate could be dispersed in a drink ofthe patient’s choice (milk, fruit juice, etc).
Sandimmune® tNovartis Pharma S.A., Huningue, France) represents marketed oral
commercial formulations (soft gelatin capsules and drink solutions) of CsA in olive ou
solution.
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Sandlmmunt Soft Gelatin Capsules (cyclosporin A capsules, USP) are
available in 25 mg sud 100 mg sfrengths.
Each 25 mg capsule contains:
CyclosporinA,USP 25mg
Àlcohol,USPdehy&ated maxl2.7%byvolume
Each 100 mg capsule contains:
CyclosporinAUSP lOOmg
Alcohol,USPdehydrated maxl2.7%byvolume
Inactive lngndknb: com ou, gelatin, glycerol, Labrafil M
2125 CS (polyoxyethylated glycolysed glycerides), red fron
oxide (25 mg anti 100 mg capsule only). sorbiol, titanium
dioxide, anti other ingredients.
Sandimmune Ont Solution (cyclosporin-A oral solution, USP) is available in 50
ml boules. Each ml coflins:
(Dyclosporin i%., USP 100 nig
Alcohol,PKHelv 12.5%byvolume
dissolved in an olive oui, Ph. HeW/Labrqfll M 1944 CS
(polyoxyethylated olek glycerldes) vehicle which must be
flirther diluted wfth milk chocolate milk or orange Juice
before oral administration.
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$andirnmune® oral formulations showed large inter- and intraindividual
variations of CsA pharmacokinetics. One of the major factors is an erratic absorption of the
drug from the gut (effect of food, bile, etc) (Lindholm et aï., 198$; Muetier et al., 1994).
furthermore. the clinical use of Sandimmun&’ was somehow Iirnited by the occurrence of
adverse events, most frequent of which are renal dysftmction, hypertension and
hepatotoxicity (Skorecki et al., 1992; Lorber et al., 1987). It should be noted that the peak
concentrations (Crnax) in blood and plasma are achieved at about 3.5 hours following
Sandimrnune® administration.
The most recent formulation of CsA (Neoral, Novartis Pharma S.A.. Iluningue,
France) promises to alleviate some of the difficulties in CsA absorption by using the
microernulsion technology to ensure uniform drug dispersion within the ahsorptive region
of the intestinal lumen (Canadian Neoral Renal Transplantation Group, 1997: Dunn et aï.,
1997). Microemulsions are bicontinuous systems that are essentially cornposed of bulk
phases of water and ou separated by a surfactant/co-surfactant-rich interfacial region. These
systems have an advantage over “conventional emulsions” in that Iiiey are
therrnodynamically stable llquid systems and are spontaneously self-forming in water with
droplet size of 100 - 200 nm (Kawakarni et cii.. 2002).
The Neoral® oral formulations consist of dispersing the drug in a mixture of
propylene glycol (hydrophil ic solvent) and com oil-mono-di-triglycerides (lypophilic
solvent) by stirring. Once dispersed, polyoxyl 40 hydrogenated castor ou (surfactant) and
an antioxidant (DL-(alpha)-tocopherol) are added (Levy et aï.. 1994). This oil-in-water
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(0/W) microemulsion preconcentrate spontaneously forms in water a homogeneous,
macroscopically transparent and thermodynamically stable monophasic solution of CsA
(Vonderscher et aÏ., 1994).
Neoral® Soft Gelatin Capsules (cyclosporin-A capsules, USP) are available in 25
mg and 100 mg strengths.
Each 25 mg capsule contains:
Cyclosporin A 25 mg
Alcohol, USP dehydrated 11.9% v/v (9.5% w/v)
Each 100 mg capsule contains:
Cyclosporin A 100 mg
Alcohol, USP dehydrated 11.9% v/v (9.5% w/v)
hwctive htgredients: Corn oil-mono-di-trigÏycerides, polyoxyl
40 hydrogenated castor ou Nf, DL-(alpha)-tocopherol USP,
gelatin NF, glycerol, iron oxide black, propylene glycol USP,
titanium dioxide USP, carmine, and other ingredients.
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Neoral® Oral Solution (cyclosporin-A oral solution, USP) is available in 50 ml
botties. Each ml contains:
Cyclosponn A 100 mg/rnl
Alcohol, USP dehydrated 11.9% v/v (9.5% w/v)
Inactive Iitgredients: Corn oil-mono-di-triglycerides, polyoxyl
40 hydrogenated castor ou NF, DL-(atpha)-tocopherol USP,
propylene glycol USP.
This formulation restilted in enhanced bioavailability in comparison to
Sandimmune® oral formulations (Sketris et al., 1994); relative independence from the
effects of food, bile flow, and gastrointestinal dysfunction; which reduced inter-and
intraindividual variability ofexposure (Kahan et aï., 1995; Kovarik et al., 1994). It is for
this reason that Neoral® is adrninistered orally from the day of surgeiy and it is now the
preferred formulation of CsA for patients undergoing solid organ and bone marrow
transplantation. Another advantage of Neoral is that the time to peak blood CsA
concentrations (Imax) ranged from 1.5-2.0 hours following oral administration. It has been
shown however that kidney damage, characterized by serial deterioration in renal fiinction
and morphologic changes in the kidneys, us a potential consequence of Neoral’ (Maeda et
al., 2002) and therefore renal function must be monitored during therapy (Canadian NeoraÏ
Renal Transplantation Study Group, 2001).
47
1.3.4.4. General approaches ttsed to intprove tite solubility/dissoltttion of poorly
soluble drugsfor oral administration
As the physiological barriers cannot be changed, ail the focus has been directed
towards trying to disguise the drug molecule in order to deliver it to the systemic
circulation across the intestinal barrier. There are a number of techniques used tc improve
the dissolution/soiubiiity and hence oral bioavailabil ity of poorly soluble drugs inc 1 uding:
A) Chemicai modifications ofdrug molecule (prodrug approach, sait synthesis, etc)
B) Physical modifications of drug molecule (particle size reduction. change in
physical forrn. etc)
C) Drug-loading in carrier systems (liposomes, emuisions, microernulsions,
polymer-based nano- and microparticles. and polymeric micelles)
A) Chemical modifications
Arnong the various approaches to minimize the undesirable drug properlies while
retaining the desirabie therapeutic activity, the chemical approaches using drug
derivatization offer a high flexibiiity and have been demonstrated as an important means of
improving drug efficacy.
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a) Prodrug approach
The prodrug approach gained attention as a technique for improving drug therapy in
the early I 970s. Nurnerous prodrugs have been designed and developed since then to
overcorne pharmaceutical and pharmacokinetic barriers in oral drug absorption (Fleisher et
aL. 1985; friedrichsen et al., 2001; Schoffski. 2004).
The term ‘tprodrug” was first introduced by Albert (Albert, I 95$) to signify
pharmacologically inactive chemical derivatives that can be converted in vivo to the active
parent drug molecules, enzymatically or nonenzymatically, to exert a therapeutic effect.
Ideally, the prodrug should be converted to the original drug as soon as the goal is reached.
followed by the subsequent rapid elimination of the released derivatizing group (Stella ct
al., 1985).
Since Albert discussed the concept of prodrugs in the late 1950s, such cornpounds
have also been called “latentiated dmgs” (Harper. 1962) and “bioreversible derivatives”
(Sinkula et aI., 1975). but “prodrug” is now the most commonly accepted term.
Usually, the use of the terni implies a covalent link between a drug and a chemical
moiety. Therefore. it is very important that the NCE has a functional group(s) that allows
conversion to a prodrug. Ihe second important criterion is that the human body should have
an enzyme or sorne other mechanism to cleave this molecule into the active entity once it is
absorbed into the blood. When both these phenomena occur, then it is possible to use this
approach flot only to increase the solubility/dissolution of a therapeutic agent but its
permeability too (Notari, 1981; Stella et al., 1985; Choi et cii., 2004). Another advantage,
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cspecially with non steroidal anti-inflammatoiy drugs cNSAID), is to reduce gastric
irritation. Many of the NSAID are either strong or weak acids and they cause gastric
irritation upon oral administration. By synthesizing ester prodrugs, this irritation bas been
significantly reduced (Bansal et ai.. 2001; Jung et aL. 2003; Larsen et aÏ., 2004). Rowever,
in some cases, the interindividual differences in metabolism and drug-food interactions may
cause problems.
Dalacin® C flavoured granules, an antibacteriai agent (Pharmacia & Upjohn Co.) is
an example of a poorly soluble drug (Clindarnycin, solubility 0.2 mg/ml) cornmercially
available in the form ofa water soluble prodrug (Clindamycin Palmitate HCI. soiubiÏity 150
rng/ml) for oral administration (CPS, 2004).
b) Sait synthesis
Ibis is the most widely used approach to increase solubility of weakly acidic or
basic NCE (Gould, 1986; Gu et ai., 1987; Ware et aL, 2004). If the NCE bas ionizable
group(s), then it is very likely that it will form a sait. The solubility of sait is typically based
on the counter ion. Selection of sait is based on many parameters such as solubility,
hygroscopicity and stability of the physical form. The most important requirernent is tbat
the counter ion should be fDA approved, if not one shouid have enough toxicological data
to support the selection ofthe counter ion.
When administered as a sait, the dissolution and hence the bioavailability’ of many
NCE increase up to a great extent, compared to their weak acid/base form. Table 1.5.
50
represents a few examples of cornrnercially available saits along with their aqueous
solubilities.
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B) Physical modifications
a) Particle size reduction
As described by the modified Noycs-Whitney mode! of dissolution (Equation 4., see
section 1.3.4. Solubility), surface area of the drug is directly proportional to its rate of
dissolution.
Reduction in particle size is an old approach to increase the surface area and hence
the dissolution rate and bioavaiiabiiity of poorly soluble drugs. Several techniques are used
for reduction in particle size such as jet miii, fluid energy miii and bail mil! (Chaurneil,
199$). compressed or supercritical C02 solvent (Gosselin et ctl., 2003a; Gosselin et aï.,
2003b), spray drying (Kawashima et al., 1975; Takeuchi et al., 1987; Ahn et al., 199$),
spray freezing (Rogers et aï., 2002; Rogers et al., 2003), etc. Figure 1.7. shows the increase
in specific surface area and dissolution of a poorly water soluble drug Collowing
micronization (Rasenack et aï., 2003).
Beside the advantage of increased dissolution rate of micronized drugs. severai
disadvantages resulting from the preparation process exist. Handling particles in sub
micron size is difficuit, and chances of airbonie contamination and serious toxicity by
inhaiation are ver)’ high (Merisko-Liversidge et cii.. 2003: Ru et ai., 2004).
C,,3-,
Figure 1.7. (A) specific surface area and (B) amount dissolved (%) of the new drug
substance ECU-01, a poorly water soluble enzyme-inhibitor with anti
inflammatoiy properties for oral administration. ECU-01 is a heterocyclic
derivate of a 3,5-dichioro-pyridine (adapted from Rasenack N. et aÏ., 2003).
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b) Change in physical form
The majority of drugs marketed in the past decades have been isolated and delivered
to the human body in their crystalline state (Bym et al., 1994). In most instances, this state
represents the lowest energy form of the drug, and the one having the greatest phvsical and
chemical stability (Yu, L.X. et al., 2003). However, amorphous forms are of substantial
intel-est because they usually are much more soluble than their crystalline counterparts
(Hancock et al., 2000; Yu, L, 2001).
Polymorphie changes may have pronounced effects on tablet performance in terms
of in vitro dissolution and consequently, in vivo absorption. For example:
a) Chloramphenicol palmitate is available in at least two different forms;
polymorphs A and B, where the polyrnorph B is the more soluble. Figure
1 .8. shows that an increase in the rate and extent of bioavailability of the
drug occurs with increasing the content of the polyrnorph B in the
administered dose (Aguiar et al., 1967). Such profile is due to increasing
rate of dissolution in presence ofhigher content ofpolyrnorph B.
b) In the case of ampicillin, the aqueous solubility of the anhydrate phase was
reported to be 20% higher than that ofthe trihydrate form at 37°C (Ah et al.,
1981). The time for 50% ofthe drug to dissolve in vitro was found to be 75
and 45 min for the anhydrate and trihydrate forrns, respectively. In vivo
blood levels following separate oral administration of the two forrns of the
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ampicillin showed higher maximum concentration of ampicillin Ciiax in
the anhydrous forrn, and an earlier time to reach maximum concentration
Tmax in the blood serum relative to the trihydrate form. Therefore. it bas been
concluded that suspensions containing ampicill in anhydrate exhibit superior
bioavailability to analogous formulations made from the trihydrate form
(Figure 1.9.).
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Figure 1.8. Mean blood serum levels obtained for identicat suspensions of
chloramphcnicol palmitate with valying ratios of A and B polymorphs
following oral administration. Percentage of polyrnorph B in the
suspension:(M) 0%; (N) 25%; (0) 50%. (P) 75% and (L) 100% (adapted
from Aguiar et aÏ., 1967).
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Figure 1.9. Ampicillin urinary excretion rates at various times after separate
administration of the two fonus anhydrate and trihydrate (adapted from Ah
etaÏ., 1981).
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C) Carrier-mediated intestinal transport of drugs - Nano and microparticles
The implernentation of carrier systems in the field of therapeutics may be defined as
the control of hurnan biologica] systems at the molecular level, using engineered micro- and
nano-devices (OHagan. 199$; Allemann et al., 199$; Haruyama. 2003). The proven
commercial and clinical successes that can be achieved with particulate dosage forms and
recent advances in teclrnology transfer and manufacturing issues suggest that these novel
systems should more often be considered au integrat part of a formulator’s armament.
Oral detivety systems with micron and submicron-sized coltoidaÏ carriers offer three
distinct advantages (Delie, I 99$; Jenkins et aï., 1994; Castelvetro cia!., 2004):
(j) improving the solubilization of dnig in the carrier system
(ii) providing some level of protection against degradation within the GI tract
(vatying pH, enzymatic activity, ...)
(iii) prolongation ofthe drug transit time, and consequently, the duration ofexposure
ofdrug molecules to the epithe]ial surface.
Many of the problems associated with oral delivery of pooriy soluble
phamiaceuticals and strategies to overcome physiological and physical barriers in the Gl
tract have been discussed in details in part 1. In part Il, the ability of carrier systems,
especia]ly micelles, to deliver poorly water soluble pharmaceuticals through oral
administration will be discussed in more details.
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2.1. ABsTR&cT
The oral delivery of drugs is regarded as the optimal means for achieving
therapeutic effects due to increased patient compliance. Unfortunately, the oral deliveiy
route is beset with problems such as: gastrointestinal destruction of labile molecules, low
levels ofmacromolecular absorption, etc. To reduce the impact of digestive enzymes and to
ensure the absorption of bioactive agents in an unaltered form. molecules may be
incorporated into microparticulate carriers. Many approaches to achieve the oral absorption
of a wide variety of drugs are currently under investigation. Among the different polymer
based drug delivery systems, polymeric micelles represent a promising delivery vehicle
especially intended for poorly-water soluble pharmaceutical active ingredients in order to
improve their oral bioavailability. Recent findings of a dextran-based polymeric micelles
study for solubilization ofa highly lipophilic drug, cyclosporin A, will be discussed.
2.2. AuTH0R KEYWORDS
Micelles, oral delivery, poorly-water soluble drugs, review.
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2.3. INTRODUCTION
Oral administration of therapeutic agents represents by far the easiest and rnost
convenient route of drug delivery, especially in the case of chronic therapies (Lavelle et cd.,
1995). Whule convenient from the patient’s perspective, oral drug formulation presents a
challenge to the chemist, who lias to design delivery systems optimizing drug stability in
the gastrointestinal tract, such that a desirable pharmacokinetic profile may be attained for a
given drug (Daugherty et cii., 1999). Indeed, the gastrointestinal (GI) tract presents a variety
of hurdles for a drug, from morphological barriers (mucus layer, microvilli, etc) to stringent
physiological factors (a wide range of pH, enzymatic activities. specific transport
mechanisms, ctc), which ail conspire to limit intestinal absorption of drug. In the case of
poorly-water soluble drugs, the dissolution time in the gastrointestinal contents may be
longer than the transit time to the intended absorptive sites (Horter et ai., 2001). Therefore.
dissolution of drugs is quite oflen the rate-limiting step which, ultirnately, controls the
bioavailability of the drug (Charman et al., 1991). This poses a major challenge for
effective deÏivery ofpoorÏy water-soluble therapeutics vici the oral route (Chen et aï., 199$).
One approach to enhance the absorption efficiency and bioavailability of highly
lipophilic drugs taken orally consists in using a particulate deliveiy system soluble or
dispersible in an aqueous environment. This strategy is based on the following premises:
(a) particulate systems provide the drug with some level of protection against degradation
within the GI tract; (b) they prolong the drug transit time and facilitate transiocation of the
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drug across epithelial barriers, thus improving drug absorption; and (c) they rnay be
targeted to specific sites and carry functionalities that assist specific absorption pathways.
2.4. Pilysico-CHEMICAL CHAw&cTEiusTIcs 0F Oi&L DELIVERY SYSTEMS
The transport of a drug across the intestinal membrane is a complex transfer process
invoïving several mechanisms. Based on the physiology of die intestinal epithelium, three
potential routes for drug transport across intestinal barriers have been considered (figure
2.1.): (1) the paracellular route, a passive, diffusional transport pathway taken by small,
hydrophilic molecules (e.g. mannitol) which can pass through the tight junction channels
between adjacent epithelial cells; (2) Transcellular passive diffusion of lipophilic molecules
through the lipid bilayer and the membrane bound protein regions of the celi membrane;
and (3) Transcellular receptor-mediated transcytosis of surface-bound ligands such as
intrinsic factor-cobalamin complexes. The extent of particle uptake through the absorbing
membrane varies considerably depending on its size, chemical composition, hydrophobicity
and charge.
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B
figure 2.1. Schematic representation of intestinal epithelial ceils showing potential
transepithelial pathways: (A) paracellular route; (B) transcellular passive
diffusion; and (C) transcellular receptor-mediated transcytosis.
A
Intestinal lumen
light junction
C
Blood capillary
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2.4.1. Particle size
The uptake of particles within the intestine and the extent of drug absorption
increase with decreasing particle size and increasing specific surface area (Florence et aï.,
2001; Sass et aÏ., 1990; Jenkins et al., 1994). Jani et al. (Jani et aï., 1989; Jani et al., 1990)
assessed the size-dependance of the uptake of nanoparticles by the rat intestine by
monitoring their appearance in the systernic circulation and their distribution in different
tissues. Afier administration of equivalent doses, 33% of nanoparticles of 50 nm in
diameter and 26% of the 100 nm nanoparticles were detected in the intestinal mucosa and
gut-associated lymphoid tissues, whereas, in the case of 500 nm particles. only J 0% were
found in the intestinal tissues. The uptake of particles larger than 1 im in diarneter was
marginal. Moreover, these micronsized particles were found only in the lymph nodes of the
small intestine (Peyer’s patches). Similar findings were reported by Desai et al. (Desai et
aï., 1996) for the absorption characteristics of nanoparticles prepared from poly(lactide-co
glycolic acid) (PLGA). The uptake of 100 nm nanoparticles in the rat intestine was
significantly increased cornpared to larger particles of I and 10 im. Therefore, size is an
important pararneter controlling the intemalization of nanoparticles into epithelia of the GI
tract, and as a rule, sizes smaller than 500 nm are required.
2.4.2. Chemical composition
A comparative study investigating a range of polymeric particles suggests that the
extent of drug absorption depends on the hydrophobicity of the polymer (Fidridge et aï.,
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1990). It would appear that particles consisting of the hydrophobic polymer
poly(styrene), are absorbed more readily than PLGA, a somewbat more hydrophilic
polymer.
2.4.3. Particle charge
Particle charge is also an important factor that determines flic extent of uptake from
the GI tract (Jani et aï., 1989; HiÏleiy et aÏ.. 1994). CarboxyÏated poly(styrene)
nanoparticles show a significantly decreased affinity to intestinal epithelia, compared to
positively charged and uncharged poly(styrene) nanoparticles (Jani et al.. 1989). Kowever,
Mathiowitz et al. (Mathiowitz et aÏ., 1997) observed a highly increased adhesion of
negatively charged poly(anhydride) copolymers to ceil surfaces. resulting in an enhanced
absorption rate of the encapsulated drug, compared to drug encapsulated in neutral
particles. Kriwet et al. (Kriwet et aÏ., 1992) in their investigation of the affinity of
negatively charged poly(acrylic acid) nanoparticles towards intestinal epithelia reached the
same conclusion. Thus, neutral and positivety charged nanoparticles have a higher affinity
to intestinal epithelia than negatively charged nanoparticles, but negatively charged
nanoparticles exhibit bioadhesive properties, which may also favor the transport process.
2.5. APPR0ACHEs
Several particulate systems have been reported as effective carriers of therapeutic
agents administered orally. Among them are liposomes, which have been used. for
example, to administer insulin by the oral route (Damgê et al., 1988). Liposome
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formulations arc particularly attractive, as they may carry Iipid-soluble drugs in the lipid
bilayer and, at the same time. water-soluble drugs in the aqueous core (Shanna et cil.,
1997). They are prepared routinely under miÏd conditions which minimize drug
denaturation during encapsulation. Unfortunately, most liposome formulations are readily
disrupted by intestinal detergents, such as bile salts. and are subject to degradation by
intestinal phospholipases. Both mechanisms trigger the premature release of the liposome
entrapped drug in the GI fluid (Okada et al., 1995; Deshmukh et al.. 1980). In addition to
liposomes, other colloidal formulations, such as emulsions and microernulsions, are
effective in the oral administration of drugs with limited solubility in biological fluids
(loorisaka et aï., 2003; Itoh et aÏ., 2002). Microemulsions (oil/water) are bicontinuous
systems composed of a continuous water phase containing nanometer sized oil droplets
separated by a surfactant/co-surfactant-rich interfacial region. Compared to emulsions. they
offer several advantages as drug delivery systems, such as high solubilization capacity,
thermodynamic stability. and case of preparation (Itoh et aï.. 2002). In several cases,
administration of microemulsions, especially formulations based on castor ou, has triggered
adverse events, most frequently renal dysftinction. hypertension and hepatotoxicity
(Vischer et al., 1983; Uchida et aÏ., 2000). Recently a new class of deliveiy system lias
been under intense scrutiny. They are nanopartic les ranging in size from 1 5 to 150 mn
(Couvreur et aï., 1993; Sakuma et aï., 2001) such as nanospheres (Jung et ai., 2000),
nanocapsules (Damgè e! aï., 198$; Sai et aÏ., 1996). hydrogels (Saffran et aï., 1986: Edman
et aL, 1980; Andrianov et ciL, 1998). and silica particles coated with proteins, labile drugs
and hormones. Matsuno et al. (Matsuno et aï., 1983) found that nearly spherical
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poly(vinylpyrrolidone)-coated silica gel particles with an average diameter of 30 nm
were taken up effectively by mouse enterocytes. Polymers investigated in nanocarrier
formulations for oral drug delivery include poly(alkylcyanoacrylates) (Sai et al.. 1996). and
terpolymers of methyl methacrylate, 2-hydroxyethylmethacrylate and n-butylacrylate
(Kukan et al., 1991). The methodologies reviewed briefly in this section have met success
in various therapies and interested readers are referred to reviews on the subject (Kreuter,
1991; Fasano, 199$: Gershanik et al., 2000: Leuner et aï., 2000; Vasir et cii., 2003). The
focus of this article is, a yet different approach towards enhancing the bioavailability of
higbly lipophilic drugs. based on the molecular dissolution of a drug within the
hydrophobic core ofpolyrneric micelles.
2.6. MICELLEs: DEFINITION ANT) ADvANTAGES
In the latel96O’s. micelles drew much attention as drug carriers due to their easily
controlled properties and good pharmacological characteristics (Yokoyarna et aï.. 1992;
Wiedmann et al., 2002). Micelles are formed when amphiphiles are placed in water. They
consist of an inner core of assembled hydrophobic segments able to solubilize lipophilic
substances and an outer hydrophilic corona serving as a stabilizing interface between the
hydrophobie core and the external aqueous environment (Kataoka et al.. 1993). Depending
on the delivery purpose, one can select the size, charge and surface properties of these
carriers simply by adding new ingredients to the mixture of amphiphilic substances before
miceLle preparation and/or by variation ofthe preparation method.
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Micelles as drug carriers provide a set of advantages — they physically entrap
sparingly soluble pharrnaceuticals and deliver them to the desired site of action at
concentrations that can exceed their intrinsic water solubility and thus increase their
bioavailability. The stability of the drug is also increased through micelle incorporation.
Furthermore, undesirable side effects are lessened, as contact of the dntg with inactivating
species, such as enzymes present in biological fluids. are minimized, in comparison with
free drug (Yokoyama et al., 1990; Lee et aï., 1990; Torchilin. 2001). They can be prepared
in large quantities easily and reproducibly (Kataoka, 1994; Yokoyarna, 1998). By far the
rnost important feature of micellar delivery systems, which distinguish them from other
particulate drug carriers, lies in their small size (— 10 to 30 nrn) and the narrow size
distribtition (Florence et al., 2001).
Micelles made of non-ionic surfactants are widely used as adjuvants and drug
carrier systems in many areas of pharmaceutical technology and controlled drug deliveiy
(Malik et cii., 1975; Takada et aL. 1986; Lasic, 1992; Schubiger et aï., 1997; Redondo et
al.. 1998: Bardelmeijer et aï.. 2002). Such a high level of activity bas brought a great deal
of diversity to this fietd, since most groups introduced their own micelle system forrned
from unique hydrophilic-hydrophobic combinations. In almost all cases, the hydrophilic
outer sheli consists of poly(ethylene oxide) (PEO) chains. due to their high degree of
hydration and large excluded volume inducing repulsive forces. which contribute to the
stabilization ofthe micelle (Kataoka, 1994; Elbert et aï., 199$; Otsuka et al., 2001: Otsuka
et al., 2003). In addition, the PEO corona prevents recognition by the reticuloendothelial
system and therefore minimizes elimination of the micelle from the bloodstream. Thus.
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these so-called ‘stealth” properties of the PEO corona resuit in increased blood
circulation times and allow drugs to be administered over prolonged periods of time
(Kwon, G. et aï., 1994; Kwon, G.S. et al., 1995; Yamamoto et aL, 2001). A wide range of
hydrophobic blocks have been explored resulting in different micellar systems with distinct
physicochemical properties.
Surfactant micelles form only above a critical concentration, the critical miceLle
concentration (CMC) and rapidly break apart upon dilution, which can resuit in prernature
leakage of the drug and its precipitation in situ. These limitations of surfactant micelles as
drug delivery carriers triggered the search for micelles of significantly enhanced stability
and solubilizing power.
The use of polymer-based micelles lias gained mucli attention because of the high
diversity of polyrners, their biocornpatibility, biodegradibility and the multiplicity of
functional groups they display for the conjugation of pilot molecules (Andrianov et aï.,
1998).
2.7. P0LYMERIc MIcELLEs
Like their Iow molecular weight counterparts, amphiphilic polymers associate in
water to form “polymeric micelles” (Kwon, G.S. et aL, 1996), consisting ofa hydrophobic
core stabilized by a corona of hydrophilic polymeric chains exposed to the aqueous
environment (Kataoka et aï., 2001). Polymeric micelles can be used as efficient carriers for
compounds. which alone exhibit poor solubility, undesired pharmacokinetics and low
n -
stability in a physiological environment. The hydrophilic sheli contributes greatly to the
pharmaceutical behavior of polymeric formulations by maintaining the micelles in a
dispersed state, as well as by decreasing undesirable drug interactions with celis and
proteins through steric-stabilization effects. The size of polymeric micelles ranges from ---l O
to —100 nrn and usually the size distribution is nairow (Kataoka et aÏ., 2001). This
topology is similar to that of surfactant micelles, hence polymeric micelles can be expected
to solubilize hydrophobic drugs within their core. However, there are significant
differences between the two types of assembties from the physicochemical viewpoint. The
polymer concentration at which the association first takes place, sometimes known as the
critical association concentration (CAC), is lower by several orders of magnitudes than
typical surfactant CMC values. Thus, polymeric micelles are more stable towards dilution
in biological fluids. They can increase drug bioavailability and retention. since the drug is
well protected from possible inactivation under the effect of their biological surroundings
(Kwon. G.S., 2002).
Polymeric micelles have been studied extensively as delivery medium for injectable
drug formulations of poorly water-soluble drugs such as paclitaxel. indomethacin,
arnphotericin B. adriamycin and dihydrotestosterone. Overail, they proved to be highly
effective drug delivery vehicles (Zhang et aÏ., 1997; $hin et aï., 1992; Yu et aï., 199$;
Jeong et al.. 1999; Allen et al.. 2000). b date. most contributions in the area ofpolymeric
micelles for oral formulations, have been made by the group of Kabanov (Batrakova et al.,
l99$a; Batrakova et aï.. 199$b; Batrakova et aï., 1999; Alakhov et al., 2001; Kabanov, A.
et al.. 2002a; Kabanov. A.V. et aï., 2002b). Their work focused mostly on micelles formed
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from commercially available Pluronic® triblock copolyrners (also termed Poloxarner;
Poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide); PEOX-b-PPO)-b
PEO), ai-id more recently, on block ionomer complexes as carriers for DNA (Lemieux et
cii.. 2000).
Our approach towards oral drug delivery through polymeric micelles was to design
with care the chernical composition and architecture of the amphiphilic polymers forming
the polymeric micelle vehicle. b maximize our chances of success, we chose to base the
new materials on polysaccharides, which are non-toxic, naturally occurring polyrners and
readily available in a range of molecular weights. We selected hydroxypropylcellulose
(HPC), a non-ionic water-soluble cellulose derivative, and dextran (DEX), a glucose
polymer with predominantly I ,6-Œ-glycosidic linkages (Larsen, 1989). Both polymers are
non-toxic and non-irritant polysaccliarides. They are used in medicine. e.g. dextran as
plasma substitute both locally and systemically (Couch, 1965) and hydroxypropylcellulose
in oral tablet formulations, where it acts as a disintegrant (Machida et cii., 1974) and as a
binder in granulation (Skinner et ai., 1999), due to its bioadhesive properties. In order to
impart either dextran or HPC with an amphiphilic character. we linked to their backbone a
small number of hydrophobic cetyl groups, as described below in the case of dextran. We
chose to attach the hydrophobic groups to the polysaccharide hydrophilic backbone via a
short PEO linker, yielding dextran grafted with PE010-C16 (DEX-g-PEO10-C16) or HPC-g
PEO10-C16; the digit next to PEO refers to the number ofethylene oxide groups in PEO, and
the digit next to the carbon refers to the number of carbons in the alkyl chains (figure 2.2.);
and to exploit the solubilizing potential of this copolymer towards poorly water-soluble
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drugs. In aqueous solution, hydrophobically-rnodified (T-1M) polysaccharides assoc iate
into polymeric micelles above the CAC. Thus, a lipophilic drug can be entrapped in the
hydrophobic core formed by the aikyl residues, while the hydrophilic polysaccharide chains
stabilize the system in the aqueous environment. In this article, we present the design,
chemical characterization. and in-vitro evaluation of HM-dextran based polymeric micelles
as an example of the novel polymer-based nanocarriers for oral deliveiy of poorly water
soluble drugs developed recently in our group.
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2.8. SYNTHEsIs AND CHARAcTELUzATI0N 0F 11M DExTRAN C0P0LYMER5
Hydrophobically-modified DEX-g-PEO1 o-C16 grafi copolymers were synthesized
following the scheme shown in Figure 2.2. (Cristea et ai. 2003). A tosylated poly(ethylene
oxide) (10) cetyl ether (PE010-C16) vas coupted to dextran 110 (DEX; Mw 10,000 Da) by a
Williamson ether synthesis reaction. The resulting DEX-g-PEO10-Ci6 copolymers were purified
by soxhiet extraction with dichioromethane to rernove ail free PE010-C16. The extent ofgrafting
(Table 2.1.) was detennined from ‘H-NMR spectroscopy data, using the signal due to the
resonance of the terminal cetyl methyl protons (6 0.85 ppm) and the signal due to the resonance
of the anomeric protons of dextran (6 4.7 pprn) (figure 2.3.). Depending on the initial relative
concentration of dextran and PE010-C16, arnphiphilic dextrans carrying from 2.3 to 15 mol ¾
PE010-C16 (relative to the number of glucose units) were prepared in excellent yield and a high
level ofpurity.
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2.9. Pilysico-CHEMIcAL CHAR&cTEmsTlcs 0F P0LYMEffic MIcELLEs
As discussed in the introduction, the ability of polymeric micelles to act as effective
drug delivery systems is controlled, to a large extent, by their size and their critical
association concentration (CAC), defined as the copolymer concentration below which only
single chains exist. In solutions of the copolyrner of concentration higher than the CAC,
micelles and single chains coexist. This definition is used cornmonly to describe polymeric
micelles, in analogy with the CMC of surfactant micelles, although the mechanism of
micellization may not be the same for amphiphilic polymers and surfactants (Nagarajan et
ai.. 1989b; Zana. 2002). A deÏivery system is subject to “sink conditions” or severe dilution
in the gastrointestinal fluid upon oral administration. It is important to know the CAC value
in order to select dosage compositions such that the copolymer concentration rernains
above the CAC immediately upon administration. The CAC of amphiphilic copolymers is
determined by many factors, such as the nature and length of the core-forrning segments,
and the length of the hydrophilic chain. Arnphiphilic copolymers which contain highly
hydrophobic residues have lower CAC values in water than those which include the Iess
hydrophobic residues. For a series of copolymers, if the corona-forming chain is kept
constant, an increase in the molecular weight of the core-forming segment will decrease the
CAC (Alexandridis et aï.. 1994b). To a lesser extent, if the length of the core-forming
segment is maintained at a constant length, an increase in the length of the hydrophilic
chain wiÏI cause an increase in the value ofthe CAC (Astafleva et aï., 1993; Alexandridis et
aï., 1994a).
101
The CAC of polymeric micelles can be estimated by fluorescence spectroscopy
using pyrene, a hydrophobie fluorescence probe that preferentially partitions into the
hydrophobie core of the micelle. Pyrene undergoes changes in its photophysical properties
as a resuit of the change in the micropolarity it experiences upon diffusion from bulk water
(hydrophilic environrnent) into the micelle core (hydrophobie environment) (Dong et aï..
1984; Zhao et al., 1990). Two methods exist for detennining the CAC of polyrneric
micelles with pyrene fluorescence (Winnik et aÏ., 1998). The originaL method, proposed by
Kalyanasundaram et al. (Kalyanasundaram et aï., 1977), takes advantage of the changes in
the vibronic fine structure of the pyrene emission and monitors the changes in the ratio of
the intensities 1 and 13 ofthe [0,0] and [0,2] bands. respectively. More recently, it bas been
suggested that a more accurate determination of the CAC can be ohtained by monitoring
the changes in the ratio ofthc pyrene excitation spectra intensities (Wilhelrn et cii.. 1991) at
= 333 nm for pyrene in water and 2 336 nrn for pyrene in an hydrophobie medium
(Figure 2.4.). By plotting the ‘336/1333 intensity ratios versus the logarithrn of the
concentration of the aqueous solutions of copolymer, sigmoidal curves are obtained, where,
at the CAC, a sharp increase is observed in the fluorescence intensity ratio (1336/1J33) as the
polymer concentration increases (f igure 2.4.).
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Figure 2.4. Plot of the intensity ratio I33/I333 (from pyrene excitation spectra) as a
function of concentration (0.04 — 5x103 rng/1) of DEX-g-PEOi0-Ci6
copolyrners containing (.) 2.3 rnol%; (.) 6 mol% and (À) 15 rnol% of
grafted PEO1-C6 residues. Each value is the mean of two independent
measurernents. biset: Excitation spectra of pyrene (2 x i07 M aqueous
solution) rnonitored at 2m 390 nrn in absence (.) or presence (À) of HM
DEX copolyrner.
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We used the latter method to estimate the CAC of the DEX-g-PEO10-C16
copolymers. As shown in Table 2.1., the CAC values decrease with increasing molar
content of PEO,0-C16 residues linked to the dextran backbone. These rcsults are consistent
with recent evidence suggesting that the increase in the Iength of a hydrophobic residue ibr
a given length of a hydrophilic polymer chain causes noticeable decrease in CAC value and
increase in micelle stability (Nagarajan et aï., t9$9b).
The size of micelles is controlled by the length of the core-fonriing segment and the
length ofthe corona forming chain (Halperin, 1987; Nagarajan et aï., 1989a), but it depends
also on the method of micellization selected for the preparation of micelles. For micelles
produced using the dialysis rnethod, it varies depending on the organic solvent employed
(La et aï., 1996; Kim, S.Y. et aï., 1998). The choice oforganic solvent also affects the yieÏd
of micellization. for example, La et al. (La et aï., 1996) reported that the tise of
dimethylsulfoxide (DMSO) as the organic solvent gave rise to PEO-b-poly(f3-benzyl-L-
aspartate) (PBLA) micelles which were only 17 nm in size, but the micelle yield was low
(6%). Using dimethylacetamide (DMAc) as organic solvent resulted in a much higher
micelle yield, with an average particle size of 19 nm and a narrow size distribution (La et
aï., 1996). In this way, the dialysis method provides a means of tailoring the size and size
distribution of the micelles. Note that, above all, it is important to select conditions that
minimize the formation of large polymer aggregates (diarneter> 300 mu), in addition to the
desired polymeric micelles (Cainmas et al., 1997).
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We determined the size of dextran-based polymeric micelles by dynarnic laser
light scattering (DLS) at 25 °C, with a scattering angle of 90°, and found that the
hydrodynamic diameter of DEX-g-PEO10-C16 micelles ranged from 10 to 45 nm (Table
2.1). In all cases the size distribution was unimodal, indicative of the absence of free
polyrner chains and of large aggregates. Polymeric micelles formed by amphiphilic
dextrans of structure sirnilar to that of DEX1O-g-PEO1-c,,, but prepared from a higher
molecular weight dextran (Dextran 140; M 40,000 Da; DEX 40) are larger than those
fonued by DEX10-g-PEO-C, independently of the size of the hydrophobic substituent
and ofthe level of modification (Francis et al., 2003b). This observation can be taken as an
indication ofthe steric hindrance induced by the carbohydrate chains, which are expected to
take place over a larger volume for the polymer of higher molecular weight (Maksimenko
et al., 2001; Baldwin et al., 198$). It bas been shown that the uptake ofparticles within the
intestine and the extent of drug absorption increase with decreasing particle size and
increasing specific surface area (Florence et al., 2001). Thus, the small size exhibited by ah
the polymeric micelles studied here shows a favorable trend towards oral drug deliveiy.
2.10. PHYsIcAL LOADING 0F A DRuG IN DEX-g-PEO10-C16 POLYMERiIC
MIcELLEs
The hydrophobie core of the polymeric micelles is expected to serve as the loading
space for various hipophihie drugs. By design, given the nanometric size ofthe micelles, this
spaee is limited. In order to exploit ftilly this loading space, one must manipulate the many
factors that control loading eapacity and loading efficiency. In devising a drug
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incorporation strategy, one must try to match as closely as possible the polarity of the
hydrophobic micelle core to the solubility characteristics of the drug. Nagarajan et al.
(Nagarajan et aÏ., 1986) dernonstrated that arornatic hydrocarbons are incorporated to a
greater extent into poly(ethylene oxide-b-propylene oxide) and poly(N-vinylpyrrolidone-b
styrene) polymeric micelles, in comparison to aliphatic hydrocarbons. Kim et al. (Kim, S.Y.
et aÏ., 1998) showed that the arnount of indomethacin that can be incorporated into micelles
can reach 42.2 (w %) in the case of PEO-b-poly(-caprolactone), while La et al. (La et al.,
1996) obtained an indomethacin content of only 22.1 (w %) for micelles formed from PEO
b-PBLA. An increase in the length of the core forming segment tends to eniance the
loading capacity per micelle (Gadelle et aÏ., 1995). Note that a drug may reside preferably
within the core of the micelle or within the core/corona interface, depending on its
solubility characteristics (Gadelle et al., 1995).
We report here the loading capacity of DEX-g-PEO10-C16 polymeric micelles
towards cyclosporin A (CsA), a highly effective immunosuppressive agent that is used for
the prevention of grafi rejectÏon following organ transplantation (Laupacis et ai., 1982).
Chemically, CsA is a neutral cyclic undecapeptide with a molecular weight of 1202 g/rnol
(Wenger, 1983), consisting of hydrophobic amino acids linked via 11 amide bonds, seven
of which are N-methylated. four intramolecular hydrogen bonds (Vine et al., 1987)
contribute to the rigidity of its skeleton. This chemical composition is responsible for the
extremely low solubility of CsA in water (23 jig/ml at 20 °C). The oral administration of
CsA is complicated by the presence of several metabolizing enzymes: cytochrome P-450
3A4 (CYP3A4), the multi-drug transporter P-glycoprotein (PGP) in the small intestine, and
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hepatic CYP3A4 (Tjia et al., 1991). These factors, together with the poor solubility of
CsA in the aqueous fluids of the gastrointestinal tract, severely limit the absorption of CsA
through the gastrointestinal mucosa. They account for the Ïow bioavailability of the drug
and significantly increase the risks of both acute and chronic rejection (Lindholrn et aL.
1988). Commercial CsA oral formulations are mostly microemulsion-based. Whule more
effective than the original emulsion-based formulations, this formulation presents a rather
large interindividual variation in terms of CsA bioavailability (Kovarik et aï., 1994). In
view ofthe clinical importance of CsA, much effort has been placed towards designing oral
formulations leading to acceptable bioavailability. A number of innovative drug delivery
approaches including rnixed micelles (Takada et aï., 1985), charged nanoparticles (El
Shabouri, 2002), liposomes (Al-Meshal et aÏ., 1998), lipids (Ueda et al., 1983), surfactants
(Chang et aÏ., 1996), microspheres (Kim, S.J. et aÏ., 2002), and microernulsions (Ritschel et
aï., 1990) have been investigated in order to improve the unfavorable absorption
characteristics of CsA.
We chose to incorporate CsA into DEX-g-PEO10-C16 polyrneric micelles by a
dialysis method, which involved treatment of an aqueous polymer solution with a solution
of CsA in ethanol. Ethanol was used as solvent to prevent any cytotoxic effect that could be
caused by trace organic solvent in the final formulation. The initial CsA loading varied
from 2.5 — 40 % (w/w CsA/polymer). The rnixed solutions were extensively dialyzed
against distilled water. In this process, the organic solvent is slowly replaced by water so
that micelles start to form and to incorporate the lipophilic drug inside their hycirophobic
core (figure 2.5.). Afier completion of the dialysis, the solutions were filtered to eliminate
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excess CsA and the filtrate was freeze-dried yielding a free flowing powder which
readily dispersed in water to form polymeric micelles of size and size distribution nearly
identical to those of micelles devoid ofCsA.
The amount of CsA incorporated in the micelles was determined by a high
performance liquid chromatography quantitative assay of the CsA extracted from freeze
dried micelles with acetonitrile, a non-solvent of the copolymer but a good solvent of CsA.
Drug loading (DL) was caÏculated using Equation (1):
DL(%)100(Wc/WM) Equation (1)
Where Wc is the weight of CsA loaded in micelles and WM is the weight of
micelles before extraction. The amount of CsA released upon dissolution was plotted
against the CsA concentration added initially for each preparation. Both free ami micelle
entrapped CsA were measured with this assay. The amount of free CsA is expected to be
low, since the undissolved fraction of the drug should have been removed by filtration afier
dialysis.
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We evaluated first the ability of the PE010-C16 micelles to solubilize CsA and
found that a high level of CsA (17.5% w/w) was incorporated in the surfactant micelles, an
indication of the favourable solubilizing characteristics of PE010-C16 towards CsA. Next,
we assessed the incorporation of CsA within polymeric micelles. The maximum amount of
CsA loaded within the micelles was 1, 7 and 8% (w/w), for DEX-g-PEO10-C16 containing
2.3, 6 and 15 mol% PE010-C16, respectively (figure 2.6.). In ail cases, the arnount of CsA
incorporated was larger in the case of polymeric micelles than in the case of unmodified
dextran, which proved to have a very low affinity for CsA. By comparing the highest CsA
loading percentage in the various polymers, it is apparent that the CsA loading increases
with increasing molar content of PE010-C16 grafied on the dextran backbone. Other
structurai features of the copolymers also affect the micellar loading capacity towards CsA.
For example, micelles formed by polymers of higher molecular weights (e.g. DEX4O) are
not as effective CsA carriers as those based on DEXIO (francis et aï., 2003b). Also, for a
constant number of PE010-C,7 units grafted per dextran chain, PEO10-C16-based micelles
seern more effective in solubilizing CsA than PE010-C18-based micelles, indicating that the
micropolarity of a hydrophobic core made up of hexadecyl-PEO chains rnight present a
better solubilizing rnicroenvironment than that offered by the octadecyl-PEO moieties
(Francis et al., 2003b).
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figure 2.6. CsA final loading (w/w %) in micelles of DEX-g-PEO10-C16 containing (u)
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2.11. CYT0T0xIcITY STuDY
The human colon adenocarcinoma, Caco-2 ceils, are generally selected to estimate
in vivo drug absorption. as they retain many features of small intestinal epitheÏial cells
(Dantzig e! aï., 1990; Hidalgo et cii., 1989). Thus, we used Caco-2 ceils to study the
cytotoxicity of DEX-g-PE010-C16 polymeric micelles, using the colorirnetric MTT assay
(Hansen et aï., 1989). The celi viability in the presence of micelles was cornpared to that in
the presence of unmodified DEX as weIl as of free PE010-C16 surfactant residues (Figure
2.7.).
Celi growth was severely inhibited by PE010-C16, even at surfactant concentrations
below I g/l. Such deleterious effect is consistent with the reported propensity of
poly(ethylene oxide) aikyl ethers to affect membrane integrity (Dimitrijevic et aï., 2000). In
contrast, the polysaccharide DEX showed no toxicity up to a concentration of 10 gIÏ,
confirming the reported inertness of dextrans. Turning now to the effect of DEX-g-PEO10-
C16 (15 rnol%), we deterrnined that it exhibited no significant toxicity towards Caco-2 ceils,
up to concentrations of 10 g/1 or concentration of PE010-C16 (0.05 g/1) equivalent to a
PE010C16 concentration showing a significant cytototoxic effect (60% ceIl viability). This
important resuit indicates 1) that the polyrner purification method efficiently removed any
free PE010-C16 from the polymer, and 2) by graffing the PE010-C10 residues onto dextran,
we succeeded in minirnizing their toxic effect on celis. The non-toxic hydrophilic dextran
chains forming the polymeric micelle outer sheli may be in contact with the ceils and
effectjvely insulate them from the surfactant residues assembled in the inner core.
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2.12. CoNcLusioN
The experimental evidence reviewed in this article led us to conclude that polyrneric
micelles present a number of enabling properties for oral delivery of lipophilic drugs. for
example, HM-dextran form nanosized assemblies characterized by a low onset of
micellization and a high solubilization power towards highly lipophilic drugs. Moreover,
they present no significant cytotoxicity. Initial results indicate that the transport of a HM
dextran-entrapped lipophobic drug is enhanced, compared to free drug (Francis et aï.,
2003a). Current research on particulate delivery systems is focused on gaining a better
understanding of the mechanisms, efficiency, and reproducibility of the perrneability of
both the carrier and/or the drugs across the GI tract, and analysis of the effect of carrier
composition on these parameters.
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THE AIM 0F THE PREsENT STuDY
The ultimate goal of our study is to develop a novel oral formulation especially
intended to increase the oral bioavailability of poorly-water soluble drugs. The project
relies on the design, characterization and development of polyrneric micelles capable of
solubilizing high levels of lipophilic drugs and eventually facilitating their transfer across
intestinal epithelial ceils.
To reach our goal, polysaccharide-based polymeric micelles have been proposed.
Cyclosporin A (CsA) was the drug of choice for encapsulation in the different proposed
polymeric micelles.
In chapter 3, we present the physicochemical characterization and solubilization
efficiency ofvarious dextran-based polymeric micelles with varying chernical composition.
‘8olubiÏization of cyclosporin A in dextran-g-polyethyÏeneglycolalkyÏ ether potymeric
micelles”, Fur. J. Pharm. Biopharrn. (2003), 56 (3) 337-346.
In chapter 4, we present the physicochemical characterization and solubilization
efficiency of various hydroxypropylcellulose-based polymeric micelles with varying
chemical composition.
“Solubilization of poorly water soluble drugs in micelles of hydrophobicalÏy modifled
hydroxypropylcellulose copolymers”, J. Control. Release (2003), 93 (1) : 59-68.
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In chapter 5, we investigated the permeability of CsA-loaded in polymeric
micelles across Caco-2 intestinal epithelium, compared to free CsA under the same
conditions.
“Engineering polysaccharide-based polymeric micelles to enhance permeability of
Cyclosporin A across Caco-2 celis” Pharm. Res. (2004), in press.
In Chapter 6, we studied the possibility to utilize the specffic uptake mechanism for
Vitamin B12 (VB12) to enhance the oral uptake of CsA loaded in VB12-rnodified polymeric
micelles.
“Vitamin B12-targeted polymeric micelles for improving Cyclosporin A permeability across
Caco-2 cdl monolayers” Biomacrornolecules (2004), to be submitted.
In Chapters 7 and 8, the general discussion and the perspective will be presented,
respectively.
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3.1. ABsT1cT
Solubilization of the poorly water-soluble drug, Cyclosporin A (CsA), in aqueous
dispersions of dextran-grafted-polyethyleneglycolalkyl ether (DEX-g-PEG-C,,) polymeric
micelles was examined as a function of copolymer structure. In aqueous solution, DEX-g
PEG-C,7 form polymeric micelles of low critical association concentrations (CAC) and
small micelle sizes as determined by fluorescence spectroscopy and dynamic light
scattering (DLS). Copolymers with longer polysaccharide chain showed larger CAC and
mean diameter. The percentage of CsA loading into micelles was determined by high
performance liquid chromatography. It was significantly larger in polymeric micelles
compared to unmodified dextrans. It increased with increasing number of PEG-C units
grafied per dextran chain and decreasing dextran molecular weight. The cytotOxiCity of
DEX-g-PEG-C16 polymeric micelles towards Caco-2 cells, tested by MTT cytotoxicity
assay, was significantly lower than that offree PEG-C16 molecules. It can be concluded that
the length of the hydrophilic part as well as the content and chemical nature of the
hydrophobic substituents have an important effect on the ability of polymeric micelles to
solubilize poorly-water soluble drugs.
3.2. AuTH0R KEYWORDS
Polymeric micelle; Poorly water soluble drug; Oral delivery; Cyclosporin A;
Dextran; Polyethyleneglycolalkyl ether; Solubilization; Cytotoxicity.
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3.3. INTRODUCTION
Peroral drug administration represents by far the easiest, most common and most
convenient route of drug delivery, especiaÏly when repeated or routine administration is
necessary (Chen et al., 1998). For effective delivery via the oral route, a therapeutic agent
must first dissolve in the gastrointestinal lumen (Florence et al.. 1 993). This can pose major
challenges in the case of poorly-water soluble drugs (Gershanik et al., 2000). A drug may
be deflned as “poorly solubl&’ if its dissolution rate is slower than the transit time to its
absorptive sites (Horter et aÏ., 2001). The dissolution of a poorly water-soluble drug in the
gastrointestinal contents is quite oflen the rate-limiting step that, ultimately, controls the
bioavailability ofthe drug at its site of action (Charman et aÏ., 1991).
One approach to enhance the solubility and bioavailability of a highly lipophilic
drug is to dissolve it on the molecutar level in the hydrophobic core of a deÏivery system.
itself soluble or dispersible in the aqueous environment. In the late I 960s. surfactant
micelles drew much attention as drug deliveiy carriers, due to their good pharmacological
characteristics (Wiedmaim et aÏ., 2002). They are widely used as adjuvants and drug carrier
systems in many areas of pharmaceutical technology and controlled drug delivery (Lasic.
1992). Surfactant micelles form only above a critical concentration, the critical micelle
concentration (CMC) and rapidly break apart upon dilution which could result in a
premature leakage ofthe drug and its precipitation in situ.
These limitations of surfactant micelles as drug deliveiy carriers triggered ihe search
for micelles of significantly enhanced stability and solubilizing power. Like their low
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molecular weight counterpart, amphiphilic polymers associate in water to forrn
“polymeric micelles” (Kwon et aÏ., 1996) consisting of a hydrophobic core stabi]ized by a
corona of hydrophilic polymeric chains exposed to the aqueous environment (Kataoka et
aÏ., 2001). The size ofpolymeric micelles ranges from l0 nm to 100 nm and usually the
size distribution is narrow (Kataoka et aÏ., 2001). This topology is sirnilar to that of
surfactant micelles, hence polyrneric micelles can be expected to solubilize hydrophobic
drugs within their core. However, there are significant differences between the two types of
assemblies from the physico chemical viewpoint. The polymer concentration at which the
association first takes place, sometimes known as the critical association concentration
(CAC), is lower by several orders of magnitudes than typical surfactant CMC values. Thus,
polymeric micelles are more stable towards dilution. From the pharmaceutical point of
view, these amphiphilic carriers can solubilize more poorly-water soluble drugs within their
hydrophobic core than most surfactant micelles. They can increase drug bioavailability and
retention, since the drug is well protected from possible inactivation under the effect of
their biological surroundings (Kwon et al., 1996).
Cyclosporin A (CsA) is a highly effective immunosuppressive agent that is used for
prevention of grafi rejection following organ transplantation (Laupacis et aÏ., 1982). CsA is
a neutral cyclic undecapeptide with a molecular weight of 1202 g/mol (Wenger, 1983),
consisting of hydrophobic amino acids linked via 11 amide bonds, seven of which are N
methylated. Four intramolecular hydrogen bonds (Vine et aÏ., 1987) (figure 3.1.) contribute
to the rigidity of its skeleton. This chemical composition is responsible for the extremely
low solubility of CsA in water (23 tg/rnl at 20 °C). The oral administration of CsA is
1—,
Ii
complicated by the presence of several metabolizing enzymes: cytochrorne P-450 3A4
(CYP3A4), the multi-drug transporter P-glycoprotein (PGP) in the small intestine, and
hepatic CYP3A4 (Tjia et al., 1991). These factors, together with the poor solubility ofCsA
in the aqueous fluids of the gastrointestinal tract. severely limit the absorption of CsA
through the gastrointestinal mucosa. They account for the low bioavailahility of the drug
and significantly increase the risks of both acute and chronic rejection (Lindholm et aï.,
1988). In view of the clinical importance of CsA, much effort has been directed towards
designing oral formulations leading to acceptable bioavailability. A number of iimovative
drug deliveiy approaches including mixed micelles (Takada et aï., 1985), charged
nanoparticles (El-Shabouri. 2002), liposomes (Al-Meshal et al., 199$), lipids (Ueda et al..
1983), surfactants (Chang et aï., 1996), microspheres (Kim e! aÏ., 2002), and
microenuLisions (Ritschel et aï., 1990) have been investigated in order to improve the
unfavorable absorption characteristics of CsA.
1—,
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figure 3.1. Chemical structure of cyclosporin-A showing 11 arnino acids and 4
hydrogen bonds.
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We set out to investigate the suitability of polymeric micelles as carriers in the
oral delivery of CsA. This drug was selected, flot only because of its clinical importance,
but also since it is representative of a number of new, highly water-insoluble drugs in
cunent development. The chemical composition and architecture of the amphiphilic
polymers forming the polymeric micelle drtig calTiers was selected with care, taking into
account the following requirements. The hydrophilic sections of the polymer should have
high water solubility and be non-toxic, and ideally should enhance the bioavailability ofthe
drug transported within the micelle. We selected dextrans, which are branched
polysaccharides introduced in medicine in the early 1 950s as non-toxic plasma substitutes
(Clagett et aL, 1998). They are readily available in a range of molecular weights (Couch,
1 965) and their chemical modification has been studied extensively (Moriyama et aÏ., 1996;
Maksirnenko et al., 2001; Sayer et al., 2002). In order to impart dextran with an
amphiphilic character, we linked to its backbone a small number of polyethylene glycol n
aikyl ether (PEG-C,7; C,EO10) chains (figure 3.2.). Nonionic surfactants such as
polyethyleneglycol alkyl ethers are known to enhance drug absorption. In fact, the effect of
PEG-C,3 has been reported in several studies to be superior to those of fatty acid esters and
sorbitan derivatives (Sakai et aÏ., 1986; Siegel et aÏ., 1985). However, several PEG-C,1
surfactants suffer from adverse effects on mucosal integrity (Dimitrijevic et al., 2000).
13$
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Figure 3.2. Chernical structure of DEX-g-PEG-C,1 copolymer where n16 and 1$ for
DEX-g-PEG-C16 and DEX-g-PEG-Cig, respectively.
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The objectives of the work presented here were (1) to determine the
physicochemical properties of the polymeric micelles formed in aqueous solutions of
hydrophobically-modifled dextrans (DEX-g-PEG-C,j; (2) to assess the solubility of CsA in
DEX-g-PEG-C micelles; and (3) to evaluate the cytotoxicity of the polymeric micelles.
The latter study was of particular importance in view of the known toxicity of the PEG-C,,
surfactants when they are not linked to polymers. Ihe effects of the polymer molecular
weight, the level of hydrophobic substitution. and the chernical nature of the hydrophobic
substituents on the properties of the polymeric micelles were examined using fluorescence
spectroscopy, dynarnic light scattering, CsA assay by high-perforrnance liquid
chromatography (HPLC) and MTT cytotoxicity assay.
3.4. MATERIALs AND METH0Us
3.4.1. Materials
Cyclosporin A (CsA). polyethyleneglycolcetyl ether (PEG-C16; C16E010; Brij 56).
polyethyleneglycolstearyl ether (PEG-Cis; C18E010; Brij 76), sodium chloride (NaCl),
monobasic sodium phosphate NaH2PO4). dibasic sodium phosphate (Na2HPO4). sodium
dodecyl sulfate (S. D. S) and 3 -(4,5 -dimethylthiazol-2-yl)-2, 5 -diphenyl tetrazolium brorni de
(MTI) were purchased from Sigma—Aldrich (St. Louis, MO). Optical grade pyrene (99%),
dichloromethane (DCM) and deuterated dirnethyl sulfoxide (DMSO-d6) were purclrnsed
from Aldrich Chemical Co. (Milwaukee, WI). Dextran 110 (DEX1 0; 1000CI Da) and
dextran 140 (DEX4O; M’., 40000 Da) were supplied by Pharmacia Fine Chemicals
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(Uppsala, Sweden). HPLC-gradc acetonitrile (ACN) and water were obtained from
Anachernia Science (Montreal, PQ, Canada). Ethanol (95%) was obtained from
Commercial Alcohols Inc. (Brampton, ON, Canada). The Caco-2 celi une was purchased
from American Type Culture Collection (ATCC, Rockville. MD) at passage 18. Dulbeccos
modified Eagle medium (DMEM), penicillin—streptomycin (10000 U/ml penicillin G and
10000 tg/m1 streptomycin), fetal bovine serum (FilS), 0.25% (w/v) trypsin — I mM
EDTA4Na (1 x) and non-essential amino acids NEAA) were suppÏied by Invitrogen Inc.
(Burlington, ON, Canada).
3.4.2. Synthesis of DEX-g-PEG-C,1 copolymers
Hydrophobicaily-modified DEX-g-PEG-C,1 grafi copolymers were synthesi zed
following a procedure reported by our group (Cristea et aÏ., 2003). Briefly, the terminal
hydroxyl group of PEG-C was tosyÏated in good yield using the joint action of the amines
Et3N and Me3N HCÏ. Subsequently, the tosylated PEG-C,1 was coupled to dextran of
various molecular weights (10000 and 40000 Da) by a Williamson ether synthesis. The
resulting DEX-g-PEG-C,7 copolymers were purified by a dichiorornethane soxhiet
extraction to remove ail free PEG-C,7. They were characterized by 1H NMR spectroscopy of
their solution in DMSO-d6 using a Bruker ARX-400 400 MHz spectrometer (Milton. ON,
Canada).
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3.4.3. Critical association concentration (CAC) of DEX-g-PEG-C,, polymeric
micelles
The CAC of the DEX-g-PEG-C,1 copolymers were estirnated by fluorescence
spectroscopy using pyrene. a hydrophobie fluorescence probe that preferentiafly partitions
into the hydrophobie core of the micelle. It undergoes changes in its photophysical
properties as a resuit of the change in the micropolarity it experiences upon diffusion from
bulk water (hydrophulic environment) into the micelle core (hydrophobie envïronment)
(Dong et al., 1984; Zhao et al., 1990). Two methods exist for determining the CAC of
polymeric micelles with pyrene fluorescence (Winnik et aï., 199$). The originat rnethod,
proposed by Kalyanasundaram et al. (Kalyanasundaram et al., 1977), takes advantage of
the changes in the vibronic fine structure of the pyrene emission and monitors the changes
in the ratio of the intensities I and 13 of the [0,01 and [0,2] bands, respectively. More
recently, it has been suggested that a more accurate determination of the CAC can be
obtained by monitoring the changes in the ratio of the pyrene excitation spectra intensities
(Wilhelm et aï., 1991) at ?333 nxn for pyrene in water and 2336 nm for pyrene in an
hydrophobie medium. The latter rnethod was used here and is exemplified in Figure 3.3.
where we present excitation spectra of pyrene in water and in the presence of the non ionic
surfactant PEG-C16 at a concentration higher than its CMC.
Samples for spectroscopie analysis were prepared as follows. Two-rnilliliter
aqueous solutions of increasing potymer concentration (0.04—5x1 rng/I) were equilibrated
overnight with pyrene saturated water ([Py] 6_7x1OE7 M). Excitation spectra were
monitored at 2em39° nm (excitation and emission bandpass: 2 nm). Fluorescence spectra
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were recorded at 25 oc on a series 2 Aminco Bowman spectrofluorirneter (Spectronic
Instruments inc.. Rochester. NY).
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Figure 3.3. Excitation spectra of pyrene (2 x 1 O M aqueous solution) monitored at 2-en
390 nm in absence (.) or presence (À) of PEG-C6 at a concentration of
5x103 mg/1.
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3.4.4. Physical loading of CsA in DEX-g-PEG-C,, polymeric micelles
A dialysis method was employed to prepare CsA-loaded polymeric micelles. A
DEX-g-PEG-C,7 solution (5 mg/ml) in deionized water (Milli-Q water purification system,
Millipore, Billerica, MA) and a CsA solution (5 mg/ml) in ethanol were prepared
separately. Each solution was stirred 1 h at room temperature. Subsequently, different
mixtures of polymer with varying CsA concentrations (2.5—40% w/w) were prepared by
mixing the two solutions to a final volume of 4 ml.
The different mixtures were stirred for 2 h at room temperature. To rernove free
CsA and form CsA-loaded micelles. the mixtures were transferred into a pre-swo]len serni
permeable SpectralPor Ï dialysis membrane (molecular weight cutoff 6000—8000 g/mol,
Spectrum Laboratories Inc., Laguna Hills, CA) and were dialyzed against distilled water for
48 h. During the first 2 h, the water was exchanged two times (eveiy hour) anci then six
times during the following 46 h. After a total of 48 h of dialysis, each solution was fïltered
through a 0.22-jim pore-size nylon filter (Whatman Inc., Clifion, NJ) and the filtrate was
freeze-dried in the absence of any lyoprotectant.
3.4.5. Micelle size measurement
The hydrodynamic diameter of CsA-free as well as CsA-loaded DEX-g-PEG-C,1
polymeric micelles in aqucous solution was evaluated by dynamic laser light scattering
(DLS) using a Malvem system (Autosizer 4700. Malvem Instruments Ltd. Malvem. UK)
during 180 s at 25 °C, with a scattering angle of 90°. Samples were passed through 0.22-
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im pore-size filter before size measurement to remove dust particles. It was verified
that the filtration step did flot significantly influence the mean micelle size. The correlation
decay functions were analysed by the cumulant method to determine the Z-average size.
The constrained regularized CONTIN method was used to obtain the particle size
distributions. The values in Table 3.2. represent the average particle diarneter together with
the polydispersity index obtained for the same sample. Ail measurements were performed
in triplicate; the data presented are the rnean±S.D.
3.4.6. HPLC analysis
The micelle-incorporated CsA was extracted from freeze-dried micelles using ACN.
The resulting suspensions were sonicated for 10 min then agitated for $ h. They were then
filtered through 0.45-tm pore-size Gelman GHP Acrodisc filters (Waters, Milford, MA)
and assayed by HPLC (Ugazio et aï., 2002) using an Agilent Technologies HP 1100
chromatography system with a quaternary pump, a UV-visible detector, a column
thermostat and a HP Vectra computer tAguent Technologies, Waldbronn, Germany)
equipped with HP-Chemstation software. A symrnetry octadecyl-sitane Cig (5 rm, 250x4.6
mm i.d.) column and the corresponding guard column of sirnilar characteristics (20x3.9
mm i.d.) (Waters) were used. The mobile phase consisted of ACN/water (80:20) with a
flow rate of 1.2 ml/min. The column was thermostated at 70 °C. In ail cases. the injection
volume was 50 iI and the run time was 10 min. The CsA peak. monitored at 210 nm.
appeared at a retention tirne of 6.5 min. A CsA calibration curve was prepared using
standard solutions of concentrations ranging from 3.125 to 400 rng/l. with a first-order
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correlation coefficient (r2) greater than 0.99. Finally, the extent of drug loading (DL)
was calculated using Equation (1):
DL(%)=lOO(Wc/WM) Equation (1)
where Wc is the weight of CsA loaded in micelles calculated using the calibration
curve. and WM is the weight of CsA-loaded micelles before extraction with ACN.
3.4.7. CeIl culture
The hurnan colon adenocarcinoma cefls, Caco-2, were grown as described
previousÏy (Hidalgo et aï., 1989). Briefly, Caco-2 ceils were routinely maintained in
DMEM with 4.5 g/l D-glucose. supplemented with 10% (v/v) heat-inactivated FBS. 1%
(v/v) NEAA and 1% (v/v) penicillin—streptomycin antibiotics solution (100 U/ml penicillin
G and 100 tg/ml streptomycin). Cells were allowed to grow in a monolayer culture in 75-
cm2 T-flasks in an incubator at 37 °C with controlled atmosphere containing 5% C02 and
90% relative humidity. Culture medium was changed eveiy 48 h and cells were passaged at
$0—90% confluency at a split ratio of 1:3 using 0.25% tiypsin—1 mM EDTA.
3.4.8. Colorimetric MTT cytotoxicity assay
The ceil viability in presence of dextran T10, PEG-C16 or DEXÏO-g-PEG-C16 (7
mol%) was evaluated using the MIT colorimetric assay. Caco-2 celis were seeded in
triplicate in 96-well culture plates at a density of approximately 5x10 cells in 100 pi ofcell
culture medium per well. The cells were cultured at 37 °C in a humidified atrnosphere of
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5% C02 in air for 48 h. Subsequently, increasing concentrations of dextran T10, PEG
or DEX1O-g-PEG-C16 (O—10 g/l in culture medium) were added to the ceils. Caco-2
ceils were further incubated at 37 °C for 4 h. Thereafier, ccli viability was determined by a
MTT test according to the procedure described by Mosmaim (Mosmaim, 1983). The test is
based on mitochondrial dehydrogenase ce!! activity as an indicator of cet! viabiiity. Ten
microliters of 5 mg/ml MTT solution in phosphate-buffered saline (PBS; 75 mM NaC1. 53
mM Na2 HPO4, 13 mM NaH2PO4, pH 7.2) were added to each we!!. Afier 4 h of additional
incubation at 37 °C, 100 tl of 10% S.D.S in 0.01 N HC! solution were added to each we!!
to stop the reaction and to ensure solubilization of formazan ciystals. The plates were
incubated ovemight at 37 °C, afier which the optical density values were measured at 570
nrn using a multiweli-scanning spectrophotometer (PowerWave Biotek Instruments,
Winooski, VT).
3.5. RESULrS AND DISCUSSION
3.5.1. Characterization of the modified dextrans
Various modified dextrans were prepared. They differed in three molecular aspects:
(i) the molecular weight of dextran (10000 and 40000 Da or ca. 62 and 247 g!ucose units
per chain, respectively): (ii) the level of graffing, i.e. the number of hydrophobic
substituents linked to the chain: and (iii) the size of the hydrophobic group (hexadecy! or
octadecyt). The association properties, summarized in Table 3.1., were gathered from
fluorescence probe experiments that yie!d the critical association concentration, and from
14$
DLS measurements that give the average size of the polymeric micelles (Table 3.2.).
The 1H-NMR spectroscopy data, surnmarized in Table 3.1.. showed that DEX-g-PEG-C,,
copolymers with different molar content in PEG-C,7 (2—7 mol%) were synthesized. The
degree of substitution was calculated as ‘MCX 1 °°“a, where ‘Me is the average integral of the
signal due to the terminal methyl protons of the PEG-C,7 groups (-O.$5 ppm) and la is the
integral ofthe signal due to the anomeric protons ofdextran (4.7 ppm).
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3.5.2. Critical association concentration (CAC) of DEX-g-PEG-C,, micelles
A fluorescence assay described in detail in the experirnental section was used to
determine the polymer concentration at which micellization first takes place. The
hydrophobic pyrene probe was added to polymer solutions of increasing concentration and
pyrene excitation spectra were measured for ail solutions. The excitation spectrum
undergoes a small shifi to longer wavelengths as the probe passes from a hydrophilic to a
hydrophobic environment (Figure 3.3.). This shift is quantified in terms of the ratio,
1336/1333, ofthe fluorescence intensities at 336 and 333 nrn.
Plots of the 1336/1333 ratios versus the logarithm of the concentration of the aqueous
solutions of DEX-g-PEG-C,, of varying compositions are shown in Figure 3.4., together
with those of solutions of the surfactants PEG-C16 and PEG-C18. $igmoidal curves were
obtained for ail the DEX-g-PEG-C,1 copolymers. The CAC value was determinect for each
polymer solution from the intersection of two straight unes (the horizontal line with an
almost constant value of the ratio 1336/1333 and the vertical line with a steady increase in the
ratio value). The estirnated CAC values are presented in Table 3.1. The CAC values
decrease with increasing molar content of PEG-C,1 residues Iinked to the polyrner
backbone, for each hydrophobie group and each dextran molecular weight. The CAC
values of DEX4O-g-PEG-C,1 are larger than those of the corresponding DEXI O-g-PEG-C,1
sampies. when determined in terrns of weight of polymer. It is more insightfui to compare
the CAC in ternis of the alkyl group concentration (Figure 3.43 and Table 3.1 .). These
results are consistent with recent evidence suggesting that the increase in the length of a
152
hydrophobic residue at a given length of a hydrophilic polymer chain causes noticeable
decrease in CAC value and increase in micelle stability (Nagarajan et aï., 1989).
3.5.3. Size of the DfX-g-PEG-C micelles
The hydrodynamic diarneters of polymeric micelles, determined by DLS, ranged
from 10 to 30 nm (Table 3.2.). In ail cases the size distributions were unirnodal, indicative
of the absence of free polymer chains. We note that the micelles formed by DEX4O-g-PEG-
C,1 are larger than those formed by DEX1O-g-PEG-C,,, independently of the size of the
hydrophobic substituent and of the level of modification. This observation can be taken as
an indication of the steric hindrances induced by carbohydrate chains, which are expected
to take place over a larger volume for the polymer of higher molecular weight
(Maksirnenko et aÏ., 2001; Baldwin et al., 1988). It bas been shown that the uptake of
particles within the intestine and the extent of drug absorption increase with decreasing
particle size and increasing specific surface area (Florence et aÏ., 2001). Thus, the small
size exhibited by ah the polymeric micelles studied here show a favorable trend towards
oral drug delivery.
Figure 3.4. Changes in the ‘336 nrn”333 nm ratio of pyrene fluorescence intensity with the
different concentrations (0.04 — 5x103 mg!!) of (A) (.) PEG-C16 and (o)
PEG-Cis: and (B) () DEXIO-g-PEG-C16 (3 rnol%): (À) DEXIO-g-PEG
Ci6 (7 mol%); (.) DEX4O-g-PEG-Ci6 (2.3 mol ¾); (.) DEX4O-g-PEG-Ci6
(3.5 mol%) and (O) DEXYO-g-PEG-Cig (3.9 rnol%) copolyrners. Each value
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3.5.4. Characterization of the CsA-loaded polymeric micelles
Cyclosporin A was incorporated into the polymeric micelles hy a dialysis method
which involved treatment of an aqueous polymer solution with a solution of CsA in
ethanol, followed by extensive dialysis of the rnixed solution against water. The arnount of
CsA released upon dissolution of the CsA-loaded polymeric micelles was then deterrnined
by an HPLC assay and plotted against the CsA concentration added initially for each
preparation. Both free and micelle-entrapped CsA were measured with this assay. The
amount of free CsA is expected to be low since the undissolved fraction of the drug was
removed by filtration afier the dialysis procedure. We evaluated first the ability of the
surfactant micelles to solubilize CsA (figure 3.5.). Both PEG-C16 and PEG-C18 micelles
were able to incorporate relatively high levels of CsA, 17.5% (w/w) and 13% (w/w).
respectively.
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Figure 3.5. CsA loading (w/w %) in micelles ofPEG-C16 (.) and PEG-C18 (o) at 2.5 —
40 (w/w %) of initially added CsA. Mean + S.D. (n 3).
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Next, we assessed the incorporation of CsA within polymeric micelles. in the
case of polymers prepared with DEXIO, the maximum amount of CsA loaded within the
micelles was 4 and 4.8% (w/w), for DEXÏO-g-PEG-C16 (3 mol%) and DEX1O-g-PEG-C16
(7 mol%), respectively, while DEXIO-g-PEG-Cis (3.9 mol%) resulted in a maximum CsA
loading of 3% (Figure 3.6.A.). The micelles formed by the potymers of higher motecular
weights were flot as effective CsA carriers (Figure 3.6.B.). Nonetheless, in all cases the
amount of incorporated CsA was larger in the case of polymeric micelles than in the case of
unmodified dextrans, which have a very low affinity for CsA (figure 3.6.). The entrapment
efficiency of polymeric micelles remained low (<35%) and further work will be aimed at
improving the drug loading procedure.
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Figure 3.6.
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Several trends are apparent if one compares thc highest CsA loading percentages
determined for the various polymers (Table 3.1.). The percentage of CsA loading increases
with increasing number of PEG-C,1 units grafted per dextran chain. For a constant number
of PEG-C,1 units Q-2 units/dextran chain), the CsA loading achieved with DEX I O-g-PEG
C13 (3.9 mol%) is lower than that determined for DEX1O-g-PEG-C16 (3 mol%). These
results are consistent with the fact that PEG-C16 micelles are more effective in solubilizing
CsA than PEG-C18 micelles, 17.5 and 13%, respectively (Figure 3.5.). They may be taken
as an indication that the micropolarity of the hexadecyl-PEG chains core might present a
better solubilizing core than that offered by the octadecyl-PEG moieties.
DLS measurements carried out on CsA-loaded micelles confirmed that the integrity
of the micelles was preserved during the loading process and that the size of the micelles
was not altered substantially, although a slight increase in micelle diameter was noted in ail
cases (Table 3.2.).
3.5.5. In vitro cytotoxicity study
The cytotoxicity of DEX1O-g-PEG-C16 (7 mol%), DEX1O, and PEG-C16 was
examined using a MIT assay performed with Caco-2 cells. The dose-dependent v:iability of
Caco-2 cells treated with the various materials for 4 h is presented in Figure 3.7. As
anticipated, free PEG-C16 surfactant inhibited ceil growth even at concentrations below I
g/l. Such deleterious effect is consistent with the propensity of polyethyleneglycol aikyl
ether surfactants to affect membrane integrity (Dimitrijevic et cii., 2000). Also, the
polysaccharide DEXYO showed no toxicity up to a concentration of 10 g/l, confirming the
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reported inertness of dextran. Tuming now to the effect of DEX1O-g-PEG-C16 (7
mol%), we determined that it exhibited no significant toxicity towards Caco-2 ceils. up to
concentrations of 10 g!! or concentration with PEG-C16 content (0.05 g!!) equivalent to that
showing cytotoxic effect (80% ceil viability) when present free in direct contact with the
celi. This important resuit indicates that by grafling the PEG-C residties on dextran, we
succeeded in minimizing their toxic effect on ceils. The non-toxic hydrophilic dextran
chains forming the polymeric micelle outer sheil may be in contact with the celis and
effectively insulate them from the surfactant residues assembled in the inner core.
100
90
80
70
60
50
40
Q
30
20
10
O
160
Figure 3.7. Effect of unrnodified dextran T10 (À). PEG-C16 (.) and DEX1O-g-PEG-C16
(7 rnol%) (.) concentration (0 - 10 g/1) on Caco-2 ccli viability measured by
MTT assay following 4 h incubation at 37 oc! 5% C02. Equivalent
concentrations of ftee PEG-C16 and PEG-c16 graffed to dextran T10
backbone are indicated in the figure by stars. Mean ± S.D. (n = 3).
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3.6. CoNcLusioN
In the present study, the solubilization potential of different DEX-g-PEG-C,,
copolymers to poorly-water soluble drugs has been studied. We showed that the ability of
hydrophilic, non-toxic dextran polymers to encapsulate lipophilic drugs, such as
cyclosporin A, can be increased by grafiing hydrophobie PEG-C,7 domains on the dextran
main chain. In aqueous solution, polymeric micelles are formed with low CAC values and
relatively small micelle mean diameter. On the cellular level, they presented no significant
cytotoxicity. Therefore, this new macromolecular system exhibits promising characteristics
for the development of a novel polymeric drug carrier for the oral deliveiy of poorly water
soluble drugs.
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4.1. ABsTt&&cT
The main objective of this study is to exploit the solubilizing potential of
hydroxypropylcellulose-g-poÏyoxyethylene aikyl ether (HPC-g-(POE),-C,1) polymeri c
micelles towards poorly water soluble drugs in order to improve their oral bioavailability.
Hydrophobically modified HPC graft copolymers of various compositions were
synthesized by attaching hexadecyl or octadecyl residues to the hydrophilic HPC hackbone
via short POE linkers of different lengths. The onset of micellization was estimated by
fluorescence spectroscopy. The hydrodynarnic diameter of different HPC-g-(POE)3-C,1
micelles was evaluated by dynamic light scattering (DLS). Cyclosporin A (CsA), a poorly
water soluble immunosuppressant. was selected as model drug. CsA-loaded HPC-g
(POE)-C,1 micelles were prepared by a dialysis procedure and the amount of CsA
incorporated in the micelles was assayed by high-performance liquid chrornatography.
Following 24-h incubation with human colon adenocarcinoma, Caco-2 celis, the
cytotoxicity of various HPC-g-(POE),-C,, copolymers was evaluated using the MTT
colorimetric assay and cornpared to those of unmodified HPC and free (POE)-C,,. In
aqueous solution, different HPC-g-(POE)-C,1 copolymers formed polymeric micelles of
low critical association concentrations (CAC) and micelle mean diameters ranging from 7$
to 90 nm. CsA loading into HPC-g-(POE)-C,, polymeric micelles was significantÏy larger
than in unmodified RPC. It increased with increasing number of (POE)-C,1 units grafted
per HPC chain. On the cellular level, unmodified HPC showed no cytotoxicity, while free
(POE)1.-C,, molecules inhibited cdl growth. Most importantly, the study revealed that HPC
g-(POE).-C,7 exhibited no significant cytotoxic effect.
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4.2. AuTH0R KEYWORDS
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4.3. INTRODUCTION
Oral drug delivety continues to be the preferred gateway of a drug into the
bloodstrearn, especially when repeated or routine administration is necessary (Lavelle et cil.,
1995). However, for effective deliveiy via the oral route, a therapeutic agent must first
dissoïve in the gastrointestinaÏ lumen (Horter et aÏ., 2001; Charman et aÏ.. 1991). This
represents a major challenge in the field of pharmaceutical drug formulation. namely the
design of an oral dosage form for highly lipophilic drugs, that would enhance their
notoriously poor bioavailability (Florence et aï., 1993). Arnong various strategies
investigated for oral deliveiy of poorly water soltible dnigs, such as nanosuspensions
(Muller et al., 2001), microemulsions (Itoh et aÏ., 2002), lipids (Gershanik et aÏ., 2000) and
liposomes (Minato et al.. 2003), the use of polymers has gained much attention because of
their high diversity. biocompatibility, biodegradability and the multiple functional groups
they display for the conjugation of various pilot molecules (Andrianov et cil., 1998).
Among the different polymer-based drug delivery systems, “polymeric micelles represent
a promising delivery vehicle for poorly water soluble pharmaceutical active ingredients
(Kataoka et al., 2001; Trubetskoy, 1999). Polymeric micelles form spontaneously when
amphiphilic polymers. containing both hydrophilic and hydrophobic fragments, are
dissolved in water. They consist of a hydrophobic core created upon assembly of the
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hydrophobic residues stabilized by a corona of highly hydrated hydrophilic polymeric
chains (Jones et aÏ., 1999).
A review of past achievements readily convinces one that, in the case of injectable
drug formulations, polymeric micelles are highly effective drug delivery vehicles (Zhang et
aï.. 1997; Mizumura et al., 2002). They have been largely ignored, however. in oral drug
delivery formulations. We present here a study of polyrneric micelles as drug carriers
capable of solubilizing high levels of lipophitic drugs, so as to improve their absorption
from the gastrointestinal tract and, consequently, their hioavailability following oral
administration.
Cyclosporin A (CsA), a highly lipophilic undecapeptide (Vine et cii.. 1987), was
selected as model drug. Its water solubility, 23 jig/ml at 20 °C, is extremely low. csA is
administered as immunosuppressant to prevent allografi rejection following vanous organ
transplantations (Hamwi et aï., 2000). Its oral administration has aiways been complicated
due to the presence of the metabolizing enzyme cytochrome P-450 and the multidrug
transporter P-glycoprotein (P-gp) in the small intestine (Wacher et al., 1998).
We set out to investigate the suitability of polymeric micelles as carriers in the oral
delivery of CsA. Hydroxypropylcellulose (HPC), a non-ionic water-soluble polymer, was
selected to form the hydrophilic sheli ofthe micelles. HPC is widely used as an excipient in
oral solid dosage forms, in which it acts as a disintegrant (Machida et aL, 1974), and as a
binder in granulation (Skinner et aï., 1999). It is essentially a non-toxic and non irritant
polysaccharide (Final report on the safety assessrnent ofhydroxypropylcellulose, 1986).
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Our strategy is (1) to prepare hydrophobically modifïed
hydroxypropylcelluloses, (HPC-g-(POE)-C) (see Figure 4.1.) by attachrnent of
hydrophobic cetyl (C16) or octadecyl (C18) groups to hydrophilic HPC via a short
polyoxyethylene (POE) linker of varying length; (2) to monitor the formation and
characteristics of HPC-g-(POE)-C,, micelles in aqueous environment (3) to exptoit the
solubilizing power of HPC-g-(POE),-C,, polyrneric micelles towards CsA; and (4) to
evaluate the cytotoxicity of the polymeric micelles towards epithelial intestinal ceils. This
approach will allow us to create nanosized entities. which entrap CsA in their hydrophobie
core while forming a stable aqueous suspension via the steric stabilization prornoted by
hydrated HPC chains.
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Figure 4.1. Chemical structure of HPC-g-(POE)-C,7 copolymer where n = 16 and 12 for
(POE),-C16 and (POE)-C18, respectively, andy = 10 and 20 for (POE)1o-C,1
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4.4. MATERIALs AND MET110D5
4.4.1. Materials
CsA, polyoxyethylene (20) cetyl ether [(POE)20-C1 6; Ci 6H33(OCH2CH2)200H; Brij
5$J, polyoxyethylene (20) steaiyÏ ether [(POE)20-C18 C18H37(OCH2CH2)200H; Brij 78®],
polyoxyethylene (10) cetyl ether [(POE)10-C16; C16H33(OCH2CH2)ioOH; Brij 561. sodium
chloride (NaCI), monobasic sodium phosphate (NaH2PO4). dibasic sodium phosphate
Na2HPO4), sodium dodecyl sulphate (S.D.S), HPC (M $0,000 Da, molar substitution
level (MS): 3.7, where MS is defined as the average number of aikylene oxide per
anhydroglucose unit (Tezuka et aÏ., 1990; Wirick et aÏ.. 1970)) and 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were purchased from Sigrna-Aldrich.
Deuterated dimethyl sulfoxide (DMSO-d6). triethylamine (Et3N) and trimethylarnine
hydrochioride (Me3N+IC1) were purchased from Aldrich Chernicals. HPLC-grade
acetonitrile (ACN) and water were obtained from Anachernia Science. Ethanol (95%) was
obtained from Commercial Alcohols (Brampton, ON, Canada). The Caco-2 celi une was
purchased from Arnerican Type Culture Collection (ATCC) at passage 1$. Dulbeccos
modified Eagle medium (DMEM). penicillin—streptomycin (10,000 U/ml penicilLin G and
10,000 jg/ml streptomycin), fetal bovine serum (FBS), 0.25% (w/v) trypsin—1 mM
EDTA4Na and non-essential amino acids tNEAA) were supplied from Invitrogen.
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4.4.2. Synthesis of HPC-g-(POE)-C,, copolymers
Various hydrophobically rnodified HPC-g-(POE)3-C,, grafi copolymers were
synthesized as described elsewhere (Piredda et al., 2003). Briefly, the terminal hydroxyl
group of POE was activated via tosylation. Subsequently. the tosylated (POE)-C,1 was
coupled to HPC by a Williamson ether synthesis. The resulting HPC-g-(POE)-C,,
copolymers were purified by a soxhiet extraction with n-hexane to remove ail frce (POE),.
C,7 residues. The level of (POE)3-C,, graffing was determined by 1H-NMR spectroscopy in
DMSO-d6 using a Bruker ARX-400 400 MHz spectrometer.
4.4.3. Critical association concentration of the HPC-g-(POE)3.-C,, polymeric micelles
The critical association concentration (CAC) of the HPC-g-(POE),-C,, copolymers
was estirnated by fluorescence spectroscopy using pyrene, a hydrophobic fluorescence
probe that preferentially partitions into the hydrophobic core of the micelle. It undergoes
changes in its photophysical properties as a resuit of the change in the rnicropolarity it
experiences upon diffusion from bulk water (hydrophilic environrnent) into the micelle core
(hydrophobic environment) (Zhao et al., 1990; Dong et al.. 1984). An estimation of the
CAC value was obtained by monitoring the changes in the ratio of the pyrene excitation
spectra intensities (Wilhelm et ctl., 1991) at 2 =333 nm (1333) for pyrene in water and 2
=336 nrn (1336) for pyrene in the hydrophobic medium within the micelle core. The method
used is exemplified in Figure 4.2. where we present (A) a series of excitation spectra of
pyrene in water and in the presence of increasing concentrations ofthe non ionic surfactant
(POE)20-C18 and (B) traces ofthe concentration dependence ofthe ratio ‘336/1333 in solutions
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of(POE)io-C16, (POE)20-C16 and (POE)20-C18. The critical micelle concentration (CMC)
values are taken as the surfactant concentration corresponding to the onset of the increase in
the ratio ‘336/1333. The CAC value was determined for each polymer solution from the
intersection of two straight lines (the horizontal line with an almost constant value of the
ratio ‘336/1333 and a line approximating the steep upward section of the sigmoidal curve (sec
Figure 4.2.3.).
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$amples for spectroscopie analysis werc prepared as follows: A pyrene
saturated solution in deionized water was prepared by stirring ovemight a suspension of
pyrene in water, followed by filtration to remove excess undissolved pyrene microcrystals.
Polymer or surfactant stock solutions (10 g/1) were prepared in pyrene-saturated water.
They were left to equilibrate under agitation over 24 h away from light. Subsequently, the
stock solutions were diluted with pyrene-saturated water to obtain solutions of varying
polymer concentrations (1 0—i O g!!), which were further equilibrated under agitation for 24
h. Excitation spectra were monitored at 2cm=39° nm (excitation and emission siits were set
at 0.5 and 1.0 mm, respectively). Steady-state fluorescence spectra were measured at 25 oc
with a Fluorolog Tau-3 spectrometer (Jobin-Yvon Horiba) equipped with a GRAMS/32
(Galactic md.) data analysis system.
4.4.4. Physical loading of CsA in HPC-g-(POE),-C,, polymeric miceLles
A dialysis method was employed to prepare CsA-loaded polymeric micelles. A
HPc-g-(P0E)3-c0 solution (5 mg/ml) in deionized water (MiIli-Q water purification
system) and a CsA solution (5 mg/rnl) in ethanol were prepared separately. Each solution
was stirred 1 h at room temperature. Subsequently, different mixtures of polyrner with
vaiying csA concentrations (2.5—40% w/w) were prepared by mixing the two solutions to a
final volume of 4 ml, keeping the polymer concentration constant (2.5 mg!ml).
The different mixtures were stirred 2 h at room temperature. To remove free csA
and form CsA-loaded micelles, the mixtures were transferred into pre-swol]en semi
permeable Spectra/Por® I dialysis membranes (molecular weight cutoff 6000—8000 g/mol,
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Spectrum Laboratories) and were dialysed against distiÏled water for 48 h. During the
first 2 h, the water was exchanged two times (every hour) and then six times during the
following 46 h. After a total of 42 h of dialysis, each solution was filtered through a 0.22-
trn pore-size nylon filter and the filtrate was freeze-dried.
4.4.5. Micelle size measurement
The hydrodynamic diameter of fteeze-dried CsA-ftee and CsA-loaded HPC-based
polymeric micelles in aqueous solution (5 mg/ml) was evaluated by dynamic laser light
scattering (DLS) at 25 °C using a Brookbaven system with an Uniphase pBlue laser at
wavelength of 532 nm and a scattering angle of 90°. All measurernents were perforrned in
triplicate the data presented are the meanLS.D.
4.4.6. HPLC ana]ysis
hie micelle-loaded CsA was extracted from freeze-dried micelles using acetonitrile
(ACN). The resulting suspensions were sonicated in an ultrasonic bath for 10 mm, then
agitated for 8 h. They were then filtered through 0.45-i.im pore-size Gelman GHP Acrodisc
filters and assayed by high performance liquid chromatography (HPLC) (Ugazio et aï.,
2002) using an Agilent Technnologies HP 1100 chromatography system with a quaternary
pump, a UV-visible detector, a column thermostat and a HP Vectra computer equipped
with HP-Chemstation software. A symmetry octadecyl-silane Cig (5 tm, 250x4.6 mm
T.D.) column and the corresponding guard column of similar characteristics (20x3.9 mm
I.D.) were used. The mobile phase consisted of ACN/water (80:20) with a flow rate of 1 .2
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rnl/rnin. The column was thermostated at 70 °C. In ail cases, the injection volume was
50 pi and the run time was 10 min. The CsA peak, monitored at 210 nm, appeared at a
retention time of 6.5 min. A csA calibration curve was prepared using standard solutions of
concentrations ranging from 3.125 to 400 mg/l, with a first order correlation coefficient (r2)
greater than 0.99. Finally. the extent of drug loading (DL) was calculated using Equation
t Ï):
DL(%)l00(Wc/WM) Equation (1)
where W is the weight of CsA loaded in micelles calculated using the calibration
curve and WM is the weight of CsA-loaded micelles before extraction with ACN. It should
be noted that the minimum amount of CsA detectable by this assay is 0.05% w/w.
4.4.7. Celi culture
The human colon adenocarcinoma celis, Caco-2, were grown as described
previously (Hidalgo et cil., 1989). Briefly, Caco-2 cells were routinely maintained in
DMEM with 4.5 g!! D-glucose, supplemented with 10% (v/v) heat-inactivated FBS. 1%
(v/v) NEAA and 1% (v/v) penicillin—streptomycin antibiotics solution (100 U/ml penicillin
G and 100 jtg/ml streptomycin). cens were allowed to grow in a monolayer culture in 75
cm2 T-flasks in an incubator at 37 °c with controlled atmosphere containing 5% cc2 and
90% relative humidity. cihure medium was changed every 48 h and cells were passaged at
80—90% confluency at a split ratio of 1:3 using 0.25% trypsin—1 mM EDTA.
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4.4.8. Colorimetric MTT cytotoxicity assay
The ccli viability in presence of unrnodified HPC, free (POE)20-C16, (POE)20-C18
and (POE)10-C16 surfactants, or various HPC-g-(POE).-C,, copolymers was evaluated using
the MIT colorimetric assay. Caco-2 ceils were seeded in triplicate in 96-well culture plates
at a density of approxirnately 5xlO cells in 100 41 of celi culture medium per well. The
ceils were cultured at 37 oc in a humidified atmosphere of 5% C02 in air for 4$ h.
Subsequently, increasing concentrations of unmodified HPE, free (POE)1-c,, residues or
various HPc-g-(POE),-c,, copolymers (O—10 g/l in culture medium) were added to the
celis. caco-2 celis were ftirther incubated at 37 oc for 24 h. Thereafler, ccli viabiiity was
deterrnined by a MTT test according to the procedure described by Mosmann (Mosmann,
1983). The test is based on mitochondrial dehydrogenase ceil activity as an indicator ofcell
viability. Ten microliters of 5 mg/ml MIT solution in phosphate-buffered saline (PBS; 75
mM NacI, 53 mM Na2HPO4, 13 mM NaH2PO4, pH 7.2) were added to each well. After 4 h
ofadditional incubation at 37 °c, 100 pi of 10% S.D.S in 0.01 N HCI solution were added
to each well to stop the reaction and to ensure solubilization of formazan crystals. The
plates were incubated ovemight at 37 °C, after which the opticai density values were
measured at 570 uni using a multiwell-scanning spectrophotometer (PowerWave; Biotek
instruments).
18]
4.5. RESU LTS AND DISCUSSION
4.5.1. Characterization of the modified HPC copolymers
Various hydrophobically rnodified HPC copolymers were synthesized (figure 4.1.
and Table 4.1.). They differed in three molecular aspects: (j) the level of grafiing, i.e. the
number of (POE),-C,, substituents tinked to the HPC backbone; (ii) the size of the (POE)1
rnoiety; and (iii) the size ofthc hydrophobic aikyl group (C?,; hexadecyl group or octadecyl
group). They were purified thoroughly to ensure compiete rernovai of unreacted (POE)-C,,
and residual solvent. Analysis by GPC confinried that the molecular weight of HPC was
flot affected significantly by the chemicai modification (data not shown). The degree of
grafting was deten;ined by ‘H-NMR spectroscopy, comparing the relative intensity of
signais due to the POE and C,, protons to the intensity of signais due to protons linked to
the polysaccharide backbone (Piredda et al., 2003). The association properties of the
amphiphilic polymers in water, sumrnarized in Table 4.2., were gathered from fluorescence
probe experiments, which yieid the CAC, and from DLS measurements, which give the
average size of the polyrneric micelLes, as discussed in detail in the foliowing sections.
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4.5.2. Critical association concentration of HPC-g-(POE)),-Cfl micelles
The polymer concentration corresponding to the onset of micellization was deduced
from a fluorescence assay, based on the changes in the photophysics of pyrene, a
hydrophobic probe added in minute arnounts to a polymer solution. This probe partitions
preferably in hydrophobic microenvironrnents, as described in detail in the experimental
section where we present the approach to detennine the CMC values of (POE)1-C,,.
Aqueous solutions of different HPC-g-(POE),,-C,, copolymers exhibited a shift in the pyrene
excitation spectra, sirnilar to that observed with solutions of (POE)1-C,,. Plots of the ‘336/1333
ratios versus the Îogarithm of the concentration of the aqueous solutions of HPC-g-(POE),.
C,, ofvaiying compositions are shown in f igure 4.3. The CAC values of the copolymers in
water are given in Table 4.1. in units ofmg/l ofpolymer and iO mol/l of(POE)1-C,, units.
We notice that, for a given type of hydrophobie group grafled on HPC. the CAC (rng/l)
decreases with increasing molar content of (POE)-C,, residues, reflecting the increase in
hydrophobicity of the polymer and consequent enhanced stability of the polymeric micelle.
The major driving force for the assembly of amphiphilic copolymers in water is the
removal of hydrophobie fragments from the aqueous surroundings resulting in the
formation of micelles consisting of a hydrophobie core stabilized by hydrated hydrophilic
chains exposed into water (Gao et al., 1993). The CAC values are reported also in terms of
(POE)1-C,, molar concentrations (Table 4.1.). We notice that, as anticipated, the CMC of
the free surfactants with longer (POE) segments is lower than the CMC of the
corresponding surfactant with a shorter (POE) head grotip (sec for example (POE)20-C16 vs.
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(POE)10-C16). Conversely, for the same POE segment length (20 units), the surfactant
bearing a C8 group bas lower CMC than the surfactant having C16 group. The CAC values
of the polymeric micelles, reported in units of aikyl group concentration, are nearly
identical, within experimental errors, independently of the (POE)-C,, grafting level.
Overali, though, the onset of miceliization of polymeric micelles occurs at lower aikyl
group concentrations than the CMC ofthe corresponding surfactants.
4.5.3. Size of the HPC-g-(POE)-C,, polymeric micelles
The hydrodynarnic diameters of polyrneric micelles, detemiined by DLS, ranged
from 40 to 90 nm (Table 4.2.). In ail cases, the size distributions were unimodal, indicative
of the absence of free polymer cbains and of large polymeric aggregates. We note that, for
each (POE)1-C,, substituent, the size of micelles decreases with increasing level of grafiing
on the HPC backbone. Moreover, CsA-free HPC-g-(POE)-C,7 micelles are generally larger
than the corresponding CsA-loaded micelles independently of the size of the bydrophobic
substituent and of the level of modification. it should be pointed out that the uptake of
particles within the intestine and the extent of drug absorption increase with decreasing
particle size and increasing specific surface area (Florence et aÏ., 2001). Thus, the small
size exhibited by ail the polymeric micelles studied here shows a favorable trend towards
oral drug delivery.
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Figure 4.3. Changes in the 1336 nm/1333 , ratio of pyrene fluorescence intensity as a
function of concentration (1 — I x i04 mg!!) for the (o) HPC-g-(POE)io-C16
(1 rnol%); (.) HPC-g-(POE)o-Cj6 (4 mol%); (n) HPC-g-(POE)20-C16 (1
rnol%); (.) HPC-g-(POE)20-Cit, (4 mol%); (A) HPC-g-(POE)2o-Cis (1
mol%) and (À) HPC-g-(POE)20-Cjs (3.5 mol%) copolyrners.
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4.5.4. Characterization ofthe CsA-loaded polymeric micelles
Cyclosporin A was incorporated into the polymeric micelles by a dialysis method
which involved treatrnent of an aqueous polymer solution with a solution of CsA in
ethanol, followed by extensive dialysis of the rnixed solution against water. The amount of
CsA released upon dissolution of the CsA-loaded polymeric micelles was then determined
by an KPLC assay and plotted against the CsA concentration added initially for each
preparation. The arnount of free CsA is expected to be low since the undissolved fraction of
the drug was rernoved by filtration after the dialysis procedure. We evaluated first the
ability to solubilize CsA in (POE)-C,1 micelles and by unmodified HPC (figure 4.4.).
(POE)10-C16, (POE)20-C16 and (POE)20-C18 micelles were able to incorporate relatively high
levels of CsA; 17.5%, 21% and 15.5% w/w, respectively. lnterestingly, CsA has some
affinity for unrnodified HPC, with a level of CsA incorporation of 1.4% i’/w. This effect
may reflect the presence of some “hydrophobie pockets” within the HPC structure. The
structure of HPC is known to be heterogenocts with sorne longer isopropoxyl side chains
(Klug, 1971). Next, we assessed the incorporation of CsA within polyrneric micelles (Table
4.2. and Figure 4.5.). For ail copolymer samples, the amount of CsA incorporated in the
micelles was larger than in the case of umuodified HPC (Figure 4.4.). The maximum
amount of CsA loaded within the different micelles ranged from 4.8% to 6.7% (w/w)
depending on the level ofgrafting and on the type of grafted hydrophobie modifier.
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Figure 4.4. CsA toading (% t’/w) in micelles of (POE)10-C16 (.), (POE)20-C16 t.) and
(POE)20-C18 (À) surfactants as well as umnodified HPC polyrner (+) at 2.5
— 40 (w/w %) CsA initial loading in 2.5 mg/rnl micelles. Mean + S.D. (n =
3).
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Figure 4.5. CsA loading (w/w %) in micelles of () HPC-g-(POE)jo-C16 (1 mol%); (+)
HPC-g-(POE)io-Ciô (4 rnol%), (El) HPC-g-(POE)20-C16 (1 rnol%), () HPC
g-(POE)2-Cl() (4 rnol%), (A) HPC-g-(POE)o-C18 (1 rnol%) and (Â) HPC-g
(POE)20-C18 (3.5 mol%) copolyrners at 2.5 —40 (w/w %) CsA initial loading
in 2.5 rng/ml micelles. Mean + S.D. (n 3).
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Several trends are apparent if one compares the highest CsA loading percentages
(at 40% w/w CsA added initially) detemiined for the various polyrners (Table 4.2.). The
percentage of CsA loading increases with increasing grafting level of (POE)1.-C,1 on HPC
backbone. fot a constant number of (POE)1.-C,, units (—5 units per HPC chain). the CsA
loading achieved with HPC-g-(POE)20-Cis (1.7% w/w) is tower than those detennined for
HPC-g-(POE)io-C16 (2.3% w/w) and HPC-g-(POE)20-C16 (2.5% w/w). These resuits are
consistent with the fact that (POE)10-C16 and (POE)20-C16 micelles are more effective in
solubilizing CsA than (POE)20-C18 micelles, 17.5%, 21% and 15.5% (w/w), respectively
(Figure 4.5.). This may be taken as an indication that the micropolarity of the hexadecyl
POE chains core miglit present a better solubilizing environrnent for CsA than that offered
by the octadecyt-POE moieties. It is interesting to note atso that, at Iow CsA initial
concentrations (<15% w/w), HPC-g-(POE)1-C,, polymeric micelles exhibit a
solubilizing/loading trend different from that displayed by (POE)-C micelles (Figure 4.4.
and Figure 4.5.). While the degree of CsA incorporation within (POE).-C,1 micelles
increases steadily with increasing initial CsA concentration, the level of CsA incorporation
in polymeric micelles remains low and nearly constant with initial CsA concentration
<15%, then increases rapidly as the initial CsA concentration exceeds 15%.
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Figure 4.6. Effect of(.) unrnodified HPC, (A) frec (POE)20-C16 surfactant and (o) HPC
g-(POE)20-C16 (4 rnol%) copolyrner concentration (0— 10 g/1) on Caco-2 celi
viabiÏity measured by MTT assay following 24 h incubation at 37 °C/ 5%
CO-,. Mean + S.D. (n = 3).
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4.5.5. In vitro cytotoxicity study
The cytotoxicity ofHPC, (POE)20-C16, (POE)20-C, (P0E)0-C16 and vanous HPC
g-(P0E).-C,, copolyrners was exarnined using a MTT assay perfonTied with Caco-2 ceils.
This study is of particular importance in view of the known toxicity of the (P0E).-C,?
surfactants when they are flot linked to polymers. The dose-dependent viability of Caco-2
cetls treated with unmodified HPC, free (POE)20-C16 surfactant and HPC-g-(POE)26-C16 (4
rnol%) copolymer over 24 h is presented in Figure 4.6. Similar celi viability pattems were
observed in the case of free and HPC-grafted (POE)10-C16 as welI as (P0E)2-C18 (resuits
flot shown). As anticipated, free POE-C,1 surfactants inhibited celi growth even at
concentrations below 1 g/l. Such deletenous effect is consistent with the propensity of
polyoxyethylene aikyl ether surfactants to affect membrane integrity (Dimitrijevic et aï.,
2000). The polysaccharide HPC showed no toxicity up to a concentration of 10 g/1,
confirming the inertness of HPC (Obara et al., 1992). It may also be pointed out that the
World Health Organization (WHO) has not specified an acceptable daily intake for HPC
since the levels consurned were flot considered to represent any hazard to health
(FAO/WHO, 1990). 0f interest to our study is the fact that none of the HPC-g-(P0E)-C
copolyrners exhibited any significant toxicity towards Caco-2 celis. up to concentrations of
10 g/l. This important resuit indicates that by grafling the (POE)-C,1 residues on HPC, we
succeeded in eliminating their toxic effect on celis. The non-toxic hydrophilic HPC chains
forming the polymeric micelle outer sheli are in contact with the cells and effectively
insulate them from the surfactant residues assembled in the inner core.
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4.6. CoNcLusioN
In surnrnary, we have demonstrated that aqueous solutions of HPC-g-(POE)1.-C,,
copolymers of various compositions increasc the solubility of the lipophilic drug,
cyclosporin A, through solubilization of the dnig in the hydrophobic core of polymeric
micelles, while the hydrophilic, non-toxic HPC outer shell stabilizes the system in the
aqueous milieu. The molar contents, as well as the length of the hydrophobic substituent,
have an important effect on the solubilizing power of HPC-g-(POE)-C,, polymeric micelles
towards hydrophobie dmgs. The small size of the polyrneric micelles, the very low
concentration of micellization onset and the absence of cytotoxic effects towards intestinal
ceils represent promising characteristics for the developrnent of a novel polymeric drug
carrier for the oral delivery ofpoorly water soluble drugs.
4.7. Ac]NowLEDGE1ENTs
This work was supported by the Natural Sciences and Engineering Research
Council of Canada under its strategic grants program. M.F. francis acknowledges a
scholarship from the Rx&D Health Research Foundation. We would like to thank Dr.
Patrice Hiidgen and Dr. Albert Adam for providing some useful pieces of equipment.We
would like to thank Dr. Sébastien Gouin for bis help in developrnent of earlier versions of
copolymer synthesis procedure.
194
4.8. REFERENCES
Andrianov, A. K. and Payne. L. G. (1998) Polymeric carriers for oral uptake of
microparticulates. Adv. Drug Deliv. Rev., 34, 155-170.
Charman, W. N. and Stella, V. J. (1991) Transport of lipophilic molecules by the intestinal
lymphatic system. Adv. Drug Deliv. Rev., 7, 1-14.
Dirnitrijevic, D., Shaw, A. J. and Florence, A. T. (2000) Effects of sorne non-ionic
surfactants on transepithelial permeability in Caco-2 ceils. J. Phanri. Phanriacol., 52,
157-162.
Dong, D. C. and Winnik, M. A. (1984) The Py scale of solvent polarities. Can. J. Chem.,
62, 2560-2565.
fAO/WHO (1990) Evaluation of certain food additives and contarninants: thirty-fifth report
of the joint fAO/WHO expert cornrnittee on food additives. Tech. Rep. 5cr. Wld.
Hlth. Org., No. 789.
Final report on the safety assessrnent of hydroxyethylcellulose, hydroxypropylcellulose,
methylcellulose, hydroxypropyl rnethytcellulose and cellulose gum (1986) J. Am.
Cou. Toxico!., 5, 1-60.
Florence, A. T. and Hussain, N. (2001) Trancytosis ofnanoparticle and dendrirner delivery
systems: evolving vistas. Adv. Drug Deliv. Rev., 50, S69-S89.
Florence, A. T. and Jani, P. U. (]993) in Pharmaceutical Particulate Carriers: Therapeutic
Applications (Ed, Rolland, A.) Marcel Dekker Inc., New York, pp. 65-107.
195
Gao, Z. and Eisenberg, A. (1993) A mode! of micellization for block copolymers in
solution. Macromolecules, 26, 7353-7360.
Gershanik, T. and Benita, S. (2000) SeIf-dispersing llpid formulations for improving oral
absorption of lipophulic drugs. Eur. J. Pharm. Biopharm., 50, 179-188.
Hamwi, A., Salornon, A., Steinbrugger, R., fritzer-Szekeres, M., Jager, W. and Szekeres,
T. (2000) Cyclosporine metabolism in patients after kidney, bone marrow, heart
lung, and liver transplantation in the early and late posttransplant periods. Am. J.
Clin. Pathol., 114, 536-543.
Hidalgo, 1. J., Raub, T. J. and Borchardt, R. T. (1989) Characterization ofthe human colon
carcinoma ccli une (Caco-2) as a mode! system for intestinal epithelial permeability.
Gastroenterology, 96, 736-749.
Horter, D. and Dressman, J. B. (2001) Influence of physicochemical properties on
dissolution ofdmgs in the gastrointestinal tract. Adv. Drug Deliv. Rev., 46, 75-87.
Rob, K., Matsui, S., Tozuka, Y., Oguchi, T. and Yamamoto, K. (2002) Improvernent of
physicochemical properties of N-4472. Part 11: characterization of N-4472
microernulsion and the enhanced oral absorption. Int. J. Pharm., 246, 75-83.
Jones, M. C. and Leroux, J. (1999) Polymeric micelles - A new generation of colloidal dnig
carriers. Eur. J. Pharm. Biophanit, 48, 101-111.
Kataoka, K., Harada, A. and Nagasaki, Y. (2001) Block copolymer micelles for dnig
delivery: design, characterization and biological significance. Adv. Drug Dcliv.
Rev.,47, 113-131.
196
Klug, E. D. (1971) Sorne properties ofwater-soluble hydroxyalkyl celluloses and their
derivatives. J. Polymer Sci.: PART C, 36, 491-508.
Lavelle, E. C., Sharif, S., Thomas, N. W., Holland, J. and Davis, S. S. (1995) The
importance of gastrointestinal uptake of particles in the design of oral deliveiy
systems. Adv. Dmg Deliv. Rev., 18, 5-22.
Machida, Y. and Nagai, T. (1974) Directly cornpressed tablets containing hydroxypropyl
cellulose in addition to starch or lactose. Chem. Phann. Bull., 22, 2346-235 1.
Minato, S., Iwanaga, K., Kakemi, M., Yamashita, S. and Oku, N. (2003) Application of
polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose
on systernic and mucosal irnrnunity. J. Control. Release, 89, 189-197.
Mizumura, Y., Matsumura, Y., Yokoyama, M., Okano, T., Kawaguchi, T., Moriyasu, f.
and Kakizoe, T. (2002) Incorporation of the Anticancer Agent KRN5500 into
Polymeric Micelles Diminishes the Pulmonaiy Toxicity. Jpn. J. Cancer Res., 93,
1237-1243.
Mosrnann. T. (1983) Rapid colorimetric assay for cellular growth and survival: Application
to proliferation and cytotoxicity assays.]. Immunol. Methods, 65, 55-63.
Muller, R. H., Jacobs, C. and Kayser, 0. (2001) Nanosuspensions as particulate drng
fonnulations in therapy. Rationale for developrnent and what we can expect for the
future. Adv. Drug Deliv. Rev., 47, 3-19.
Obara, S., Muto, H., Kokubo, H.. Ichikawa, N., Kawanabe, M. and Tanaka, 0. (1992)
Primary dennal and eye irritability tests ofhydrophobically modifled hydroxypropyl
methylcellulose in rabbits. J. Toxicol. Sci., 17, 2 1-29.
197
Piredda, M., francis, M. F. and Wimiik, F. M. (2003) Hydrophobically-modified
hydroxypropyl celluloses: synthesis and self-assernbly in water.
Biornacrornolecules, in preparation.
Skinner, G. W., Harcum, W. W., Bamum, P. E. and Guo, J. H. (1999) The evaluation of
fine particle hydroxypropylcellulose as a rouer compaction binder in pharmaceutical
applications. Drug. Dcv. md. Pharrn., 25, 1121-1128.
Tezuka, Y., 1mai, K., Oshima, M. and Chiba, T. (1990) Deterrnination of substituent
distribution in cellulose ethers by 13C- and 1H-NMR studies of their acetylated
derivatives: O-(2-hydroxypropyl)cellulose. Carbohydr. Res., 196, 1-10.
Trubetskoy, V. S. (1999) Polyrneric micelles as carriers of diagnostic agents. Adv. Drng
Dcliv. Rcv., 37, 8 1-88.
Ugazio, E., Cavalli, R. and Gasco, M. R. (2002) Incorporation of cyclosponn A in solid
lipid nanoparticles (SLN). Int. J. Pharnt, 241, 34 1-344.
Vine, W. and Bowers, L. (1987) Cyclosporine: structure, pharrnacokinetics, and therapeutic
drug monitoring. Crit. Rcv. Clin. Lab. Sci., 25, 275-311.
Wacher. V. J., Silverman, J. A., Zbang, Y. and Benet, L. Z. (1998) RoTe of P-gÏycoprotcin
and cytochrome P450 3A in limiting oraL absorption of peptides and
peptidornimetics. J. Phanu Sci., 87, 1322-1330.
Wilhclm, M., Zhao, C. L., Wang, Y., Xu, R., Winnik, M. A., Mura, J. L., Riess, G. and
Croucher, M. D. (1991) Poly(styrene-ethylene oxide) block copolyrner micelle
formation in watcr: a fluorescence probe study. Macromolecules, 24, 1033-1040.
198
Wirick, M. G. and Waldman, M. H. (1970) Some solution properties of fractionated
water-soluble hydroxypropylcellulose. J. Appi. Polym. Sci., 14, 579-597.
Zhang, X., Burt, H. M., Mangold, G., Dexter, D., Von Hoff, D., Mayer, L. and Hunter, W.
L (1997) Anti-tumor efflcacy and biodistribution of intravenous po]ymeric micellar
paclitaxel. Anticancer Drugs, 8, 696-70 1.
Zhao, C. L., Winnik, M. A., Riess, G. and Croucher, M. D. (1990) fluorescence probe
techniques used to study micelle formation in water-soluble block copolymers.
Langrnuir, 6, 514-516.
CHAPTER FIvE
RESEARCU PAPER
ENGINEERiNG P0LY5AccHA1uDE-BAsFD P0LYMEmc MIcELLEs
To ENHANcE PERMEABILITY 0f CYcL05P0RIN A AcRoss
CAco-2 CELLs
Mira F. francisa , Mariana Cristeac, Yali Yangb and Françoise M. Wlflfllka,b.
a Faculty of Pharrnacy, University of Montreal, C.P. 6128 Suce. Centre-ville,
Montreal, Quebec, Canada H3C 3J7
b Department of Chemistry, University of Montreal, C.P. 612$ Suce. Centre-ville,
Montreal, Quebec, Canada H3C 3J7
ctPetm Poni” institute ofMacrornolecular Chernistry, lasi 700487, Rornania
Pharmaceutical Research, 2005; 22 (2) : 209-219.
200
5.1. ABsTRAcT
Purpose. To assess and compare the effectiveness of two types of polysaccharictc
based micelles as delivery vehicles for poorly-water soluble dmgs by monitoring their
permeability across Caco-2 celi monolayers. Methods. Dextran (DEX) and
hydroxypropylcellulose (HPC) were hydrophobically-modified (HM) by grafting
polyoxyethylene cetyl ether (POE-C16, 15 mol % and 5.4 moI %, respectively). The onset
of micellization and mean diameter of polyrneric micelles formed by HM-DEX and HM
HPC were determined by fluorescence spectroscopy and dynamic light scatterirlg,
respectively. Cyclosporin A (CsA)-loadcd polyrneric micelles were prepared by a dialysis
procedure and the amount of incorporated CsA was assayed by high performance liquid
chromatography (HPLC). The micelles stability in simulated gastric and intestinal fluids
was studied as a function of contact time, and their cytotoxicity towards Caco-2 cells was
evaluated using the MTT colorimetric assay. The bidirectional transport across Caco-2 cells
monolayers of CsA entrapped in HM-DEX and HM-HPC micelle and of the polymers
thernselves was evaluated in the presence and absence ofP-glycoprotein inhibitor. Results.
The amount of CsA incorporated in HM-HPC and HM-DEX micelles reached 5.5 and 8.5
%w/w, respectively (entrapment efficiency of 22 ¾ or more). The polymeric micelles
exhibited high stability in gastric and intestinal fluids and no significant cytotoxicity
towards Caco-2 cells. The apical to basal permeability of CsA across Caco-2 cells
increased significantly when loaded in polymeric micelles, compared to free CsA.
Conclusions. Polysaccharidc-based polymeric micelles are promising carriers for the oral
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delivery of poorly-water soluble drugs. In-vitro tests indicate that, overall, HM-HPC
micelles are more effective, compared to HM-DEX micelles.
5.2. KEY WORDS
Cyclosporin A; polymeric micelles, oral delivery, Caco-2, transport; P-glycoprotein,
dextran, hydroxypropylcellulose.
5.3. INTRODUCTION
The cyclic undecapeptide cyclosporin A (CsA) is a potent immunosuppressive agent
used to prevent allograft rejection following organ transplantations (Merion et aï., 1984;
Klornpmaker et al.. 1993). It is also effective in the treatment of patients with selected
autoirnrnune diseases, such as rheumatoid arthritis (Galla et al., 1995). CsA is CUlTCflhiy
available for oral administration in the form of a microemulsion containing, among other
components, polyoxyethylated castor ou (Cremophor EL) (Foradori et aÏ., 1994; $ketris et
aÏ., 1994). Cremophor EL is a non-ionic surfactant present in various oral lipophilic drugs
formulations, dtie to ils solubilizing properties and its ability to inhibit intestinal P
glycoprotein (P-gp) efflux (Woodcock et al., 1990; Seeballuck et aÏ., 2003). Cremophor
EL, however, is known to induce undesirable side effects, such as nephrotoxicity (Mason,
1990; Skorecki et al., 1992) and induction of anaphylactic reactions in sensitized patients
(Friedman et aÏ., 1985; Howrie et al., 1985). Consequently, there has been much effbrt
devotcd to the design and development of novel dosage forms of CsA, aimed at decreasing
202
the side effects of the current fonnulation while preserving the bioavailability and
therapeutic effects ofthe drug. Alternative approaches investigated include incorporation of
the dmg within microspheres, nanoparticles, and liposomes (Allen et aL, 1999; Chen et aï.,
2002; Sanchez et aï., 1995; Itoh et aI., 2003; Al-Meshal et al., 1998). Given the lirnited
stability of liposomes in vivo, they have flot been widely appïied in clinical use (Ozpolat et
aI., 2003; Nacka et aï., 2001; Taira et aï., 2004). Other particulate vehicles, however, have
been developed and shown promising properties in terrns of controlled drug release and
distribution (Bonduelle et aï., 1996; Molpeceres et aï.. 2000; Ugazio et aï., 2002; Daia et
aL, 2004).
It is often observed that the gastrointestinal (GI) uptake of microparticÏes is affected
significantly by particle size. For example, Desai and coworkers (Desai et aï., 1996)
reported that the uptake efficiency of particles 100 nm in diameter by the GI tract is 15 to
250-fold higher than that of micron-sized pailicles. Thus a major thmst of current research
towards more efficient oral formulation lies in the design of nanoparticles able to entrap
hydrophobic dmgs with high efficiency, to transport them through the GI tract, and to
enhance their absorption through the intestinal epithelial ceils. The main materials
investigated over the Iast few years as nanoparticulate carriers for CsA include hydrophobie
biodegradable polymers, such as poly(caprolactone) (Varela et aï., 2001), poly(D,L-Iactic
acid) (Gref et aï., 2001), positively charged chitosan hydrochloride (De Campos et aï.,
2001), and hydroxypropyl methylceilLilose phthalate (HPMCP) (Sertsou et aï., 2002).
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We reported recently the synthesis and physico-chernical properties of
arnphiphilic polymers consisting of a polysaccharide main chain decorated with lipidic side
chains rnade-up of n-hexadecyi or n-octadecyt chains (Francis et aï., 2003a; Francis et al.,
2003b). When placed in an aqueous environment, these polymers spontaneously assemble
in the form of micelles with a hydrophobic core sulTounded by a hydrophilic corona made
up by highly hydrated polysaccharide chains. Unlike surfactant micelles, which tend to
disintegrate upon dilution triggering lysis of ccli membranes (Lasic, 1992; Hofland et aï.,
1992), polymeric micelles are rernarkably stable towards dilution and tend to exhibit
minimal cytotoxicity (Yu et aï., 1998; Kim, S.C. et al.. 2001; Jevprasesphant et aï., 2003).
Several considerations need to be taken into account in designing amphiphilic polymer
formulations, the most important factor being the choice of the polymer backbone. In our
studies, we opted to construct the polymeric micelles from non-toxic polysaccharides,
either dextran (DEX-C1 6) or hydroxypropylcellulose (HPC-C1 6) (Figure 5.1.). Dextran,
consists of f3-D-glucose units, predorninantly linked by 1-6 glycosidic iinkages (Larsen,
1989). It possesses excellent biocompatibility and has been used in medicine as plasma
substitute, due to its known innocuousness both locally and systemically (Couch, 1965).
More recently, dextran-based gels and prodrugs have been investigated as carriers for a
variety ofbioactive agents (Draye et al., 1998; Kim, 1.S. et aï., 2000; Zhang et aï., 2002;
Mehvar, 2000). Hydroxypropylcellulose is a common excipient in oral formulations, due to
its excellent processability, disintegrant and bioadhesive properties. The latter feature is of
interest in our application as well, since it may promote the contact of HPC-based micelles
with the intestinal epithelial cells and their transport through the cdl membranes.
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(A)
(B)
Figure 5.1. Chemical structures of unlabelled and f luorescein-labelled (A) DEX-C16 (15
mol %) and (B) HPC-C16 (5.4 mol ¾) copolyrners.
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Iwo main factors contribute to the bioavailability of orally-absorbed drugs: (1)
their resistance to the in vivo metabolic environment, in particular changes in pi-1 and
presence of enzymes; and (2) their intestinal absorption which is mainly controlled by the
solubility of the drug in the intestinal lumen and by the drug pemieability across the
intestinal barrier. There are two routes oftransepithelial drug transport by passive diffusion
(Pade et aÏ., 1997): the transcellular route through the celi membrane and the paracellular
route from the tight junction to the lateral space. In the case of hydrophobic dmgs, the
contribution of the transcellular route predominates. In order to assess, whether polymeric
micelles may promote dnig bioavailability it is necessary to quanti1ï the transport of the
micelles through the intestinal balTier by an in vitro assay (Audus et aÏ., 1990). The Caco-2
ceil line, which is derived from human colon adenocarcinoma, undergoes spontaneous
differentiation in culture, forming monolayers of polarized enterocytes that possess
morphological and functional similarities to the srnall intestine (Hidalgo et aÏ., 1989;
Cogbum et aÏ., 1991; Delie et aÏ., 1997; Armrsson et aÏ., 2001). In particular, Caco-2 cells
express on the apical (AP) surface the P-gp efflux pump(Hosoya et aÏ., 1996), an
absorption barrier limiting the oral bioavailability of hydrophobie dmgs from the
gastrointestinal tract (Hunter et aÏ., 1997). The pemieability assay through Caco-2
monolayers bas emerged as a leading method for deteniining the apparent pemieability
coefficient of drugs and to investigate their absorption mechanisms (Delie et aÏ., 1997;
Artursson et aÏ., 1997; krishna et al., 2001; Kamm et aÏ., 2000; faassen et aÏ., 2003), sijice
a strong correlation was observed between in vitro penneability across Caco-2 celis and in
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vivo human absorption for a variety of compounds (Artursson et al., 1991; Yee, 1997;
Yarnashita et aÏ., 1997).
The aim of this work is to investigate, using the Caco-2 ceil model, the
transepithelial transport of CsA incorporated within dextran- and HPC-derived polyrneric
micelles. We monitor (1) the penueability of CsA through Caco-2 celi membranes in the
absence and presence of Pluronic P85 used as a P-gp inhibitor and (2) the transport of the
polymer micelle itself We use a radiolabelled CsA to track the dmg as it crosses the
epithelial barrier and, to assess the fate of the polymers, we use a fluorescent marker
covalently linked to the polyrners. We assess as well the stability of HPC—C16 and DEX-C16
micelles exposed to simulated biological fluids. This smdy will add to our knowledge of
the fate of nanoparticles as they traverse the intestinal membrane and will allow us to
compare the properties ofHPC- and DEX-based polymeric micelles.
5.4. MATERIALS AND METHODS
5.4.1. Materials
Cyclosporin A (CsA), polyoxyethylene (10) cetyl ether (POE-C16;
C1 6H33(OCH2CH2)1 0OH; Brij 56), hydroxypropylcellulose (H PC; MW 80,000 Da, molar
substitution level (MS): 3.7, where MS is defined as the average number of alkylene oxide
per anhydroglucose unit (Tezuka et al., 1990; Wirick et aÏ., 1970)), monobasic potassium
phosphate (KH2PO4), sodium chloride (NaCl), (5
-( [4,6-dichlorotriazin-2-yl] ammo)
fluorescein (DTAF), N-(2-hydroxyethyl)-piperazine-N’-(2-ethanesulfonic acid) (HEPE S)
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and 3 -(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium brornide (MTT) were
purchased from Sigrna-Aldrich (St. Louis, MO). Optical grade pyrenc (99 %),
dichioromethane (DCM), deuterated dirnethyl sulfoxide (DMSO-d6), triethylarnine (Et3N)
and trimethylamine hydrochioride (Me3N.HCI) were purchased from Aldrich Chemical Co.
(Milwaukee, W1). Dextran T10 (DEX; MW 10,000 Da) was supplied by Amersharn
Biosciences (Uppsala, Sweden). HPLC-gradc acetonitrile (ACN) and water were obtaincd
from Anachernia Science (Montreal, PQ, Canada). Ethanol (95 %) was obtained from
Commercial Alcohols Inc. (Brampton, ON, Canada). The Caco-2 ccli une was purchased
from Arnerican Type Culture Collection (ATCC, Rockville, MD) at passage 1 8.
Dulbecco’s rnodified Eagle medium (DMEM), penicillin-streptornycin (10,000 U/ml
penicillin G and 10,000 pg/rnl streptornycin), fetal bovine serum (FBS), 0.25 % (w/v)
trypsin — 1 mM EDTA.4Na (iX) and non-essential arnino acids (NEAA) were supplied
from Invitrogen Life Technologies (Burlington, ON, Canada). Poly(cthylene oxide)27-b-
poly(propylene oxide)39-b-poly(ethylene oxide)27, also known as Pluronic P$5® or P85, was
provided by BASF Corp. (Parispany, Ni). [3H] Cyclosporin A (8.00 Ci/rnrnoi) was
purchascd from Arnersham Phannacia Biotech (Piscataway, Ni). Ultrapure watcr, used for
all aqueous solutions, was from a Milli-Q Filtration system (Millipore, Bedford, MA).
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Table 5.1. Characteristics of the polymers used in the present study
Number ofPOE-C16 bPolymer Grafted POEC16a DTAF concentration
units per polymer
composition (mol %) (mol DTAF/g polymer)
chain
DEX-C6 15.0±0.5 9 -
HPC-C16 5.4±0.5 25
-
Ï
DTAF-DEX-C16 15.0 ± 0.5 9 5.45 ±0.05
DTAf-HPC-C16 5.4 ± 0.5 25 ] 5.70 ±0.05 x 1OE6
fronJÏfMR spectra (Francis et aI., 2004)
b from UV/Visible spectra (see experimental section)
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5.4.2. Synthesis of Fluorescein-labelled HM-polysaccharides
The Iabelled polymers were prepared by modification of HPC-C16 and DEX-C16
(f igure 5.1.), which were synthesized following the general procedure reported elsewhere
(francis et aÏ., 2004). The composition and molecular characteristics ofthese polymers are
listed in Table 5.1. The solubility characteristics of the two polyrners are different,
therefore the labelling procedure had to be adapted to each sample as follows:
Freparation of D TAf-HFC-C16.. Hydroxypropylcellulose-grafted-polyoxyethylene
(10) cetyl ether (HPC-C16, 300.0 mg) was dissolved in a 1/1 v/v ofwater/acctone mixture
(50 ml). The pH ofthe solution was adjusted to 10 using aqueous NaOH (5 N). A solution
of 5-DTAf (8.0 mg, 0.0 15 mmol) in aqueous NaOH (15 ml, pHlO) was added in five
portions to the polymer solution at time intervals of 30 min. At the end of the addition, the
reaction mixture was kept at room temperature for 17 h. Subsequently, it was dialyzed
extensively against distilled water (membrane MW eut-off: 6,000-8,000 dalton, Spectnim
Laboratories Inc., Rancho Dominguez, CA) and isolated by freeze-drying; yield: 107.2 mg.
The degree of DTAF substitution was determined by quantitative UV/Visible
spectrophotornetry (Hewlett-Packard 8452A photodiode array spectrometer, Hewlett
Packard, Palo Alto, CA). The labelled polyrner was dissolved in aqueous solution (pH 9).
DTAf was used as reference (molar extinction coefficient s492Ifl: 70 000 cm*moF’ at 2
492 nm) (BÏakeslee, 1977).
Preparation ofDTAF-DEX-C,ô: Dextran-grafted-polyoxyethylene (10) cetyl ether
(DEX-C16, 300 mg) was dissolved in water (50 ml). The pH ofthe solution was adjusted to
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10 with aqueous NaOH (5 N). A solution of 5-DTAf (29.6 mg, 5.6x105 mol) in
aqueous NaOH (15.0 ml, pH=l0) was added portion-wise over 2 h. to the polymer solution.
At the end of the addition, the reaction mixture was stirred at room temperature for 17 h. It
was dialyzed extensively against water (membrane MW eut-off: 3,500 dalton). The
dialyzed polymer solution was fiirther purified by ultrafiltration through an Amicon YM3
ultrafiltration membrane (Amicon, Beverly, MA). The Iabelled polymer was isolated by
freeze-drying; yicld: 132 mg and its degree of labelling was deterrnined by UV/Visible
spectrophotometry.
5.4.3. Characterization of 11M DEX and HPC in solution
The critical association concentrations (CAC) of DEX-C and HPC-C16 in aqueous
solution were estimated by steady-state fluorescence spectroscopy using polymer solutions
of increasing concentration in pyrene-saturated water ([Py] 7 xl 0’ M) and monitoring
the changes in the ratio ofthe pyrene excitation spectra intensities (Zhao et al., 1990) at 2. =
333 nm (1333) for pyrene in water and 2. =336 nrn (1336) for pyrene in the hydrophobie
medium within the micelle core. The hydrodynamic diarneter of dmg-free and drug-loaded
polymeric micelles in water was evaluatcd by dynamic laser light scattering (DLS) at 25°C
with a scattering angle of 90°.
5.4.4. Physical loading of CsA in 11M DEX and HPC polymeric micelles
A dialysis method was employed to prepare CsA-Ioaded polymeric micelles.
Polymer solutions (5 mg/ml) in deionized water, and a CsA solution in ethanol (5 mg/ml)
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were prepared separately. Subsequently, different mixtures of polymer with varying
CsA initial concentrations (2.5 — 40 % w/w) wcre prepared. Following 4$ h of dialysis,
each solution was filtered through a 0.22-jim pore-size filter and the filtrate was freeze
dried. CsA was extracted from freeze-dried micelles using acetonitrile (ACN). The
resulting suspensions were sonicated in an ultrasonic bath for 10 min then agitatcd for $ h.
They were then filtered and assayed by HPLC using a syrnrnetry octadecyl-silane Cig
column. The mobile phase consisted of ACN water ($0 t 20) with a flow rate of 1.2
ml/min. The column was thermostated at 70 °C. The CsA peak, monitored at 210 nrn,
appeared at a retention time of 6.5 min. A csA calibration curve was prepared using
standard solutions of concentrations ranging from 3.125 - 400 mg/l, with a first order
correlation coefficient (r2) greater than 0.99. Drug loading (DL) was calculated using
Equation 1:
DL(%)=100(WC/WM) (I)
Where W is the weight ofcsA loadcd in micelles and WM is the weight of micelles
before extraction.
5.4.5. Stability study
The stability of CsA-loaded polymeric micelles in gastrointestinal fluid was
monitored by measuring the release of CsA entrapped within micelles as a ftmction of time
when in contact with simulated gastric and intestinal fluids. Simulated gastric fluid was
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prepared according to USP XXIV, using a solution ofNaCI (2.0 g/l, pH 1.2 by addition
of HCI). Simulated intestinal fluid was also prepared according to USP XXIV. Monobasic
potassium phosphate (6.8 g) was dissolved in 250 ml distilled water, and 190 ml of 0.2 N
NaOH and 400 ml of purified water were added. This solution was adjusted to a pH of 6.8
with 0.2 N NaOH and diluted to 1000 ml. Dialysis bags (MW eut-off: 6,000-8,000 dalton)
containing a solution of CsA-loaded micelle (15 mg, CsA concentration 5 % t’/w) in
simulated gastric or intestinal fluid (3 ml) were placed into flasks containing 1 80 ml of the
corresponding simulated fluid. The flasks werc shaken at 100 rpm and the temperature was
maintained at 37°C during $ h. At specific time intervals, 10 ml aliquots were taken from
the release medium (dialysate) and replaced by the corresponding fresh simulated fluid (10
ml) in order to keep the system under sink conditions. At the end of the experirnent, the
dialysis bags were eut open and their content was allowed to leak into the release medium.
An aliquot of this solution was sarnpled to determine the concentration conesponding to
100 % release. The aliquots were freeze-dried. The CsA content ofthe residue isolated was
assayed by the HPLC method described above. Release of free CsA was also perforrned as
a control. AI! stability tests were performed in tripticates; the data presented are the mean +
S.D.
5.4.6. Cdl Culture
The hurnan colon adenocarcinoma celis, Caco-2, were routinely maintained in
Dulbecco’s rnodified Eagle medium with 4.5 g!! D-glucose, supplernented with 10 % (v/v)
heat-inactivated fetal bovine semm, 1 ¾ (v/v) non-essential amino acids and a 1 ¾ (i’!v)
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penicillin-streptomycin antibiotics solution (100 U/rnl penicillin G and 100 pg/rnl
streptornycin). Ceils were allowed to grow in a monolayer culture in an incubator at 37 oc
with controlled atmosphere containing 5 % C02 and 90 % relative humidity. Ceils were
passaged at $0 — 90 % confluency at a split ratio of 1:3 using 0.25 ¾ trypsin — I mM
EDTA.
5.4.7. Cytotoxicity Assay
caco-2 ceils were seeded in triplicate in 96-well culture plates at a density of
approximately 5 x i0 celis in 100 tl of cdl culture medium per welJ. The ceils were
cultured for 4$ h at 37 °C in a hurnidified atrnosphere of 5 % C02 in air. Thereafier, Caco-2
ceils were exposed to high concentration (10 g/1) of POE-C16, DEX, HPC, DEX-C16 or
HPC-C16, followed by incubation periods of 4 h and 24 h. CeIl viabi]ity was evaluated
using the MTT colorimetric assay as previously described (Mosmann, 1983; Hansen et al.,
1989). The assay is based on the reduction ofMTT by mitochondria in viable ceils to water
insoluble fonnazan crystals. The absorbance was rneasured with a multiweil-scanning
spectrophotorneter (PowerWave; Biotek Instruments, Winooski, VI) at 570 nm.
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5.4.8. Transport studies of CsA-loaded micelles of 11M polysaccharides across
Caco-2 ccli monolayers
Transport of CsA-loaded polymenc micelles across Caco-2 ceils was evaluated as
follows: celis were seeded onto polycarbonate filter inserts in 6 well Transwe1l’ dishes
(Coming Costar Co., Cambridge, MA) at a density of approximately $ x i04 cells/cm2.
Celis were incubated for 21 - 25 days to atlow confluency, full maturation, including P-gp
expression (Hosoya et al., 1996) and increased transepithelial electrical resistance (TEER)
due to the formation of tight junctions in the ccli monolayer (Bailey et aÏ., 1996). The
culture medium was rcplaced (1.5 ml apical (AP) side and 2.6 ml basolateral (BL) side)
eveiy other day for thc first week and daiiy thcreafier. The integrity of the Caco-2
monolaycrs was evaluated both bcforc and immediatcly afier die study using a Millicel®
Electrical Resistance System equipped with STX-2 electrodes (Miliipore Corp., Bedford,
MA). Typical TEER values exceeded 300 Q/cm2. Prior to experiments, the culture rncdium
of Transwei1’-grown Caco-2 ccli monolayers was replaced with prewarmed (37 °C)
transport rncdium consisting of Hanks’ balanced sait solution (HBSS) supplemented with
25 mlvi glucose and 10 nilvl HEPES (pH 7.4). The ccli monolaycr was equilibrated for 30
min at 37 oc before undcrtaking the transport studies. The AP and BL chambers receivcd
1.5 and 2.6 ml of transport medium, respectivciy. Afier cquilibration, TEER values of
monolayers werc detcnuined in tripiicates. Thc amounts of CsA and polymcr transportcd
across Caco-2 ccli rnonolayers were detenuined as dcpicted in figure 5.2.
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Copolymer assayed
by fluorescence
measurements
CsA-loaded micelles
in donor chamber
z
CsA and copolymer
in receiver cham ber
CsAassayed by
liquid scintillation
counting
figure 5.2. Schematic representation of the procedure used to study the transport of
CsA-loaded polymeric micelles across Caco-2 ccli monolayer.
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5.4.9. Transport of CsA
CsA—]oaded fluorescently labelled polyrneric micelles or free CsA were placed in
HBSS transport medium in arnounts such that the final concentration of CsA was I jiM (0.6
1iCi [3H] CsA together with unlabeled CsA). It shoutd be noted that the CsA (luM)
containing polymeric micelles were prepared from solutions containing 25 ¾ (v’/w) of
CsA, a concentration for which the final CsA loading in polymeric micelles (5 % w/w) is
the same, within experirnental uncertainty, for DEX-C16 and HPC-C16 (sec f igure 5.3.).
The solutions were loaded in the AP or BL (donor) cornpartrnents. At predeterrnined time
points over a 4-h period, aliquots (400 ui) were withdrawn from the opposite (recciver)
chamber. After sample withdrawal, an equivalent volume of the transport medium was
added to the receiving cornpartmcnt to maintain a constant receiver fluid volume. Studies
of CsA transport in presence of P-glycoprotein inhibitor (PGI) were conducted using
Pluronic P85 unirners (P85, 30 1tM in transport medium) (Nernrkar et al., 1996;
Batrakova et al., 199$a; Batrakova et al., 1998b). P85 solution was added to the AP side of
monolayers, and following sampling, equal volumes were replaced using P85-containing
solution. At the end of the experiment, TEER values were measured in triplicates to assess
the integrity of the ccli monolayers. The aliquots rernoved during the testing periods were
placed in scintillation vials (along with the pipet tip used for sampling) and diluted with 10
ml of scintillation liquid (Ultirna Gold°, Packard BioScience, Meriden, CT). The amount of
transported CsA was determined by liquid scintillation counting using a Tri-Carb® liquid
scintiLlation analyzer (Packard Instrument Co., Meriden, CI) after correction for changes of
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volume and concentrations by the replacement media. At the end of the study, the
Caco-2 monolayers were solubilized using a I % Triton X-100 solution. The total protein
content was determined using the bicinchoninic acid (BCA) protein assay (Pierce Chernical
Co., Rockford, IL). Transport resuits were norrnalized for total protein content of the celis
in each well. Alt experiments were perfonried in triplicates; the data presented are the mean
± S.D.
5.4.10. Calculation of apparent CsA permeabïlity coefficients (P)
The apparent perrneability coefficients crnls) of CsA expressed in cmls, were
calculated using Equation 2:
P, (crnls) =
—.--
(2)
ACo Ut
Where dO/dt is the rate of appearance of CsA on the receiver side (prnol/s), A is the
surface area of the monolayer and C0 is the CsA concentration (pM) on the donor side at t =
0.
5.4.11. Transport of 11M polysaccharides
The polymer permeability across Caco-2 ceils was deterrnined by a fluorescence
assay using the intrinsic fluorescence of the labelled HM-polysaccharides. Solutions of
CsA-loaded fluorescein-labelled polyrneric micelles (CsA content of I jiM) in HBSS
transport medium (24 x l0 mg/ml) were placed within the AP or BL (donor)
cornpartments. For penneability studies in presence of PGI, P85 solution (30 1iM) in the
transport medium was placed on the A? side of the ceIl monolayers. The transport of CsA
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and polyrner was allowed to proceed for 4 h under the sarne conditions as above. The
fluorescence intensity of the solutions recovered from the AP and/or BL (receiver)
compartrnents was deterrnined using a Cary Eclipse fluorescence spectrophotometer
(Varian Scientific Instruments inc., Muigrave, Victoria, Australia). Samples wcre excited at
= 493 nm, and the emission intensity was rnonitored at = 519 mri. The arnount of
transported polymer was calculated using a predetennined standard curve and calibrated
with the protein content ofthe ceils in each well, as described above.
5.4.12. Statistical analysis
Ail experiments were performed in triplicate; the data presented are the mean +
S.D., standardized on individual well protein concentrations. The differences between the
mean values were analyzed for significance using ANOVA test. Resuits were considered
statistically significant from the control when f<O.05.
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Figure 5.3. CsA loading (¾ w/w) in micelles of(.) DEX-C16 (15 mol %) copolymer
and (Â) HPC-C16 (5.4 mol ¾) copolyrner at 2.5 — 40 (w/w %) CsA
initial loading. biset: CsA loading (% w/w) in presence of (+) free POE
C16 surfactant as well as unmodified (.) DEX and (o) HPC polymers.
Mean ± S.D. (n = 3).
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5.5. RESULTS
5.5.1. Cytotoxicity assay
The toxicity of DEX-C16, HPC-C16 DEX, HPC, and POE-C16, a neutral
surfactant analogous in structure to the hydrophopic chains linkcd to DEX or HPC,
towards Caco-2 celis was evaluated by the MTT cytotoxicity assay following 4-h and
24-h periods of incubation at 37°C/5 % C02.. As anticipated, DEX and HPC proved to
be non-toxic towards Caco-2 celis, even when added at a concentration as high as 10 g!1.
The study also revcaled that neither DEX-C16 nor HPC-C16 exhibited any significant
cytotoxicity towards Caco-2 celis after incubation periods as long as 24 h and at
concentrations as high as 10 g!l. (figure 5.4.). The ccli viability drarnatically decrcased
in the presence of POE-C16 even at concentrations below 1 g/l (data flot shown),
confirming prior reports (francis et aï., 2003a Francis et aï., 2003b). Thus linking POE
C16 to non-toxic polymers effectively alleviates their inherent toxicity. They are
confined within the hydrophobic core of the micelles. for them to escape from the
micellar assernbly, it is necessary to break an ether bond, known to be stable against
hydrolysis over a wide range ofpH values.
>1
w
C.)
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POE-C16 DEX HPC HM DEX HM HPC
Figure 5.4. Caco-2 celi viability dctermined by MTT colorimetric assay following 4
h (closed colurnns) and 24 h (open colurnns) incubation periods in
presence of 10 g/I offree POE-CI(, surfactant, umriodified DEX and HPC
polysaccharides as well as HM copolyrners of DEX-C16 and HPC-C16.
Mean + S.D. (n = 3).
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5.5.2. Characterization of CsA-free polymeric micelles
In aqueous solution, DEX-C16 and HPC-C16 fonii micelles that can entrap up to
8.5 % wlw ofCsA, incorporated within the hydrophobic core ofthe micelle by a dialysis
process. The size of the micelles, which can be determined readily by dynamic laser
light scattering, varies depending on the polymer structure. Micelles with average
hydrodynamic diameters of 12 mii and 72 nm are formed in aqueous solutions of
DEX-C16 and HPC-C16, respectively (Table 5.2.). in both cases, the micelle size
distributions were unimodal, indicative of the absence of free polymer chains and of
large aggregates. The onset of micellization (CAC) takes place in solutions of veiy low
polymer concentration, as determined by a fluorescence assay based on the changes in
the fitiorescence of pyrene. a hydrophobie probe added in minute amounts (- 7 x I O
mol/l) in the polymer solutions. In terms of polymer weight concentrations, the CAC of
DEX-C16 (4 mg/l) is significantly lower than that of HPC-C16 micelles (17 mg/l) (Table
5.2.). This may be accounted for by the fact that the average number of glucose units per
alkyl chain is significantly smaller for DEX-C16 compared to HPC-C16, rendering the
former polymer more hydrophobic (TabLe 5.1
.). We note that CAC values for the two
polymers, reported in units of hexadecyl group concentration, are nearly identical,
taking a value significantly lower than the critical micelle concentration (CMC) ofPOE
C16(Table 5.2.).
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5.5.3. Characterization of CsA-Ioaded polymeric micelles
The extent of CsA incorporation, via a solvent exchange dialysis process, in
DEX-C16, HPC-C16 and POE-C16 micelles as well as in DEX and HPC used as controls,
was assessed as a ftrnction of the initial CsA/polyrner weight ratio, keeping the polymer
concentration constant (2.5 rng/ml) and valying the amount of CsA added at the onset of
dialysis (2.5 — 40 % w/w). The loading of CsA within either DEX-C16 or HPC-C16
micelles depends strongly on its initial concentration (Figure 5.3.): it remains low (- I
¾ w/w) under conditions where it represents Iess than 15 % of the total weight content
of the dialysis mixture. The ¾ CsA incorporation increases sharply when its initial
concentration exceeds 15 ¾ (w/w) and reaches a saturation value of- 8.5 % and 5.5 ¾
in the case of DEX-C6 and HPC-C16, respectively. CsA-loaded polymeric micelles
were isolated in the powder form by lyophilization. The dry powder readily solubilized
in water, without alteration in the size of the micelles and without premature release of
CsA, as confirrned by light scattering measurernents.
We note (Figure 5.3.) that for an initial concentration of CsA equal to 25 %
(w/w), the dnig incorporation within DEX-C16 and HPC-C16 micelles is similar ( 5.4 %
w/w or 22 ¾ entrapment efficiency). These conditions were selected to prepare ah the
CsA-loaded micelles ernployed in the stabihity and transport tests described below,
ensuring that in ah the comparative studies the CsA/polymer weight ratio in the micelles
is kept constant. h should be mentioned that the solubilizing ability of the modified
polyrners towards CsA is higher by a factor of 9, cornpared to that of eithcr DEX or
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HPC, for which the maximum CsA loading level was of 0.6 and 1.3 % w/w,
respectively (Figure 5.3., inset).
5.5.4. Stability of CsA loaded micelles in simulated gastric and intestinal fluids
The release rates of CsA from polyrneric micelles in a simulated gastric fluid
(pH 1.2) and in a simulated intestinal fluid (pH 6.8) were monitored by an in vitro
release assay, in which CsA-loaded micelles (5.4 w/w %) captured in dialysis bags were
placed in contact with simulated fluids during 8 h. An identical arnount of free CsA was
placed in contact with the fluids, serving as control. The amount of free CsA in the
dialysate was monitored as a function of contacting time. The release data recorded for
each type of fluid presented the same features (Figure 5.5.): a srnall fraction of CsA, 4
¾ and 12 % for HPC-C16 and DEX-C16, respectively was released from the micelles
after 4 h; but this amount was much lower than that recorded in control experirnents (-
85 %). A possible explanation for the high stability of micelles in simulated biological
fluids of acid pH, is that the POE-C16 residues are linked to the polysaccharide
backbone through ether linkages, which, tinlike cornrnonly-used ester linkages, are
stable towards pH changes and enzymatic degradations.
Figure 5.5. Release profile of CsA at 37 oc in (A) sirnulated gastric fluid at pI-l 1.2
and (B) simulated intestinal fluid at pH 6.8, from (.) free CsA solution
(control); (.) CsA-loaded DEX-C16 polyrneric micelles and (À) CsA
loaded HPC-CI, polymeric micelles. Mean + S.D. (n 3).
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5.5.5. Transport study
Experirnents were designed that wouid aliow to detect the transport of (1) C’sA
across Caco-2 ccli monolayers (radioactivity measurements) and (2) the host polyrneric
micelles (fluorescence measurements). Moreover, as CsA is a good substrate for P-gp
(Augustijns et al., 1993; Fricker et aÏ., 1996; Chiu et aÏ., 2003), AP to BL and BL to AP
transport measurements were carried out in the presence and absence of P85. Nenirkar
et al. reported that the P85 free unimers were responsible for inhibiting P-gp efflux
transport (Nerurkar et aÏ., 1996). In this study, P85 was added to the AP compartment at
a concentration of 30 tM, a value Iower than the P85 CMC (67 iM) (Miller et al.,
1997; Batrakova et al., 1998b) to ensure that P85 copolymer is in the fonri ofunimers in
ail measurernents. In ail cases, TEER values were monitored throughout the
experiments: the addition of micelles and/or P85 to either the AP or BL side of Caco-2
monolayers for up to 4 h did not affect TEER values significantly, confirming that the
integrity of the ccli monolayers was preserved.
Monitoring first the transport of CsA across Caco-2 celi monolayers (Figure
5.6.), we note that after a 240-min incubation, the AP-BL permeability of micelle
loaded CsA increased by factors of 1 .5 and 3 (compared to free CsA) when loaded in
DEX-C16 and HPC-C16 micelles, respectively. In ail cases, the transport was biphasic
with respect to incubation tirne: slow or insignificant transport was dctected during the
first 30-min contact, followed by a ncarly linear increase in transport upon prolonged
incubation.
Figure 5.6. CsA (pmol/mg protein) transported across Caco-2 monolayers after 240
min-incubation in the AP-BL direction in absence (A) and presence (B)
of P85, and in the BL-AP direction in absence (C) and presence (D) of
P85 for free CsA (À) and CsA loaded in DEX-C16 (.) and HPC-C16 (.)
polymeric micelles. Mean ± S.D. (n 3). (*) Statistically significant
compared to free CsA and (**) statistically significant compared to both
free CsA and CsA-loaded in DEX-C16 polymeric micelles.
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Moreover, in the presence of P85, CsA transport was significantly enhanced
in the AP-BL direction, but nearly precluded in the BL-AP direction (figure 5.6.B and
Figure 5.6.D), in agreement with recent reports on the major role of the P-gp efflux
mechanisms in detenriining CsA transport in Caco-2 celis (Augustijns et al., 1993;
Wacher et aï., 199$; Batrakova et aL, 1999; $eeballuck et aï., 2003). The permeability
coefficient (f) of CsA transported in the AP-BL direction was highcr in the case of
CsA loaded in polymeric micelles compared to free CsA, especially in the presence of
P85 (Figure 5.7.).
Next, we investigated the bidirectional perrneability across the Caco-2 celi
monolayers of the host polysaccharides, using fluorescein-Iabelled copolymers, in order
to assess whethcr CsA is transported across the Caco-2 celis in free form or entrapped
within micelles. Indecd, the polyrners are transported across Caco-2 monolayers, as
indicated by the detection of fluorescence in the receiver compartrnent. Under ail
circurnstances (AP-BL, BL-AP, without P85, with P85) the amount oftransported HPC
Ci6 was greater than that of DEX-C16 (Figure 5.8.). The permeability of both
polysaccharides was higher in the BL-AP direction, compared to the AP-BL
permeability. These resuits are comparable to those reported for the in vitro
permcability of polyamidoamine (PAMAM) water soluble dendrimers
(Wiwattanapatapee et aï., 2000; El-Sayed et al., 2002; El-Sayed et aï., 2003).
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figure 5.7.
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across Caco-2 monolayers following 4h incubation with Caco-2 ceils.
Mean ± S.D. (n 3). (*) Statistically significant compared to DEX-C16
polymeric micelles.
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5.5.6. Structure of the polymeric micelles and its effect on their transport
through Caco-2 cells monotayers
The polysaccharides employed in this study were prepared based on design
guidelines we had established through a systematic evaluation of key structural
parameters controlling the effectiveness of HM-DEX and HM-HPC as CsA carriers
(Francis et aï., 2003b; Francis et aï.. 2003a). The molar content of (POE)-C,1 residues is
the determining factor, within a family of polymers, dextran or HPC, which affects the
physico-chemical properties of the polymeric micelles. Within a series of polymers, the
following trends emerge: (1) CAC values decrease with increasing (POE)-C,, chains: (2)
the number of (POE)-C chains must remain below a limiting value of 20 mol ¾ and 8
mol %, for DEX and HPC respectively, in order to preserve micellar solubility in water;
and (3) the CsA loading efficiency of polymeric micelles increases with increasing
(POE)-C,1. The size of the polyrner frarnework plays a role as well: micelles formed by
DEX-C16 constructed from a dextran 40,000 dalton in size were less effective CsA
carriers than those based on the shorter dextran (10,000 dalton) (Francis et al.. 2003a).
For particulate drug formulations, the carrier size is one of the key parameters
that determine the extent of drug absorption and much has been debated on the optimal
size of micro- and nano-particles in relation to their uptake by the intestine. It is
generally assumed that the uptake is inversely proportional to particle size. anct most
published data support this hypothesis (Jani et al., 1990; Ebel, 1990; Simon et aï., 1995;
Carr et al., 1996). However, several studies on the uptake of nanoparticles, such as
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dendrimers 2 to 5 nm in diameter, point to the possible existence of an optimal
colloidal size for the efficient entrapment of particles in the mucous and subsequent
transport through intestinal epithelial cells. (Florence et ai., 2001). The HPC-C16 and the
DEX-C16 micelles investigated differ by a factor on nearly 10 in terrn of diameter, but
both types are substantially larger than dendrirners, and their size is within the range
considered to be ideal for mucosal uptake.
Our in-vitro study indicates that both DEX-C16 and HPC-C16 micelles are
effective carriers for CsA. A comparison of the properties of the two carriers (Table
5.3.) points to the enhanced performance of HPC-C16 micelles as judged by the Caco-2
permeability assay employed here. Unmodified dextran dissolves rapidly in water and
has a low affinity for the mucous layer (Miyazaki et al., 2003). By linking hydrophobic
chains to dextran, one succeeds in decreasing its solubility in water and in solubilizing
sufficient amounts of CsA, but one does not affect the low affinity for the mucous ofthe
polymer itself The superior properties of HPC-C16, compared to DEX-C16 nlay be
attributed to the bioadhesive properties of HPC (Ponchel et al., 1998; Vasir et aÏ., 2003).
HPC-C16 micelles readily adhere to the Caco-2 cell monolayers, allowing the slow
diffusion of the encapsulated drug to the basal side, while DEX-C16 micelles tend to
remain suspended in the apical side.
Li
Table 5.3. Comparison between Hydrophobically-Modified (HM) DEX and HM
HPC copolyrners.
DEX-C,6 HPC-C16
Leakage of loaded CsA in 135 6.2
simulated gastric fluid (%)
Leakage of loaded drug in, 158 5.6
simulated intestinal fluid (¾)
AP to BL transport of CsA 280 620(pmol/rng protein)
AP to BL transport of CsA in
presenceofP85 870 1070
(pmollrng protein)
BL to A? transport of CsA 850 750(pmol/mg protein)
BL to AP transport of CsA in
presence of P85 70 170
(prnol/mg protein)
AP to BL transport of
polymer (mg/rnl polyrner per 0.75
mg protein)
BL to AP transport of
polymer (mglrn) polymer per
-)
mg protein)
‘7-,
Li
5.6. CONCLUSION
The coupling of hydrophobic groups to water soluble polysaccharides
significantly promotes the solubilizing power of either dextran or
hydroxypropylcellulose towards CsA. Moreover the bioadhesive characteristics of HPC
enhance the association of polymer micelles towards Caco-2 ccli monolayers and
facilitate the internalization of the polymer and the transport of the drug. The
polysaccharide-based polymeric micelles offer unique opportunities for the oral deliveiy
of lipophilic drugs. They are non-toxic and stable in biological fluids. Their size is
optimal for effective drug delivery and they possess a high encapsulation. They
effectively carry their cargo through model intestinal cell walls. Collectively, the results
of this research will aid in understanding the relationship between structural features of
polysaccharide-based carriers, their ability to solubilizc lipophilic drugs and their
intestinal permeability, with the prospect of designing novel polymeric carriers for oral
drug deiivery.
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5.8. NOTATIONS
AP Apical side
BL Basolateral side
CsA Cyclosporin A
DEX Dextran TlO
HPC Hydroxypropylcellulose
HPLC High Performance Liquid Chrornatography
POE-C16 Polyoxyethylene (10) cetyl ether
P-gp P-glycoprotein
PGI P-glycoprotein inhibitor
P85 Pluronic P85
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6.1. ABSTRACT
Vitamin 812 (VB12)-modifled dextran-g-polyoxyethytene cetyl ether (DEX-g
POE-C16) was synthesized by linking VB12 residues to a DEX-g-POE-C16 copolymer
via a 2,2’-(ethylenedioxy)bis(ethylarnine) spacer. The level of VB12 substitution on
DEX-g-POE-C16 copolymer reached 1.68% (w/w). Cyclosporin A (CsA), a poorly
water soluble immunosuppressant, was selected as model drug. CsA-loaded polyrneric
micelles were prepared by a dialysis procedure. CsA permeability across Caco-2 ceils in
VB12-rnodified and unrnodified polymeric micelles was monitored in the presence and
absence of intrinsic factor (IF). Following 24 h of transport, the apical to basal
permeability ofCsA loaded in V312-modified DEX-g-POE-C16 polymenc micelles was
significantly higher than that in unmodified micelles. In the case of V312-targeted
micelles, the amount oftransported CsA increased by 1.8 and 2.3 times in absence and
presence of 1f, respectively, compared to unrnodified micelles. Therefore, VB12-
modified polymeric micelles enhanced the permeability of CsA across intestinal celis, a
promising feartire for the developrnent of novel targeted polymeric drug carriers for the
oral delivery of poorly-water solttble drugs.
6.2. KEYWORDS.
Polyrneric micelles; Vitarnin B12; synthesis; Poorly-water soluble drtigs;
Cyclosporin A; Oral, Caco-2, Permeability.
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6.3. INTRODUCTION
Over the last few years, we have assessed the applications of polysaccharide
based micelles as vehicles for the oral delivery 0f poorly-water soluble drugs (Francis et
aï., 2003b; Francis et aï., 2004; f rancis et aï., 2005a). The micelles were forrned by self
assernbly of hydrophobically-modified polyrners consisting of a dextran (DEX) or
hydroxypropylcellutose (HPC) backbone to which were linked at random a smaÏl
number of hexadecyl groups. Unlike surfactant micelles, which tend to disintegrate
upon dilution triggering lysis of ccli membranes (Lasic, 1992; Hofland et aï., 1992), the
polyrneric micelles were remarkably stable towards dilution and exhibited minimal
cytotoxicity (Yu et aï., 199$; Kim et al., 2001; Jevprasesphant et aï., 2003). Their
ability to act as delivery agents for hydrophobic drugs was demonstrated in the case of
cyctosporin A (CsA), a notoriously watet insoluble dmg with poor bioabsorption
properties. The micelles exhibited high entraprnent efficiency for CsA (22% w/w), small
particle size (11 nm), and veiy low onset of micellization (4 rng/1), ail promising
characteristics of carriers for the oral delivery of poorly-water soluble dmgs (Francis et
aï., 2005a; francis et al., 2003a). Additionally, the permeability of CsA through model
intestinal ccli membranes increased significantly, compared to the free drug (Francis et
al., 2005a).
In this communication we describe the use of the endogenous intestinal pathway
for vitamin 312 (VB17) absorption in order to enhance the absorption of hydrophobic
drugs entrapped within polysaccharide micelles. Compared to other vitamins, VB12 is
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unusually large and cannot be taken up by the intestine by simple diffusion. Instead,
it is transported through the intestine by receptor-enhanced endocytosis. The process is
initiated by complexation of VB1, with intrinsic factor (IF), a protein produced in the
stomach (Nicolas et al., 1995; Okuda, 1999). Upon reaching the srnali intestine, this
complex binds to 1F receptors iocated in the luminal surface of the intestine (Levine et
aï., 1984; Tang et aÏ., 1992), stimulating intemalization of VB12, which afier several
hours appears in the portai circulation bound to transcobalamin II (TCII), another VB12
binding protein (Bose et al., 1997; Brada et aÏ., 2001). This complex, but highly
effective, mechanisrn has been used previously to lure proteins and peptides though the
intestinal wail. For example, the oral absorption of a-interferon, luteinizing hormone
releasing hormone analogues, eiythropoietin, or granulocyte colony-stimulating factor
(G-CSF) (Russeil-Jones et al., 198$; Russell-Jones et aÏ., 19955; Habberfield et al.,
1996; Russell-Jones, 1998) was substantially enhanced by linking them to VB12. The
approach reported here does flot require chemical modification of the drug, instead it
relies on the decoration with VB12 residues of the corona of miceiies entrapping in their
hydrophobic core the drug to be transported. Compared to the prodrug approach
employed previously, this methodology is amenable to deliveiy of drugs of suitable
solubiiity characteristic without chemical modification. Note that the amenability of Ibis
mechanism to enhance the transport of nanoparticles was demonstrated previously by
Russell-Jones et al. (Russell-Jones et aÏ., 1999). The focus of our study is a
demonstration of the transport of the encapsulated drug itself.
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in the following sections, we describe the synthesis and miceliization of
V812-modified DEX-g-PEO-C16 (Figure 6.1.), and we assess the ability of VB12-
rnodified micelles to entrap CsA. Ihe permeability of CsA loaded within VB12-micelles
through intestinal enterocytes, was evaluated in vitro using the human colon
adenocarcinorna, Caco-2, celis. Monolayers of Caco-2 ceits, derived form human
colorectal adenocarcinorna, are widely accepted as effective to predict intestinal drug
permeability in humans (Delie et aI., 1997; Artursson et aÏ., 1997). Caco-2 celi
monolayers rnorphologically resemble srnall intestinal absorptive ceils and express
typical small intestinal enzymes and receptors associated with the brush border (Hauri et
aÏ., 1985; Matsurnoto et aI., 1990). It has been shown that, after reaching confluency,
Caco-2 ceils express both the If receptor in the apical membrane, and the transporter
protein TCII which facilitates the transport oC VB12 out of the enterocyte to the portai
circulation (Dix et aÏ., 1987; Ramanujam et aÏ., 1991). from a comparison of the
properties and performance of V312-rnodifled micelles to those of their precursor, we
conclude that the VB12 pathway can be used effectively for polymeric micelles and
provide options for the dellvery of hydrophobic drugs.
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6.4. EXPERIMENTAL SECTION
6.4.1. Reagents and materials
Vitamin 312 (cobalamin, V312) 99% was obtained from Amersharn Biosciences.
Cyclosporin A (CsA) and intrinsic factor [‘rom porcine gastric mucosa (If) were
purchased froin Sigma. Ethylenediamine (amine 1) 99+% (d 0.899), 2.2’-
(ethylenedioxy)bis(ethylamine) 98%, 1 , 1 ‘-carbonyldiirnidazole (CDI), 4-
(dimethylamino)pyridine 99% (DMAP), ammonium hydroxide 2$-30%,
dirnethylsuifoxide (DM50) 99.9%+ and hydrochioric acid 37% were purshased ftom
Aldrich Chemicai Co. The modifled dextran, DEX-g-PEO-Cjô was synthesized as
described previously (francis et aï., 2003b; Francis et aï., 2003a). it bas a molecttlar
weight of 8602 g/mol and the level of C16 incorporation is 15 moi%. Isopropanol,
acetone and silica gel 60 were purchased from Merck KGaA. The Spectra/Por 1
dialysis membrane (molecular weight cutoff 6,000-8.000 dalton) was obtained from
Spectmm Laboratories, Inc. The Caco-2 ccli une was purchased from ArneHcan Type
Culture Collection (ATCC) at passage 18. Dulbecco’s modified Eagle medium
(DMEM), penicillin-streptomycin (10,000 U/ml penicillin G and 10,000 tg/ml
streptomycin), fetal bovine serum (F85), 0.25% (w/v) trypsin — 1 mM EDTA.4Na (IX)
and non-essential amino acids (NEAA) were supplied from Invitrogen Life
Technologies. Poiy(ethylene oxide)27-b-poly(propylene oxide)39-b-poly(ethytene
oxide)27 (Pluronic pgs, P85) was provided hy BASf Corp. [3H] Cyclosporin A (8.00
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Ci/nnnol) was purchased from Amersharn PhanTiacia Biotech. Ultrapure water, used
for ail aqueous solutions, was from a MiIIi-Q filtration system (Millipore).
6.4.2. Synthesis of Dextran-g-PEO-C 16-amine-VB12 copolymer
Dimethylaminopyridine (DMAP) (55 mg) was added to a solution of DEX-g
PEO-C16 (275 mg) in DMSO (25 ml), kept at room temperature under N2. The resulting
mixture was stirred for two hours. A 2,2-(Ethylenedioxy)bis(ethylamine)-modified VB12
(70 mg) was added in one portion to the solution. The reaction mixture was kept at room
temperature under N2 for three days. Dilute aqueous HCI (0. 1M) was added drop wise
until neutral pH was attained. The reaction mixture was transferred into a dialysis
membrane (MW cutoff 3,500 daÏton) and extensively dialyzed against distilled water.
The product was isolated by freeze-diying. The degree of VB12 substitution xvas
determined spectrophotornetrically using a calibration curve prepared with standard
solutions of VB12 in DMSO (concentration: 6.3x103 5x1OE2 mg/rnl, ?L = 360 nrn, r2>
0.99).
6.4.3. Instrumentation
H NMR spectra were recorded with Bniker ARX-400 400 MHz spectrometer.
fluorescence spectra were obtained using a SPEX industries f Iuorolog 212
spectrorneter equipped with a GRAMS/32 data analysis system. UV-visibIe spectra
were measured with with a Hewlett Packard $454 A Photodiode array spectrometer,
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equipped with a Hewlett-Packard 89090 temperature controller. Light scattering
measurernents were can-ied out using a Malvern system (Malvem Instruments Ltd).
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Figure 6.1. Synthetic sequence for the preparation of VB12-rnodified DEX-g-PEO-C16 copolyrner.
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6.4.4. Characterization of V8i2-DEX-g-PEO-C16 copolymer
The critical association concentration (CAC) vas estirnated by a fluorescence
assay (Zhao et aÏ., 1990) using pyrene as a probe, as describe previously in the case of
DEX-g-PEO-C16 micelles (Francis et aï., 2003a). Polymer solutions of increasing
concentration were prepared in pyrene-saturated water ({Py] — 7 x i0 M). They were
equilibrated ovemight prior to spectroscopic analysis. The changes in the ratio of the
pyrene excitation spectra intensities was monitored at 2 333 nm (1333) for pyrene in
water, and 336 nrn (I3) for pyrene in the hydrophobic mcdiurn within the micelle
core. The hydrodynarnic diameter of dnig-free and drug-loaded polymeric micelles in
water was evaluated by dynamic laser light scattering (DLS) at 25°C with a scattering
angle of 90°. Micelle aqueous solutions (3 rng/rnl) were prepared for analysis.
6.4.5. Physical loading of CsA in VB12-DEX-g-PEO-C16 polymeric micelles
CsA was incorporated into VB12-DEX-g-PEO-C16 micelles by a dialysis process
(Francis et aï., 2003a; Francis et al., 2005b). The amount of CsA within polyrneric
micelles was determined by an HPLC assay (Ugazio et al., 2002; francis et aï., 2003a;
Francis et al., 2005b).
6.4.6. CelI Culture
The human colon adenocarcinoma cells, Caco-2. were routinely maintained in
Dulbecco’s rnodified Eagle medium with 4.5 g/l D-glucose, supplemented with 10%
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(v/v) heat-inactivated fetal bovine senim, 1% (v/v) non-essential arnino acids and 1%
(v/v) penicillin-streptornycin antibiotics solution (100 U/ml penicillin G and 100 pg/rnl
streptomycin). Ceils were allowed to grow in a monolayer culture in 75 cm2 T-flasks in
an incubator at 37 oc with controlled atmosphere containing 5% C02 and 90% relative
humidity. culture medium vas changed every 48 h. Ceils were passaged at 80 - 90%
confluency at a spiit ratio of 1:3 using 0.25% trypsin — Ï mM EDIA.
6.4.7. Permeability of CsA Ioaded in VB12-DEX-g-PEO-C16 polymeric micelles
across Caco-2 cells
The amount of CsA incorporated into VB2-DEX-g-PEO-Ci6 micelles that is
transported across a caco-2 cdl monolayer (Figure 6.2.) was measured using tritiated
[3H] csA, following a protocol described previously for DEX-g-PEO-C16 micelles
(francis et al., 2005a). The apparent perrneability coefficients of csA expressed
in cmls, were calculated using the following Equation:
1UQ
F(J) (cni/s) = Equation (1)
ACo dt
where UQ/dt is the rate of appearance of CsA on the receiver side (prnol/s), A is
the surface area of the monolayer and C0 is the initial CsA concentration (pM) on the
donor side at t 0. AIl experirnents were performed in triplicate. The data presented are
the mean + $.D., standardized on individual well protein concentrations. The differences
between the mean values were analyzed for significance using ANOVA test. Results
were considered statistically significant from the control when P < 0.05.
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figure 6.2. Schematic representation ofthe pi-ocedure used to stucy the transport of
CsA-loaded polymeric micelles across Caco-2 ccli mon olayer.
Apical side
CsA-Ioaded micelles
in donor chamber
z
CsA and copolymer
in receiver chamber
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6.5. RESULTS AND DISCUSSION
6.5.1. Preparation and micellization of VB12-DEX-g-PEO-C16
The 5’OH group of the ribose moiety V312 was selected as linking site,
following a procedtire developed by Joncs et al. (Russeil-Jones et al., 1995a; McEwan et
al., 1999). The synthesis consists in two steps, first covalent linkage of a bifunctional
spacer rnoiety to the 5’OH group of VB12, followed by reaction of the linker terminal
position to DEX-g-PEO-Ci6. Ethylenedioxybis(ethylamine) was selected as linker, in
view of its water solubility and chain flexibility. It was added in large cxcess to
carbonyldiimidazole (CDI) activated VB12. Next, the terminal amine of the linker also
activated with CDI was bound to hydroxyl groups of DEX-g-PEO-C16, yielding VB 2-
DEX-g-PEO-C16 (Figure 6.1.). The level of VB2 incorporation along the polymer
chain, detennined by absorbance spectroscopy, was 1.6$ w/w %, or 0.33 mol ¾, relative
to the number of glucose units. The levcl of V312 was kept low in order to preserve the
micellization properties of DEX-g-PEO-Cjô and the ability of the micelles to entrap
CsA, two important properties that needed to be confinned.
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Maximum Mean diametere (nm) ± SD
cAca
Sample CsA loadingb CsA-free CsA-loaded(mg/l)
(°“°) micelles micelles
UnmodifiedDEX-g-PEO-C16 3.8±0.2 8.5±0.6 11±5 14±6
VB12-modified DEX-g-PEO-C16 7.4 ± 0.4 6.5 ± 0.4 31 ± 2 33 ± 3
change in 1336 nm/’333 nm ratio of pyrene fluorescence with Iog polymer
concentration at 25 oc.
bDeteined by HPLC analysis with IJV detection at 210 nm.
cDeteined by DL$ measurements at 25 oc with a scattering angle of 90 0
Table 6.1. Characteristics of unmodified and VB12-modified DEX-g-PEO-C16
polymeric micelles.
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Dynamic lïght scattering measurements carried out with aqueous solutions of
VB12-DEX-g-PEO-Ci6 confinned the presence of patricles 31 nm in size, a diarneter
nearly three times larger than that of the DEX-g-PEO-C16 micelles (‘- 11 nm). In both
cases, the size distribution was unirnodal, indicative of the absence of detectable
arnounts of either free polyrner chains or large aggregates. The onset of micellization in
solutions of VB12-DEX-g-PEO-C16, or critical association concentration (CAC). vas
deterrnined by a fluorescence probe technique, using the changes in pyrene
photophysical characteristics upon solubilization of Py within the hydrophobic core of
micelles (Zhao e! al., 1990). The CAC ofVBi2-DEX-g-PEO-Ciô turned out to be higher
than that of the parent copolymer, but it remained sufficiently low to prevent
demicellization to occur upon dilution (Table 6. 1.). Taken together, the light scattering
results and the fluorescence measurements indicate that the conjugation of VB2 onto
modified dextran did flot preclude micellization, but the bulk and hydrophilicity of the
VB12 moiety Ied to the formation of larger micelles and an increase in the polymer
concentration needed for micellization to occur.
6.5.2. Incorporation of CsA in VB12-DEX-g-PEO-C16 micelles
The extent of CsA incorporation via a solvent exchange dialysis process into the
polyrneric micelles was assessed as a function of the initial CsA/polymer weight ratio,
keeping the polymer concentration constant (2.5 mg/rnl) and varying the arnount ofCsA
added to the initial dialysis mixtures (2.5 — 4f) % w/w). In both cases, the level of CsA
incorporation increased rapidly with increasing initial CsA concentration above a
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minimal threshold value of ‘-15 w/w % (Figure 6.3.). The amount of CsA
incorporation reached a saturation value of ‘— 8.5 °À) in the case of VB12-modified
micelles, a value slightly lower than that measured for CsA loading in unrnodified
micelles, possibly reflecting the increased hydrophilicity ofthe VB12-modified micelles.
In ail cases, however, the CsA ioaded micelle isolated in the dried form by
lyophilization were readily dispersible in water, forming micelles slightly larger in size
than virgin micelles (Table 6.1), with no trace ofunbound CsA.
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figure 6.3. Perrneability study in the AP-BL direction across Caco-2 monolayers
following (A) 4-h and (B) 24-h incubation with CsA loaded in (.) DEX
g-PEO-C16 polymeric micelles, and VB17-modified DEX-g-PEO-C16
polymeric micelles in absence(.) and presence (À) of intrinsic factor.
Mean + S.D. (n 3). (*) Statistically significant compared to CsA-Ioaded
in DEX-g-PEO-C16 polyrneric micelles.
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6.5.3. Uptake and transport of CsA incorporated within VB12-conjugated
micelles by Caco-2 ceils
Receptor-mediated endocytosis and transport of radiolabeled CsA in VB2-
modified micelles were assessed next in vitro using Caco-2 monolayers, as depicted
schematically in Figure 6.2. The VB12-modified micelles were added alone or in the
presence ofintrinsic factor (IF) to the apical side of Caco-2 cell monolayers, which were
incubated for 4 h or 24 h at 37 oc after addition of the micelles. Experiments were
conducted trnder identical conditions with csA-Ioaded micelles devoid of VB12.
Subsequently, the amount of CsA transcytosed was deterrnined via radioactivity
measurements. The results presented in Figure 6.4. point to a significant enhancement of
the amount oftransported csA when it is incorporated within VB12-conjugated micelles,
compared to the amount of CsA transporteci by unmodifled micelles. The data also
suggest that the transcytosis is even more efficient when extrinsic IF is added to the
medium, further supporting our hypothesis that the VB12-specific pathway is involveci in
the transport rnechanism ofVB12-rnicelles. Other rnechanisms may be in effect as well,
since some level of csA transport through the Caco-2 cell monolayer occurs even in the
absence ofVB12 conjugation, through an intrinsic factor-independent pathway (Muthiah
et al., 1987; Russell-Jones et aÏ., 1999). This could be possibly due to the expression of
sorne TCII receptors on the apical surface of Caco-2 celis, as sttggested by Bose et al
(Bose et al., 1997).
267
Table 6.2. Permeability coefficient (Papp, cmls) values of CsA across Caco-2
monolayers, in absence and presence of intrinsic factor (IF).
Papp (cm/s) ± S»
CsA-loaded polymeric micelles
4-h incubation 24-h incubation
[Unmodified DEX-g-PEO-C16 4.0 ± 0.2 1.4 ± 0.1
I VB12-modifiedDEX-g-PEO-C16 6.5± 1.1* 2.6±0.3*j VB12-modified DEX-g-PEO-C16 + IF 7.7 ± 1.0* 3.3 + 0.4
Statistically significant compared to CsA-loaded in DEX-g-PEO-C16 polymeric
micelles.
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We rnonitored the amount of CsA transported through the Caco-2 ceil
monolayer for up to 24 h after injection ofCsA loaded micelles and detenriined the CsA
concentration in the basal compartment several times (Figure 6.4.B). It is worth noting
that the CsA transport trends are the same for the three experiments, featuring a rapid
increase in the amount of transported CsA over the first 4 to 5 hours following micelle
injection. followed by a continuous, but slower, increase in CsA transport, with no sign
of leveling-off after 24 h. Following 24 h of transport, the arnount of transcytosed CsA
is twice as large in the case of VB12 —rnodified micelles, compared to the naked
micelles. These observations are confirmed quantitatively in terms of the apparent
permeability of CsA, Papp, through Caco-2 celI membranes (Table 6.2.).
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Permeability coefficient (Papp, cmls) of CsA-loaded in polymeric
micelles of DEX-g-PEO-C16 and VB12-modified DEX-g-PEO-C16
polymeric micelles in absence and presence of intrinsic factor, following
(A) 4-h and (B) 24-h of incubation with Caco-2 celis. Mean ± S.D. (n
3). (*) Statistically significant compared to CsA-loaded in DEX-g-PEO
C16 polymeric micelles.
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To gain further insight into the transport mechanism, we rneasured the
amount ofCsA intemalized in the celis, but not expelled in the basal side, as well as the
arnount of CsA trapped in the filters used in the set-up. following a 4-h incubation
(Figure 6.5.A), the amount of intemalized CsA, in the case of CsA entrapped in VB12-
micelles is significantly larger that the amount of CsA transported through the
membranes. The trend is reversed afler a 24-h incubation: the arnount of CsA
transported through the cdl membrane exceeds by a factor of nearly 2, the amount of
CsA kept within the ceils. We note also that in the case of CsA entrapped in unmodified
micelles, there is no difference, after a 4-h incubation, in the arnounts of CsA within the
ceils and in the basal side, whereas after 24-h the transported CsA exceeds the amount
of CsA within the cell. Under all conditions, sorne CsA remained trapped in the filter,
but in negligible amotints.
It is generally recognized that there exist a delay of approximately 3 to 4 h
(Ramanujam et aÏ., 1991; Rothenberg et al., 1978), between the time of formation of the
IF/VB12 complex, intemalization, the release of VB12 in the enterocyte, and the
intracellular formation of the TCII/VB12 complex eventually released by the cell
(Quadros et al., 1999; Pons et aÏ., 2000; Alsenz et aÏ., 2000). Our data reflect this delay,
providing further strength to the effectiveness of the VB12 pathway in the transport of
V312-decorated micelles.
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figure 6.5. Cumulative amount of CsA (pmol/mg protein) Ïoaded in polymeric
micelles of DEX-g-PEO-C16 and VB2-rnodified DEX-g-PEO-C16
polymeric micelles in absence and presence of intrinsic factor,
following (A) 4-h and (B) 24-h of incubation with Caco-2 celis. The
extent of transported CsA (closed colunms), intemalized CsA (open
columns) and CsA bound to luter membrane (dashed colunms) are
presented in the figure. Mean + S.D. (n = 3). (*) Statistically
significant cornpared to CsA-loaded in DEX-g-PEO-Ciô polymeric
micelles.
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FinalÏy, the addition of micelles and/or If to the apical side of Caco-2
monolayers for up to 24 h did flot affect TEER values signiflcantly, suggesting that the
integrity of the monolayers was rnaintained ail over the pemieabiiity experirnent.
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6.6. CONCLUSIONS
This investigation dernonstrates that Iinking the large VB12 molecule to
hydrophobicalÏy-rnodified dextran does not preclude the formation of polymeric
micelles of size and stability amenable to drug delivery applications. Moreover we have
presented strong evidence that the VB12 pathway is effective in the transport of drug
loaded VB12-modifled micelles tbrough model intestinal ceil monolayers, signiflcantly
enhancing the amount of dmg transported. Overali, the approach offers a promising and
realistic option for oral delivery of poorly absorbed hydrophobie drugs.
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Drug research has evolved and matured through several phases beginning with the
botanical phase of the early hurnan civilizations, through to the synthetic chemistiy age in
the tniddle of the 20th cenmiy, and flnally the biotechnology era at the dawn of the 2 [st
century. Although drug discovery and developrnent have undergone a paradigm shifi from
serendipity to a more rational approach, they rernain costly (US$ 400—650 million), tiine
consuming (10 — 15 years) and risky processes (Chess, 1998; Dickson et aÏ., 2004). As a
consequence, the pharmaceutical industry is now heading towards a better appreciation and
integration of novel drug delivery systems, which are developed at 20% of the cost and in
half the time, allowing pharmaceutical companies to maximize the retum on their
investment through optimization of the dosage regimen without compromising the
therapeutic efficacy, giving a second life to old drugs with improved patient compliance
(Sahoo et aÏ., 2003; Allen et al., 2004).
There have been great strides jn the developrnent of successfiul commercial peroral
novel drug delivery systems for hydrophilic molecules, however, delivery of poorly-water
soluble molecules remains a goal difficult to reach. A number of approaches have emerged
(Orellana et al., 1998; Sastry et aÏ., 2000) to prornote the oral absorption of such molecules,
either by ttse of sorption promoters, or by solubilization in carrier systems as a way for
enhancing dnig concentration and stability in the harsh environment ofthe GI tract (Bay et
al., 2000).
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7.1. S0LuBILIzATI0N APPROACH
Solubilization is defined as the preparation of a therniodynamically stable solution
of a solute that is normally insoluble or very slightly soluble in a given solvent, by the
introduction of one or more arnphiphilic cornponent(s) (Attwood et aï., 1983). The
solubilization idea lias been in use in the pharmaceutical field since 1868 when it was
reported that cholesterol was solubilized to an appreciable extent in the presence of soap
(Weissmarm et aÏ., 1966). Since then, surfactants have been widely used in devcloprnent of
pharmaceutical formulations for the solubilization of many drugs (Malik et al., 1975;
Buckingham et al., 1995; Nerurkar et aÏ., 1996; Patist et al., 1998; Dimitrijevic et aï.. 2000;
Li et aï., 2001; Zana, 2002). In addition to strategies investigated for solubilization of
poorly-water soluble drugs, such as nanosuspensions (Muller et cii., 2001), microernulsions
(ltoh et al., 2002) and liposomes (Minato et aï., 2003), the use ofpolymers as active agents
in drug formulations lias gained much attention. Polyiners have long been part oC drug
formulations as passive ingredients, but it is only recently that polymers have been
endowed with specific functions in order to facilitate or target the delivery of drugs. This
approach exploits the high diversity of polymers in tenus of structure and functionalities
that enable conjugation of various pilot molecules (Sakuma et al., 2001).
In the present work, we chose to saidy “polymeric micelles” which represeni a
promising delivery vehicle for poorly-water soluble pharmaceutical active ingredients
(Halperin, 1987; Kataoka et aL, 2001; van Nostrum, 2004).
2X2
Hydrophobically-rnodified (HM) polysaccharides form polymeric micelles in
water. The size, stability, and colloidal properties of these micelles depend on their
chemical composition, the number of saccharide units and the architecture of the
hydrophobic grafts. While a number of fundamental studies of HM-polysaccharides have
been reported (Akiyoshi et al., 2000; Pelletier et al., 2001), their use as nanometric carriers
of poorly-water soluble drugs has been largely overlooked.
Therefore, we initiated a study of polysaccharide-based micelles as oral drug
deliveiy vehicles using two polysaccharides, dextran and hydroxypropylcellulose, selected
as starting materials for the following reasons
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Figure 7.1. Chemical structure of (A) dextran (DEX) showing Œ(1-6) and Œ(1-4)
glycosidic Iinkages, (B) Hydroxypropylcellulose (HPC) showing f3(1-4)
glycosidic Iinkages, and (C) polyoxyethylene aikyl ether (POE)-C,,).
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7.2. DFxTRAN (DEX)
Dextrans are glucose polymers produced by bacteria growing in sucrose-containing
media. The term “Dextran” describes a glucopyranose polyrner wherein the Œ(l-6)
glycosidic linkage predorninates, although there are also a(l-3) and u(1-4) Ïinkages (Gelin
etal., 1961) (figure 7.1.A).
Dextrans are known to present no toxicity and have been introduced into medicine
in the early I 950’s by Swedish scientists after a long search for a practical nontoxic plasma
substitute (Gronwall, 1957; de Jonge et aÏ., 2001). Since then, dextrans are increasingly
used as plasma substitutes (Atik, 1967). Besides their plasma expanding properties, they
also exert an anticoagulant effect. They have shown to be effective in preventing
postoperative venotts thrombosis and pulmonaiy embolism (Ljungstrorn, 1983; Clagett et
aï., 1998; Bergqvist, 1998). furtherrnore, dextrans are readily available and are relatively
inexpens ive.
7.3. HYDR0xYPR0PYLcELLuL0sE (HPC)
HPC is a non-ionic water-soluble cellulose ether, formed by reaction of cellulose
(containing f3(1-4) glycosidic linkages) with propylene oxide at high temperature and
pressure (figure 7.1.B). It combines organic solvent and aqueous solubility (Alvarez
Lorenzo et aI., 2000).
HPC is used as excipient in many oral solid dosage forms, in which it acts as a
binder in granulation (Skinner et aï., 1 999). In vivo, HPC tends to undergo intimate contact
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with the absorbing intestinal membrane, thus increasing residence tirne within the srnall
intestine (Eiarntrakam et aÏ., 2002). Moreover, HPC is known to present no cytotoxicity
(Obara et al., 1992). The World Health Organization (WHO) has flot specified an
acceptable daily intake for HPC, since the levels consurned are not considered to represent
any hazard to health (fAO/WHO, 1990). Finally, HPC is readily available and relatively
inexpensive.
DEX and HPC do flot form micelles in water, and have very low affinity for CsA as
shown in f igure 7.2. Therefore, a modification of their structure was required for them to
form micellar assemblies in an aqueous environrnent. for this, a small number of
polyoxyethylene aikyl groups were grafted on DEX and HPC chains.
7.4. P0LY0xYETHYLENE ALKYL ETHERS
Polyoxyethylene aikyl ethers ((POE)1-C,1, cornmercially available under the Brij®
trade name) are nonionic surfactants consisting of a hydrophobie aikyl chain attached via
an ether linkage to a hydrophilic POE chain of valying length (figure 7.1 .C).
To modify either DEX or HPC, (POE)-C,, residues were grafted by formation of an
ether linkage, since this group is more resistant to temperature and pH changes, and is inert
towards enzymatic activity in biological fluids, compared to other types of chemical bonds
such as the ester linkage (Sovak et aÏ., 1980; Cavallaro et aï., 2001; Oishi et aÏ., 2003). This
issue was important to consider for the modified polymers in order to ensure stability in the
GI enviromrient.
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from a formulation point of view, (POE)3-C,, surfactant micelles were shown to
be able to incorporate high levels ofCsA, varving between 13 —21 ¾ w/w (Figure 7.2. and
Table 7.1.), confirming the high affinity of CsA for these molecules. The (POE)-C,,
amphiphiles are readily available and relatively inexpensive. Yet, these surfactants exhibit
significant toxicity towards epithelial celis, due to the alteration ofcell membrane integrity.
HM-polysaccharides were synthesized via ether formation between a tosylated
(POE)-C,7 and hydroxyl groups of the corresponding polysaccharide. As the polyrners and
(POE)-C,, have similar solubility characteristics, the coupling could be carried out in
homogeneous solution. Under these conditions, high levets of hydrophobic modification
can be achieved and the distribution of alkyl chains along the polymer chain tends to be
random rather than “blocky”.
15-
C
o 10-
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Figure 7.2. CsA loading (% w/w) in micelles of (POE)io-C16 (+), (POE)1o-C (Â),
(POE)0-C16 (.) and (POE)20-C18 (.) surfactants as wel] as unrnodified DEX
(MW I0,000Da) (A), DEX (MW 40,000Da) (E) and HPC (O) hydrophilic
polymers at 2.5 40 (w/w %) CsA initial loading. Mean + S.D. (n = 3).
gg
7.5. DIFFERENT COPOLYMER CANDEDATES
A series of HM copolyrner candidates (Table 7.1.) was prepared by vaiying
experirnental pararneters, such as (i) the composition of the hydrophilic polysaccharide
backbone (either DEX or HPC), (ii) the motecular weight of the hydrophitic chain, for
instance, DEX of different molecular weights (10,000 and 40,000 Da or ca 62 and 247
glucose units per chain, for DEXIO and DEX4O, respectively) was used; (iii) the size ofthe
(POE). moiety consisting of 10 or 20 units, (iv) the size of the hydrophobic alkyl group
(hexadecyl or octadecyl), and (y) the level of grafting, i.e. the number of hydrophobic
substituents linked to the chain.
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Table 7.1. Characteristics ofdifferent copolymer candidates.
I Dextran
Dextran T40
HPC
o
o
o
______
I I
DEX1 O-g-(POE)i 0-C16 3.0±0.1
7.0±0.1 7±2
8±1 18±2
9±1
r
4.8±0.4
0.6±0.1
1.0±0.02
1.4±0.1
4.0± 0.1
. .
Grafted Mean MaximumPolymer composition CAC(POE)-C,, diameter CsA ]oading
(mol %) mg (nm) (wlw%)
[ (POE)10-C16 100 2.5 ± 0.3 - 17.5 ± 0.5
I (POE)1o-C18 100 3.0±0.1 - 13.1 ±0.9
(POE)20-C16 100 4.6±0.6 - 21.0± 1.5
I (POE)10-C18 100 3.7 ± 0.5 - 15.5 ± 0.8
I DEX4O-g-(POE)io-C16 2.3 ± 0.1 110.0 ± 5 23 ± 1 1.2 ± 0.1
I DEX4O-g-(POE)io-C16 3.5 ± 0.1 18.0 ± 2 30 ± 1 1.5 ± 0.1
I HPC-g-(POE)jo-Ci6 0.9 ± 0.1 ± 14 85 ± 2 2.3 ± 0.2
I HPC-g-(POE)io-C16 4.7±0.1 17±3 80±1 5.3±0.3
HPC-g-(POE)jo-C16 ± 0.5 17 ± 2 76 ± 2 5.5 ± 0.6
I HPC-g-(POE)20-Ci6 1.1 ± 0.1 L65 ± 12 90 ± 1 L 2.5 ± 0.3
I HPC-g-(POE)2o-C16 3.9 ± 0.1 [ 15 ± 78 ± 1 6.7 ± 0.4
I HPC-g-(POE)20-Cig fi.i ±0.1 135±10 85±1 1.7±0.3
I HPC-g-(POE)2o-C18 3.1 ± 0.1 22 ± 6 83 ± 2 j 4.8 ± 0.3
DEX 1 0-g-(POE) o-Ci6
DEX1 0-g-(POE) j o-c 18
15.0 ± 0.5
3.9±0.1
4±0.2
13 ± 1
11±5
21 ± I
8.5±0.6
3.0±0.2
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7.6. MIcELLAR PROPERTIES 0F HM-POLYSACCHARIDES IN WATER
In aqueous solution, HM DEX and HM HPC forrn polymcric micelles. The major
driving force for the assembly of amphiphilic copolymers in water is the removal of
hydrophobic fragments ftom the aqueous surroundings resulting in the formation of
micelles consisting of a hydrophobic core stabilized by hydrated hydrophilic chains
exposed into water (Gao et aÏ., 1993). A steady-state fluorescence spectroscopy assay was
used to determine the polymer concentration at which micellization first takes place. The
critical association concentration (CAC) values (Table 7.1.) range from 3 rng/l to 135
mg/l. They depend on (i) the nature of the polysaccharide main chain, where the CAC
values for HPC-based micelles were generally higher than for DEX-based micelles, (ii) the
molecular weight of the hydrophilic polymer, where the CAC values of grafied DEX
increased with increasing the molecutar weight of DEX, and (iii) the motar content of
(POE)1-C, residues, where the CAC values decreased with increasing molar content of
(POE)-C,, residues, for each hydrophobie group, and each polymer, reflecting the increase
in hydrophobicity of the copolymer and consequent enhanced stability of the polymeric
micelles. Similarly, Nagarajan et al. have reported that the increase in the lengtb of a
hydrophilic polyrner chain causes noticeable decrease in CA value and increase in micelle
stability in aqueous solution (Nagarajan et al., 1989).
It is oflen observed that the gastrointestinal (GI) uptake ofrnicroparticles is affected
significantly by particle size. For example, Desai and coworkers (Desai et al., 1996)
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reported that the uptake efficiency of particles 100 nrn in diarneter by the GI tract is
15 to 250-fold higher than that of rnicron-sizect particles.
The average size of the polysaccharide-based micelles was determined by dynamic
laser light scattering (DLS) at 25°C, with a scattering angle of 90°. The hydrodynamic
diameter ofthe polymeric micelles varied depending on the polymer structure, and ranged
from 10 - 90 nm (Table 7.1.). HM-DEX and I-[M-HPC micelles in dilute solution showed a
unimodal size distribution, indicative of the absence of free polymer chains and of large
aggregates. In both cases, the size of micelles decreases with increasing level ofgrafting of
(POE)-C,, substituent on the polysaccharide chain. We note that copolymers with longer
polysaccharide chain (e.g dextran T40; MW 40 000 Da; 247 glucose units per chain) fomi
micelles of larger mean diameter than those forrned by dextran T10 (MW 10 000 Da; 62
glucose units per chain) copolymers, independently of the size of the hydrophobie
substituent and of the level of modification. This observation can be taken as an indication
of the steric hindrance induced by the carbohydrate chains, which are expected to take
place over a larger volume for the polymer of higher molecular weight (Maksimenko et aï.,
2001; Baldwin et al., 1988).
It should be noted that CsA-free micelles of DEX and HPC showed mean diarneters
generally different (lower and higher, respectively) from those of the corresponding CsA
loaded micelles, independently of their content in hydrophobie substituent. Although this
aspect of the work puzzles us as well, we do not have an explanation and prefer flot to add
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speculative explanation. Most importantly, the size of the micelles was flot altered
substantially and the difference was statistically non-sgnificant.
Sass et al. (Sass et aÏ., 1990) showed that the uptake of nanoparticles within the
intestine and the extent of drug absorption increase with decreasing particle size and
increasing specific surface area. Moreover, Kriwet et ai. (Kriwet et aï., 199$) showed that
neutral nanopatricles have a high affinity to intestinal epitheli than charged nanoparticles,
which may aiso enhance the transport process. Therefore, the small size exhibited by ail the
polyrneric micelles studied here shows a favorable trenci towards oral dmg delivery.
7.7. M0RPII0L0GY 0F POLYMERIC MICELLES
It has been weil established that the particle sizes and morphologies of micellar
aggregates depend flot only on the poiymer structure (i.e. the polymer composition) but also
on preparation conditions (i.e. polyrner concentration, soivent, preparation method) (Joncs
et al., 1999). In literature, a variety of morphologies such as spheres, rods, vesicies,
lamellae, large compound micelles, tubules and hexagonaiiy packed hollow hoops have
been reported for amphiphiiic block copoiymer aggregates in dilute solutions, as observed
by transmission electron microscopy (TEM) measurernents (Zhang, L.f. et aï., 1996c;
Zhang, L.f. et cil., l996b; Zhang, L. et aï., 1996a; Liu etal., 2003 Ouhib etaL, 2005).
in aqueous environrnent, hydrophobically-modified poiysaccharide-based
copolymers are beiieved to associate into micelles consisting of a hydrophobic core made
up of the aikyl chains surrounded by a hydrophilic corona of highly hydrated
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polysaccharide chains. Although Lavasanïfar et aï. reported TEM microphotography for
PEO-based micelles prepared by a dialysis rnethod indicating the presence of spherical
particles with nanoscopic dimensions (Lavasanifar et al., 2001), at this point, we do not
have enough strong data to put forward a structure for the micelles. We rather flot base our
description of micellar structure soÏely on ouï imagination. However, the dynamic light
scattering measurements carried otit on the CsA-loaded micelles conflrmed that the
integrity of the micelles was preserved during the loading process, since the size of the
micelles was flot significantly altered.
7.8. DRUG LOADING IN HM-DEX AND HM-HPC P0LYMERIc MIcELLEs
Afier selecting the best copolyrner candidates, we evaluated their ability to
solubilize poorly-water soluble drugs. The drug loading capacity of the copolymers was
evaluated using Cyclosporin A (CsA), a highly lipophilic undecapeptide selected as model
drug. The incorporation of CsA within the hydrophobic core of micelles was perfonued by
a dialysis method. The amount of loaded CsA was quantitatively assayed by HPLC.
We assessed the incorporation of CsA within polymeric micelles in parallel to
(POE)l-C?, micelles as well as by unmodifled DEX and HPC polyrners as controls. The
level of CsA incorporation within polymeric micelles, expressed in w/w ¾ (CsA/polyrner),
ranged from 1 — $ % in the case of HM-DEX and 2 —7 % in the case of HM-HPC. The
loading efficiency varied. depending on the initial CsAi’polymer ratio, on the degree of
grafting and on the chemical composition ofthe polymer, as evidenced in f igure 7.3. The
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Figure presents CsA loading in the polymeric micelles as a function of the initial
CsA/copolyrner ratio, in the case oftwo DEX-based micelles and two HPC-based micelles
with the sarne molar content of hydrophobic residues (- 3 mol % of either (POE)10-C16 or
(POE)10-C15 for each polysaccharide) as welÏ as unmodified DEX and HPC as controls. In
the case of polymers prepared with DEXIO, the amount of CsA loaded within the micelles
was 4 % for DEX1O-g-(POE)jo-Cjô (3 mo1°/), while DEX1O-g-(POE)io-Ci8 (3.9 rnol%)
resulted in a maximum CsA loading of 3%. CsA displays a higher affinity for HPC than for
DEX, where HPC-g-(POE)-C,, micelles incorporated higher amounts of CsA compared to
DEX-g-(POE)--C,, micelles, for the same molar content of (POE)-C. This trend is
consistent with the inherent hydrophobicity of HPC due to the presence of isopropoxy
substituents, known as “the hydrophobic pockets” within the HPC structure, as reported by
Klug (Klug, 1971). This heterogenous structure of HPC explains the high affinity of CsA
for umuodified HPC, showing a level of CsA incorporation of 1.4 % w/w. The micelles
formed by the dextrans of higher molecular weights (DEX4O) were flot as effective CsA
carriers (Table 7.1.). Nonetheless, in all cases the amount of incorporated CsA was larger in
the case of polymeric micelles than in the case of unmodified dextrans and HPC (Figure
7.3), which have a much lower affinity for CsA.
By comparing the highest CsA loading percentage in the various polymers, it is
apparent that the CsA loading increases with increasing molar content ofPOE10-C16 grafted
on the dextran backbone. Other structural features of the copolyrners also affect the
micellar loading capacity towards CsA. for example, micelles formed by polyrners of
higher molecular weights (e.g. DEX4O) are flot as effective CsA carriers as those based on
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DEX1O. Also, for a constant number of P0E10-C,, units grafted per dextran chain,
POE10-C16-based micelles seem more effective in solubilizing CsA than POE10-C18-based
micelles, indicating that the micropolarity of a hydrophobie core made up of hexadecyl
POE chains might present a better solubilizing microenvironrnent than that offered by the
octadecyl-POE moieties.
It is interesting to note also that, at low CsA initial concentrations (< 15 % w/w),
HPC-g-(POE)-C polymeric micelles exhibit a solubilizing/Ioading trend different from
that displayed by DEX-based micelles (figure 7.3). While the degree of CsA incorporation
within DEX-based micelles increases steadily with increasing initial CsA concentration, the
level of CsA incorporation in polyrneric micelles remains low and nearly constant with
initial CsA concentration < 15 %, then increases rapidly as the initial CsA concentration
exeeeds 15 %.
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Figure 7.3. CsA final loading (u/u’ ¾) in micelles of (Â) DEX1O-g-(POE)io-C16 (3
mol%). (+) DEXI0-g-(POE)10-C18 (3.9 rnol%). t.) HPC-g-(POE)IV-Clf, (3.9 mol%) and t.)
HPC-g-(POE)jo-Cig (3.1 mol%) copolymers at 2.5 —40 (w/w ¾) of initially added CsA. For
comparison. CsA was incorporated in (A) unmodified dextran 110 and (n) unrnodified
HPC polymers. Mean + SD (n = 3).
0 5 10 15 20 25 30 35 40
CsA added initïally (°/
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7.9. Soirn STATE 0F CsA IN MICELLES
free Cyclosporin A is cornplete]y crystalline. It consists of white prismatic needles
prepared from acetone at —15°, showing definite specific peaks in its X-ray diffractogram
and a melting point at 148
—
151°C (The Merck Index, l3th edition, 2003). Craig et al.
(Passerini et aI., 2002) showed that, following incorporation into poly(D,L-Ïactide-co
glycolide) microspheres using the solvent evaporation method, CsA is transforrned into a
cornpletely amorphous state. Similar behavior has been detected for progesterone within
poly(D,L-lactide) microspheres, although at high progesterone loading, a crystalline state
was detected resulting in microspheres showing rough surface (Hill et al., 199$).
On the other hand, Zhao et al. reported the presence of an amorphous CsA within
CsA-poÏoxamer solid dispersion prepared using the rnelt solvent method (Zhao et al.,
1997).
In order to deterniine the solid state of CsA solubilized in the hydrophobie core of
polymeric micelles, we carried out X-ray powder diffraction and calorimetric studies on
free CsA (as received) and freeze-dried CsA-loaded poLymeric micelles in the powder
forrn. Both powder X-ray diffractograms and differential scanning calorimeuy
thermograms correÏated to show the absence of an arnorphous fonTi of CsA within
polymeric micelles. However, fiirther investigation witl be aimed at confirming that CsA
crystals preseiwed the same molecular conformation inside the micelles as in the free Corm.
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7.10. STABILITY 0F POLYMERIC MICELLES IN SIMULATED GI FLUIDS
The design of an oral drug delivery system should include stability testing in
simulated gastric fluid (pH 1.2) and intestinal fluid (pH 6.8). In order to evaluate the
stabllity of the polymeric micelles in the simulated GI fluids, the release of CsA was
evaluated both from HM-DEX and HM-HPC micelles loaded with the drug at saturation.
Micellar solutions were placed in a releasing bag scparated by a dialysis membrane (6000 -
8000 Da MW cutoff) from a receiving compartment containing gastric or intestinal fluids,
which were replaced with fresh fluid following sampling to assure sink conditions. The
membrane allowed penneation only to the free drug present in equilibrium with the
complex in the releasing cdl and not to the CsA-loaded micelles.
Compared to various nanocarrier systems, such as niosomes, liposomes and
surfactant micelles (Hu et al., 1999; Ozpolat et al.. 2003), HM-polysaccharide based
micelles represent a significant improvement by eliminating physical stability problems,
and may therefore offer irnproved bioavailability of poorly soluble drugs. We have
demonstrated that polysaccharide-based micelles were highly stable at varying pH values
during $ h of incubation at 37 °C. The high stability of micelles is due to the known
stability of the ether linkages linking the (POE)10-C16 residues to the polysaccharide
backbone in the micelle structure. Ether linkage is known to be highly stable towards pH
changes and enzymatic reactions, comparecl to ester linkage. Therefore, the micellar
structure of these polymeric carriers is maintained. The release of encapsulated csA, in
each type of fluid, reached a maximum of 12 % and 4 ¾ in the case of DEX- and HPC
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micelles, respectively, indicating that these systems are quite stable towards drug
release during the average residence time period of the macromolecular carriers in the Gli
before reaching the systemic circulation. In this period the stability of the drug carrier
towards release is very important in order to prevent the enzymatic degradation of CsA in
the stomach, as well as the metabolizing enzymes cytochrorne P-450 3A4 and the multidrug
transporter P-glycoprotein in the intestinal barrier.
The drug release from the micelles, however, takes place slowly over time, due to
the drug partition between the micelles and the aqueous solution which becomes a dynamic
process, prornoting dnig release from the micelles, when the free drug present in solution is
continuously removed by the absorption in vivo (Zuccari et aÏ., 2005).
7.11. CYT0T0xIcITY AssAY
The cytotoxicity of new polymers always needs to be performed on the cellular
level in order to evaluate the cytotoxicity of the micelle components towards the cell line
used, before performing ftirther specific studies. from previous reports, we knew that while
both HPC and DEX present no toxicity (Couch, 1965; Obara et al., 1992), free (POE).-C,,
inhibit cdl growth by affecting the integrity of celI membranes (Dimitrijevic et al., 2000).
Hofland et aï showed that, the toxicity of aikyl polyoxyethylene surfactants was related to
their hydrophilic/lipophilic balance: an increase in alkyl chain length is accompanied by a
decrease in toxicity, while an increase in the polyoxyethylene chain length causes an
increase in toxicity (Hofland et al., 1992).
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Therefore, in the present study, it was important to assess if linking (POE)1-C
chains to a polysaccharide framcwork would alleviate their toxicity. The evaluation of
polymers cytotoxicity was carried out using the colorirnetric MTT assay. The test is based
on mitochondrial dehydrogenase celi activity as an indicator of celi viability. We carried
out toxicity tests for DEX, HPC, various (POE)-C,1, and the different copolymers towards
human intestinal epithelial ceils (Caco-2 celis), which are widely used to investigate the
intestinal absorption mechanisms of dmgs (Krishna et aÏ., 2001). The effect of polymer
composition, concentration and incubation tirne on intestinal ceil viability was examined.
As expected, DEX and HPC show no toxicity at high concentrations, whereas ail studied
(POE)1-C,, inhibit cell growth, when added to cells at concentrations as low as 0.5 g/1. Like
DEX and HPC, the modified polysaccharides DEX-g-(POE)-C,, and HPC-g-(POE)-C,1
exhibit no significant cytotoxicity at a concentration as high as 10 g/l, indcpendently of the
grafting level. Even in the case of DEX- and 1-IPC-based copolymers with the highest levels
of (POE)10-C16 grafting (15 mol%, and 5.4 mol%, respectively), the cytotoxicity was
negligeable compared to equivalent concentrations of free (POE)10-C16. These results
confirm 1) that upon linking to a polymer chain, (POE)1-C,7 loses its cytotoxicity, and 2)
that the polymer purification method efficiently removed any free (POE)-C,, from the
polymer. This effect may be due to the fact that the non toxic hydrophilic polysaccharide
chains forming the polymeric micelle outer sheil stay in contact with the ceils and
effectively insulate them from the surfactant residues assembled in the inner core of the
micelle. For these to escape from the micellar assembly, it is necessaiy to break an ether
bond, known to be stable against hydrolysis over a wide range ofpH values.
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7.12. CAco-2 PERMEABILITY STUDIES
Absorption of orally adrninistered drugs, a major determinant of bioavailability, is
mainly controlled by two key factors; dmg solubility in the intestinal lumen and its
permeabilïty across the intestinal barrier. Recently, the use of Caco-2, human intestinal
epithelial cells, has emerged as a leading rnethod to investigate absorption mechanisms of
several classes of potential drugs in the early development stages (Delie et al., 1997;
Artursson et aÏ., 1997; Krislma et al., 2001; Karnrn et aÏ., 2000; Faassen et aï., 20t)3). In
order to gain insight into the absorption of solubilized CsA from the GI tract into the blood
stream, we investigated the permeabiiity of CsA entrapped in polymeric micelles across
Caco-2 ccii monolayers. Caco-2 ceils retain rnany features ofsrnall intestinal ceils (Delie et
aï., 1997; Hidalgo et al., 1989; Artursson et al., 2001), and a strong correlation was
obseiwed between in vivo human absorption and in vitro permeability across Caco-2 celis
fora variety of compounds (Arnirsson et al., 1991; Yee, 1997; Grès et al., 1998).
The efflux transporter protein, P-gp, is expressed at the apical side of the Cacc-2
monolayer and is flot expressed at the basolateral side tHosoya et aÏ., 1996). The intestinal
efflux caused by P-gp acts as an absorption barrier to limit the oral bioavailability of
hydrophobie drugs from the gastrointestinal tract (Hunter et al., 1997). In the present study,
the bi-directional transport across Caco-2 ceils was assayed by iiquid scintillation cotinting
to detennine the amount of CsA that crossed the ccli monolayer. Foliowing 240 min of
incubation with Caco-2 cells, the apical to basal penueability of CsA toaded in polyrne tic
micelles was generally higher than that of free CsA. Moreover, the bidirectional transport
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of CsA soltïbilized in HPC-g-POE-Ci6 polyrneric micelles was higher than that in
DEX-g-POE-C16 micelles, suggesting that HPC micelles adhered to the celi monolayer,
allowing a slow diffusion of solubilized CsA to the basal side, while DEX micelles
remained suspended in the apical side. A fluorescence spectroscopy technique was used to
determine the amount of host polymeric micelles that crossed the celi monolayer. Using
fluorescein-labelled micelles, we demonstrated also that the amount of transporteci HM
HPC is greater than that of KM-DEX copolymer. This property may be attributed to the
bioadhesive characteristic of HPC polymers.
It has been demonstrated that, for cornpounds that are substrates of P-gp, the use of
a P—gp inhibitor resulted in a better estimate of absorption in humans (Yee, 1997). Natural
or synthetic fatty acid ester based surfactants, such as polysorbates and solutol, have been
investigated and were found to inhibit P-gp rnediated drug efflux (Woodcock et al., 1992;
Nenirkar et aÏ., 1996). Recently, amphiphilic triblock copolymers of poly(ethylene oxide)
b-poly(propylene oxide)-b-poly(ethylene oxide), also known as Pluronic block copolymers,
have been shown to enhance cellular accumulation, membrane permeability, and to
modulate multidmg resistance of nurnerous P-gp substrates (Seeballuck et al., 2003;
Batrakova, E.V. et aï., 1998; Batrakova, E. et al., 1999a). In the present study, we chose to
use Pluronic P85 as P-gp inhibitor since it has been recently approved by the US Food and
Dmg Administration (FDA) (BASF. 1993). Pluronic P85 bas been obseiwed to block P-gp
mediated efflux in Caco-2 and bovine brain microvessel endothelial cells (Batrakova et al.,
1999) which suggested that this agent may be useful for formulations to enhance oral and
brain absorption. On the other hand, several previous smdies examining the effects of non-
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ionic surfactants on transport in celi monolayers have clearly indicated that the AP-BL
transport ofdrugs that are P-gp substrates increased at surfactant concentrations at or below
the CMC (Nenirkar et al., 1996; Batrakova et aï., 1998). In contrast, at concentrations
above the CMC, the Pluronic block copolymers were found to cause an increased efflux of
P-gp substrate from Caco-2 cells (Batrakova et al., 1998). Nerurkar et al. concluded that the
free unirners were responsible for inhibiting P-gp efflux transport (Nerurkar et al., 1996).
The CMC of Pluronic P85 has been reported to be 67 4M (Miller et al., 1997). In this
study, we used a PGI solution containing 30 j.tM Pluronic P85, to enstire that the copolymer
concentration is below the CMC, i.e. P85 copolymer is in the forrn ofunimers. it should be
mentioned that the BL-AP transport ofCsA in presence of PGI on the basal side was higher
than that shown when PGI was added on the apical side, in the case of free as well as
rnicelle-loaded CsA (data flot shown), due to the presence of P-gp transporter on the apical
side ofCaco-2 celis.
7.13. VB12-TARGETED POLYMERIC MICELLES
At this point in our understanding and in an attempt to override such inherent
intestinal barrier, we exploited the use of the cobalamin absorption pathway to further
enhance the perrneability of CsA solubilizcd in DEX-based micelles, following a receptor
mediated endocytosis mechanism. VB12 residues wcre covalently linked to the surface of
polymeric micelles. The permeability of CsA across Caco-2 monolayers increased
significantly when loaded in VB12-modified DEX-micelles compared to unmodified DEX
micelles as well as free CsA. Meanwhile, a further increase was observed in intrinsic factor
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(IF)-mediated pernieability, meaning that, in presence of If, VB12-modified polymeric
micelles were specifically trancytosed across Caco-2 ce!! monolayers through 1F receptors
on the apical side. These resuits appear to be consistent with previous flndings on a major
role of increased permeability of VBI2-conjugates across Caco-2 celis through receptor
rnediated endocytosis mechanism (Russeit-Jones et al., 1995; Alsenz et al., 2000).
However, Moestmp et aï. proposed that, in absence of If, the VB12-conjugate binds to
intracellular ICII, secreted unidirectionally from AP to BL side in Caco-2 cultures
(Ramanujam et al., 1991), and the complex is intemalized by the celis and transported to
the BL side ofthe monolayer (Moestrup et al., 1996).
In order to localize internalized CsA within Caco-2 ceils, its presence was
investigated in ce!! debris as we!! as in the insert filter membrane, where CsA may be
trapped and could flot move into the BL chamber of the Transwell. The resuits
demonstrated that; following 4-h of incubation, a!though the amount of CsA transported to
the BL chamber was flot negligible, the amount ofCsA interna!ized by the cetïs was higher.
However, the amount of CsA trapped in the filter was negligible and remained constant in
all cases. In the case of 24-h incubation period, the arnount of transported CsA was higher
than that intemalized by the cells, while the entrapment of CsA in filter membranes
remained negligible. However, it should be noted that the amount of CsA intemalized
within the celis after 24 h rernained comparable to that after 4 b of incubation with Caco-2
ce!ls.
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It has been shown that, after the binding of IF-Cbl, there is a delay where the
complex is internalized and Cbl is released inside the enterocyte. The TCII-Cbl complex is
then fonried intracellularly (Quadros et al., 1999; Pons et ai’., 2000). It has been suggested
that the transfer of Cbl from IF to ICII occurs within a delay of 3 - 4 h (Rothenberg et aï.,
1978; Ramanujam et al., 1991). further more, Alsenz et al. (Alsenz et aÏ., 2000) showed
that the phaniiacokinetics of orally administered Cbl and of Cbl conjugates were very
similar after 4h, where the highest tissue concentration in the srnall intestine with almost no
urinaiy excretion of Cbl were observed after 4h. On the other hand, betwcen 4 h ancl 24 h,
most of the Cbl conjugates disappeared from the small intestine and high concentrations
were localized in the kidney and liver with little urinary excretion.
7.14. CoNcLusioN
In this study, optimized polysaccharide-based polymeric micelle formulations with
improved chemical structures and physicochemical characteristics are proposed for the oral
delivciy of poorly soluble therapeutic agents. We succeeded in enhancing the aqueous
solubility of CsA by reaching relatively high solubilization capacity in the inner core of
polysaccharide-based polymeric micelles, and consequently increasing its pernieability
across model intestinal epithelium, compared to free CsA. Therefore, the polysaccharicle
based polymeric micelles offer unique opportunities for the oral deliveiy of poorly-water
soluble drugs, namely:
1) The small size of polyrneric micelles and their very low onset ofmicellization.
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2) The higli encapsulation capacity
3) The stability of the micelle system in simuÏated biological fluids.
4) The absence of cytotoxicity towards intestinal epithelial celis.
5) The ability to enhance the penrieabitity of solubilized drug across the intestinal
barrier versus free dnig.
Consequently, it would be expected that:
I) The nanoscopic size of polymeric micelles would resuit in an enhanced intraceltutar
drug concentration, since the uptake is size-dependent; where smaller particles are
taken up to higher degree than larger particles.
2) The stability of the drug in biological fluids would increase through micelle
incorporation, by decreasing contacts with inactivating species (enzymes) in the
gastrointestinal fluid (Yokoyama et al., 1990).
3) This may lead to decrease CsA administered dose.
4) Consequently, the undesirable systemic side effects of CsA are expected to
decrease.
To the best of our knowledge, this is the first time that the permeability of a drug
and its carrier across Caco-2 monolayers is studied.
Collectively, the results of this research will aid in understanding the relationship
between structural features of polysaccharide-based carriers in solubilizing lipophilic drugs
and their intestinal permeability, with the prospect of designing novel polymeric carriers for
oral drug deliveiy. The use of this delivery approach can, in principle, modulate both the
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pharmacokinetic bebaviour and bioavailability of the drug, resulting in an overali
increase in the drug therapeutic index.
7.15. IMPACT ON THE BIOPHARMACEUTICAL INI)USTRY
In recent years, Canada bas experienced a trernendous devetoprnent of the
phamaceutical industry. In the area of drug fomulation, research on polymeric micelles is
growing in Canada. At ieast two companies, Supratek Phanna Inc. (Montreal, QC) aiid
Angiotech Pharmaceuticals Inc. (Vancouver, BC) have patented foniiuiations based on
polyrneric micelles for parenteral deÏiveiy. Since oral dosage forrns represent more than
90% of ail drug formulations, the developrnent and long terni cornmerciaiization of an
efficient oral vehicte for poorly-water soluble dmgs could have tremendous economical
benefits for Canada. for example, the saies of CsA oral microemulsion (Neorai®) have
generated 54 million dollars in Canada in 2003 (IMS I-Iealth Canada). The present project
offers new options for oral delivery of poorly-water soluble drugs, thus warranting further
developments in pharmaceutical industry.
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CHAPTER fIGHT
SuMMARY AND PERSPECTIVE
jThere is a great need to increase the abitity to deliver the broad range of poorly
water soluble drugs efficiently by the peroral route of administration. This thesis describes
polysaccharide-based deliveiy approaches and targeting schemes for manipulating such
therapeutic agents, and enhancing their transport across the transcellular pathway in the GI
tract.
This study has increased our understanding of the effcct of the chemical structure of
amphiphilic copolymers on their efficiency to encapsulate lipophilic dmgs, a crucial
property to allow their transcellular transport from the small intestine to the systemic
circulation following oral administration. Initial work on targeting via VB12-absorption
pathway neds to be continued to take full advantage ofthe flexibility ofa polymeric micelle
structure, in order to enhance the oral absorption of drugs via specific uptake pathways
across the intestinal epithelium.
To achieve the final goal of producing polymeric micelles acting as effective oral
drug carriers, further aspects must be examined before starting the maturation process from
in vitro investigations to in vivo studies. for instance, the solid state of CsA solubilized
within the micelle hydrophobie core needs to be investigated on the molecular level.
Quantitative studies aimed at enhancing the dnig loading in the micellar system are also
needed. Three specific areas appear to be very important for the prodtiction of polyrneric
micelle vehicles able to overcorne the limited success in this area: that is, increasing the
grafting level of the hydrophobie residues in the micelle structure without losing their
solubility, using different hydrophobie moieties and polysaccharide of various MW, and by
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using other rnethods of drug loading such as the direct dissolution method and the ou
in-water emu]sion method. The bioadhesive properties of HPC-based micelles need to be
evatuated more in depth, towards the intestinal mucin layer. f inaliy, the biological fate
(rnetabolismlelimination) of the entrapped CsA and of the polymeric carriers needs to be
investigated. These basic studies vill put efficient tools at the pharmaceutical scientist’s
disposai, bringing new means for enabling lipophilic dnigs to overcome the GI tract
absorption barrier.
The information gathered through this research is a step towards the realization of
the full potential of polyrneric rnicelle-based oral dosage forms with economically viable
commercial-scale production, so as to bridge the gap between a research concept and
market products. Although a recipe for immediate success is beyond the scope of this work
us certainly difficuit to offer, it would seem that the use of polyrneric micelle system as a
chemical passport for the oral delivery oftherapeutics remains a field rich in opportunities,
with many interesting aspects to explore.
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J.C. Leroux, M. Francis, E. Roux, F.M. Winnik.
J 3(11 International Svinposiuni on Microencapsulalion 2001. Anger. Fronce.
4. “In vitro Evaluation ofpH-Sensitive Niosorne/Polymer Complexes”
M.F. Francis*, G. Dhara, F.M. Winnik and J.C. Leroux.
84” c’SC (Canaclian SocietvJr Chemistn) Con/èi-ence anci Exhibition 200], Montreal (PQ.), Canada. [Oral
communication].
*NISED Best Student Oral Presentation Award 2001
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3. “Synthesis and Characterization of Folate Derivatives of Hydrophobically-modified poly(N
isopropylacrylamides)”
D. Dubé, M. Francis, i-M. Winnik and i.C. Leroux.
84 cSC (‘a,,adian Societcfor Chemistrv) conference ami Exhibition 2001, Montreal (PQ,, canada.
2. “Study of the Mechanisms of Destabilization of pH-Sensitive Niosomes by N-isopropylacrviamide
Copolymer Under Weakly Acidic Conditions”
M.F. Francis, G. Dhara. F.M. Winnik and J.C. Leroux.
J QWC Forum des Sciences Pharmaceutiques 2001, Montreal (PO,, Canada [Oral Communication].
“Destabilization of Niosomes and Liposomes by pi-I-Sensitive N-isopropylacryiamide Copolymers Under
Weakiy Acidic Conditions”
M. Francis, G. Dhara, F.M.Winnik, J.C. Lerotix.
AAPS Phar,n. Sci. Supplement, 2000; 2 (4) : 2000.
.4APS (Ainerican Association oJ Pharmaceutical Scientists) Annual Meeting and Exposition, 2000, Octoher
29 - November 2, Indianapolis (Indiana), U.S.A.
Volunteer Activities
2001 — 2004 Representative of Graduate Sttidents in “Research Committee” of the Facuity of Pharmacy,
University of Montreal
Scholarships, Distinctions and Honors
2004 Manulife Financial Corporation — Ph.D. Student Distinction Prize, facuity of Graduate Studies,
University ofMontreal, Montreai (Qc), Canada.
2003 Amerjcan Association of Pharmaceutical Scientists (AAPS) Award of the Pharmaceutics and
Drug Delivery (PDD) section, October 28t11, Sait Lake City (Utah), U.S.A.
2003 ClllRlBioContact-Quebec Next Generafion Award, BioContact Quebec, a symposium on the
biophannaceutical partnership between North America. Europe and Asia, October 3a, Quehec city
(Qc), Canada.
2003 Banque de Montreal
— Ph.D. Student Distinction Prize, Facuity of Graduate Studies, University of
Montrcal, Montreal (Qc), Canada.
2003 Controlled Release Society (CRS)
- Capsugel Graduate/Postdoc Award for Innovative Aspects of
Gastrointestinal Drug Absorption and Delivery, sponsored by the CR5 and Capsugel, a division of
Pfizer, July 210 Giasgow, Scotiand, United Kingdom.
2002 — 2003 Novartïs Pharma Canada Exceiience Schotarship, Montreal (Qc) Canada
2002 McKesson Canada Prize for academic distinction (Ph.D. graduate studies in Pharmaceutical
sciences), Montreal (Qc), Canada.
2001 and 2002 Ph.D. Student Distinction Prize in Pharmaceutical sciences, Facutty of Phanriacy,
University ofMontreal, Montreai (Qc), Canada
2001 MSED Best Student Oral Presentation Award, 86th Canadian Society of Chemistry (CSC)
Conference and Exhibition, Montreal (Qc), Canada.
2001 and 2002 J.A. De Sève Distinction scholarship, Montreai (Qc), Canada.
2091 —2005 Rx & D Health Research Foundation (HRF)/Canadian Institutes of Health Research
(CIHR). Ph.D. graduate studics schoiarship in Phannacy, Ottawa (ON), Canada.
2001 — 2003 Exemption of Differential Universitv Fees for International Students, Faculty ofGraduatc
Studies, University of Montreal, Montreai (Qc), Canada.
2001 Aventis Class Prize, M.Sc. graduate studies in Pharmaceuticai Sciences, Montreal (Qc), Canada.
1999—2001 Canadian International Development Agency (CIDA) Distinction scholarship for Master
studies, Ottawa (ON), Canada.
199$ Distinction and Honor degrec, Factiity ofpharmacy, University ofAlexandria, Aiexandria, Egypt.
U Controlled Release Society (CRS)
U American Association ofPhannaceutical Scientists (AAPS).
U Canadian Socicty for Phaniiaceuticat Sciences (CSPS).
U Canadian Society for Chcmistry (CSC).
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